Complexing agent salt formulations of pharmaceutical compounds
Patent Information
- Application Number
- JP2023529879
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-11-18
- Filing Date
- 2021-11-17
- Publication Date
- 2024-11-26
AI Technical Summary
Pharmaceutical compounds with basic nitrogen atoms face challenges in formulation due to issues such as limited solubility, hydrophobicity, and the presence of ionic functional groups, leading to difficulties in widespread use, particularly in subcutaneous, sublingual, and intranasal delivery, where high levels of excess ions from conventional complexing agents like sulfobutyl ether β-cyclodextrin (SBEBCD) are undesirable.
Formulation of pharmaceutical compounds with basic nitrogen atoms as salts using complexing agents in their free acid form, eliminating excess ions by directly forming salts with the compound, enhancing solubility, stability, and bioavailability through the use of cyclodextrins like SBEBCD, which are deprotonated to act as counterions, thereby reducing osmolarity and eliminating the need for additional buffers.
The resulting salts improve solubility and stability, increase bioavailability, and reduce osmolarity, making them suitable for subcutaneous, sublingual, and intranasal administration with reduced irritating effects on tissues, while allowing long-term storage and easy redissolution for use.
Smart Images

Figure 2022109050000001
Abstract
Description
[Technical Field]
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 115,445, filed November 18, 2020, U.S. Provisional Application No. 63 / 115,451, filed November 18, 2020, U.S. Provisional Application No. 63 / 115,453, filed November 18, 2020, and U.S. Provisional Application No. 63 / 115,458, filed November 18, 2020, each of which is incorporated by reference in its entirety. [Background technology]
[0002] Pharmaceutical compounds and their derivatives, such as ketamine, methoxetamine, deschloroketamine, dextromethorphan, tryptamine, phenethylamine, opioid compounds, cathinone, 3,4-methylenedioxyamphetamine, alkylamino-substituted benzofurans, amphetamine, aminoindan, and stimulants, are useful for various medicinal purposes. These compounds can be used to treat, for example, pain, depression, mood disorders, PTSD, impulsivity and impulse control disorders, personality disorders, cognitive disorders, sleep disorders, inflammatory disorders, and many other mental and physical disorders. However, compounds may have many physicochemical properties that make them difficult to formulate for widespread use as pharmaceutical agents, including the presence of basic amines, limited solubility, hydrophobicity, and essentially ionic functional groups. Summary of the Invention
[0003] Provided herein are formulations and salts of pharmaceutical compounds having a basic nitrogen atom. In some embodiments, the pharmaceutical compound having a basic nitrogen atom includes a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or a compound that modulates the NMDA receptor. In some embodiments, the pharmaceutical compound having a basic nitrogen atom does not include ketamine. In some embodiments, the pharmaceutical compound having a basic nitrogen atom includes a derivative or analog of ketamine. In some embodiments, the pharmaceutical compound having a basic nitrogen atom includes methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticidone), 3-methoxyphencyclidine, methoxyeticlidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, pharmaceutical compounds having a basic nitrogen atom have hallucinogenic properties, including, but not limited to, tryptamine, phenethylamine, and lysergamid classes of molecules. In some embodiments, pharmaceutical compounds having a basic nitrogen atom include opioids, including opioid receptor antagonists. In some embodiments, pharmaceutical compounds having a basic nitrogen atom have empathogenic or entactogenic properties, including, but not limited to, cathinones, 3,4-methylenedioxyamphetamine, aminoalkyl-substituted benzofurans, amphetamines, aminoindans, stimulants, and other compounds. In some embodiments, the formulations and salts provided herein utilize complexing agents (e.g., cyclodextrins) that have multiple acidic functional groups in their free acid forms to form salts with pharmaceutical compounds having basic nitrogen atoms (e.g., amines). In some examples, the resulting salts have multiple molecules of the protonated pharmaceutical compound ionically bonded to a single complexing agent.Such an approach can be used with any pharmaceutical compound or potential pharmaceutical compound (e.g., an existing drug containing a basic nitrogen atom, a new chemical entity containing a basic nitrogen atom, or any research chemical entity containing a basic nitrogen atom of interest for pharmaceutical purposes) to form a salt with a complexing agent, which may offer numerous advantages in various formulations, including subcutaneous, sublingual, and intranasal formulations. In some instances, the compound, including compounds that act on NMDA receptors, possesses dissociation properties upon administration to the subject. The formulations and salts provided herein utilize complexing agents with deprotonated acidic functional groups as counterions to the protonated forms of basic nitrogen-containing compounds, particularly cyclodextrin complexing agents such as sulfobutyl ether β-cyclodextrin (SBEBCD). While SBEBCD and other similar such complexing agents with anionic functionality can be used to enhance the solubility and stability of many formulations in many situations, the traditional use of these agents lacks utility in certain situations due to high levels of excess ions. In some instances, this is due to the fact that such complexing agents, with their multiple acidic functional groups, are primarily commercially available as their sodium or other alkali metal salts. Therefore, when used in conventional ways, large amounts of excess sodium or other unnecessary or undesirable component ions are added to the formulation. The present disclosure solves this problem by pairing a pharmaceutical compound having a basic nitrogen atom in its free base form with such a complexing agent in its free acid form, thus directly forming a salt between the complexing agent and the compound, and eliminating the presence of substantial excess ions.
[0004] Such formulations and salts provided herein have many advantages over others. In some instances, the solubility of either the pharmaceutical compound itself or the pharmaceutical compound / complexing agent salt complex is improved compared to formulations utilizing the salt form of the complexing agent. Furthermore, for certain compounds where the pKa of the compound's basic nitrogen atom is at or near a physiologically acceptable pH, formulations using the salts provided herein can achieve the desired pH without the need for any additional buffers or excipients. Furthermore, due to the multidentate nature of the acidic functional groups on the complexing agents provided herein, formulations using the salts provided herein may have reduced osmolality compared to formulations using a salt of the complexing agent and the compound, as well as compared to formulations using a salt of the compound itself. All of these benefits may also have the effect of making the compound more absorbable and bioavailable, particularly for sublingual or intranasal delivery administration, since increased solubility at the pH of saliva or nasal mucosa increases bioavailability and transmucosal absorption. Furthermore, in some instances, the salts and pharmaceutical compositions can be stored as powders for long-term storage, thus increasing the stability of such salts and compositions. In some instances, the salts and pharmaceutical compositions are easily redissolved at the time of use, whether as intermediates in the manufacturing process of a pharmaceutical composition or as a pharmaceutical composition to be used directly.
[0005] In one aspect, provided herein is a pharmaceutical composition comprising: (i) a compound containing a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof; and (ii) a complexing agent that is an acid-substituted cyclodextrin containing multiple acidic functional groups, wherein the multiple acidic functional groups comprise acidic groups that act as counterions to the protonated nitrogen atom of the pharmaceutical compound. In some embodiments, the pharmaceutical compound having a nitrogen atom comprises a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound. In some embodiments, the pharmaceutical compound does not comprise ketamine. In some embodiments, the pharmaceutical compound comprises a derivative or analog of ketamine. In some embodiments, the pharmaceutical compound comprises methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticidone), 3-methoxyphencyclidine, methoxyeticyclidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound comprises a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound comprises an opioid. In some embodiments, the pharmaceutical compound comprises a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin.
[0006] In another aspect, provided herein is a pharmaceutical composition, the pharmaceutical composition comprising: (i) a pharmaceutical compound that contains a basic nitrogen atom and is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclo-hexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound, or an enantiomer, mixture of enantiomers, or isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent that contains a plurality of acidic functional groups.
[0007] In another aspect, provided herein is a pharmaceutical composition comprising: (i) a pharmaceutical compound that contains a basic nitrogen atom and is methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticridone), 3-methoxyphencyclidine, methoxyeticyclidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine, or an enantiomer, mixture of enantiomers, or isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent that contains a plurality of acidic functional groups.
[0008] In another aspect, provided herein are pharmaceutical compositions comprising: (i) a pharmaceutical compound that contains a basic nitrogen atom and is a tryptamine, phenethylamine, or lysergamide compound, or an enantiomer, mixture of enantiomers, or isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent that contains a plurality of acidic functional groups.
[0009] In another aspect, provided herein is a pharmaceutical composition comprising: (i) an opioid containing a basic nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant pharmaceutical compound thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent containing multiple acidic functional groups.
[0010] In another aspect, provided herein is a pharmaceutical composition comprising: (i) a pharmaceutical compound that contains a basic nitrogen atom and is a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, a hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent that contains a plurality of acidic functional groups.
[0011] In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or a compound that modulates NMDA receptors. In some embodiments, the pharmaceutical compound is not ketamine. In some embodiments, the pharmaceutical compound is methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticidone), 3-methoxyphencyclidine, methoxyeticlidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound is a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the pharmaceutical compound is cathinone, 3,4-methylenedioxyamphetamine derivative, aminoalkyl-substituted benzofuran, substituted amphetamine, aminoindan, stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin. In some embodiments, the complexing agent is sulfobutylether-β-cyclodextrin. In some embodiments, the pharmaceutical composition has a lower osmolality than a composition comprising a salt of the pharmaceutical compound and a salt of the complexing agent. In some embodiments, the pharmaceutical composition has substantially the same osmolality as a solution of the sodium salt of the complexing agent at the same concentration.
[0012] In some embodiments, the pharmaceutical composition has a lower osmolality than a solution of the sodium salt of the complexing agent at the same concentration. In some embodiments, the pharmaceutical composition is substantially free of excess ions. In some embodiments, the medicament is formulated for subcutaneous, intramuscular, sublingual, or intranasal administration. In some embodiments, the complexing agent comprises a substituted cyclodextrin.
[0013] In some embodiments, the complexing agent comprises a cyclodextrin substituted with at least one acidic functional group. In some embodiments, the cyclodextrin is substituted with 3 to 8 acidic functional groups. In some embodiments, the cyclodextrin is SBEBCD. In some embodiments, the composition has a ratio of complexing agent to pharmaceutical compound comprising a protonated nitrogen atom of about 1:4 to about 1:10. In some embodiments, the pharmaceutical composition has an osmolality of about 850 mOsm / kg or less. In some embodiments, the pharmaceutical composition has a pH of about 4 to about 7. In some embodiments, the complexing agent is present in an amount of about 10 mg / mL to about 600 mg / mL. In some embodiments, the pharmaceutical composition further comprises about 0.1 to about 20 molar equivalents of a non-ionized pharmaceutical compound relative to the amount of complexing agent.
[0014] In one aspect, provided herein is a pharmaceutically acceptable salt of a compound pharmaceutical, the pharmaceutically acceptable salt comprising (i) a pharmaceutical compound containing a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a conjugate base of a complexing agent containing multiple acidic functional groups, wherein the conjugate base of the complexing agent serves as a counterion to the pharmaceutical compound. In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or a compound that modulates the NMDA receptor. In some embodiments, the pharmaceutical compound is not ketamine. In some embodiments, the pharmaceutical compound is methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticidone), 3-methoxyphencyclidine, methoxyeticyclidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound is a tryptamine, phenethylamine, or lysergamide compound. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the pharmaceutical compound is a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin. In some embodiments, the salt is in a solid form. In some embodiments, the solid form is a crystalline form. In some embodiments, the solid is an amorphous form. In one embodiment, the solid form is a lyophilized powder. In some embodiments, the salt is dissolved or suspended in an aqueous medium. In some embodiments, the salt is dissolved or suspended in an organic solvent. In some embodiments, the salt is substantially free of excess ions. In some embodiments, the complexing agent comprises a substituted cyclodextrin.In some embodiments, the complexing agent comprises a cyclodextrin substituted with at least one acidic functional group. In some embodiments, the cyclodextrin is substituted with 3 to 8 acidic functional groups. In some embodiments, the cyclodextrin is SBEBCD. In some embodiments, the composition has a ratio of complexing agent to pharmaceutical compound containing a protonated nitrogen atom of about 1:4 to about 1:10.
[0015] In another aspect, the present disclosure provides a compound of the formula: [A] a [B] Provided herein are pharmaceutically acceptable salts of pharmaceutical compounds having the formula: wherein A is a pharmaceutical compound containing at least one basic nitrogen atom, B is a complexing agent containing multiple acidic functional groups, and a is a number from 1 to 7, selected so that the total number of basic nitrogen atoms in A is equal to the number of acidic functional groups in B. In some embodiments, at least one basic nitrogen atom is an amine. In some embodiments, at least one basic nitrogen atom is included in a heterocycle. In some embodiments, at least one basic nitrogen atom has a pKa value of about 4 to about 10. In some embodiments, the pharmaceutical compound contains only a single basic nitrogen atom. In some embodiments, a is equal to the number of acidic functional groups. In some embodiments, the pharmaceutical compound contains two or more basic nitrogen atoms. In some embodiments, the complexing agent is a cyclodextrin. In some embodiments, the complexing agent has Formula (I):
[0016] [ka] or a stereoisomer, a mixture of stereoisomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein R 1 are each independently H or optionally substituted alkyl, wherein at least one R 1 is substituted with an acidic functional group, and R 2 are each independently H or optionally substituted alkyl, and n is 6, 7, or 8.
[0017] In some embodiments, the complexing agent is SBEBCD. In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or a compound that modulates NMDA receptors. In some embodiments, the pharmaceutical compound is methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticridone), 3-methoxyphencyclidine, methoxyeticlidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound is ketamine. In some embodiments, the pharmaceutical compound is not ketamine. In some embodiments, the pharmaceutical compound is a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound is N,N-dimethyltryptamine, N,N-diethyltryptamine, or mescaline. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, morphine, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, 3-methylthiofentanyl, naloxone, or naltrexone. In some embodiments, the pharmaceutical compound is a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin.In some embodiments, the pharmaceutical compound is a cathinone, an aminoalkyl-substituted benzofuran, or an aminoindan.
[0018] In one aspect, provided herein is a pharmaceutical composition comprising: (i) a compound comprising a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof; (ii) a complexing agent comprising a plurality of acidic functional groups, wherein the plurality of acidic functional groups comprises a conjugate base of an acid that acts as a counterion to the protonated nitrogen atom of the pharmaceutical compound; and (iii) an additional molar equivalent of a non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition is formulated for sublingual or intranasal administration. In some embodiments, the complexing agent is a cyclodextrin. In some embodiments, the complexing agent is sulfobutylether-β-cyclodextrin. In some embodiments, the molar ratio of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:10. In some embodiments, the additional molar equivalent of the pharmaceutical compound is about 0.1 to about 20 moles of pharmaceutical compound per mole of complexing agent. In some embodiments, the pharmaceutical composition has a pH of about 4 to about 10. In some embodiments, the pharmaceutical composition has an osmolality of about 250 mOsm / kg to about 500 mOsm / kg. In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound. In some embodiments, the pharmaceutical compound is ketamine. In some embodiments, the pharmaceutical compound is not ketamine. In some embodiments, the pharmaceutical compound is a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the pharmaceutical compound is a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin.
[0019] In one aspect, there is provided a method for preparing a pharmaceutical composition, the method comprising: The method comprises mixing a) the free base form of a pharmaceutical compound containing at least one basic nitrogen atom, or its enantiomer, mixture of enantiomers, or isotopic variant, with b) the free acid form of a complexing agent containing at least one acidic functional group. In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound. In some embodiments, the pharmaceutical compound is methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticridone), 3-methoxyphencyclidine, methoxyeticlidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound is not ketamine. In some embodiments, the pharmaceutical compound is a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound is N,N-dimethyltryptamine, N,N-diethyltryptamine, or mescaline. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, morphine, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, 3-methylthiofentanyl, naloxone, or naltrexone.In some embodiments, the pharmaceutical compound is cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin. In some embodiments, the pharmaceutical compound is cathinone, an aminoalkyl-substituted benzofuran, or an aminoindan.
[0020] In one aspect, a method of preparing a pharmaceutical composition is provided, comprising combining a pharmaceutically acceptable salt provided herein with an additional molar equivalent of a pharmaceutical compound disclosed herein, wherein the additional molar equivalent of the pharmaceutical compound disclosed herein is non-ionized.
[0021] In another aspect, there is provided a method for preparing a pharmaceutical composition, the method comprising: The method comprises mixing a) the free base form of a pharmaceutical compound containing at least one basic nitrogen atom, or its enantiomer, mixture of enantiomers, or isotopic variant, with b) the free acid form of a complexing agent containing at least one acidic functional group. In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound. In some embodiments, the pharmaceutical compound is methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticridone), 3-methoxyphencyclidine, methoxyeticlidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound is not ketamine. In some embodiments, the pharmaceutical compound is a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound is N,N-dimethyltryptamine, N,N-diethyltryptamine, or mescaline. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, morphine, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, 3-methylthiofentanyl, naloxone, or naltrexone.In some embodiments, the pharmaceutical compound is cathinone, 3,4-methylenedioxyamphetamine derivative, aminoalkyl-substituted benzofuran, substituted amphetamine, aminoindan, stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin. In some embodiments, the pharmaceutical compound is cathinone, aminoalkyl-substituted benzofuran, or aminoindan. In some embodiments, the molar ratio of the pharmaceutical compound containing at least one basic nitrogen atom to the number of moles of acidic functional groups in the free acid form of the complexing agent is about 1:1 to about 10:1. In some embodiments, the method further comprises adding an additional molar equivalent of the pharmaceutical compound in free base form. In some embodiments, the step of adding an additional molar equivalent of the pharmaceutical compound in free base form is performed after removing the liquid medium from the pharmaceutical composition.
[0022] In some embodiments, the pharmaceutical compound is tryptamine. In some embodiments, the tryptamine is optionally substituted on the tryptamine ring. In some embodiments, the pharmaceutical compound is N,N-dimethylpropionamide. In some embodiments, the pharmaceutical compound is a tryptamine selected from N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine, N-methyl-N-propyltryptamine, N-methyl-N-isopropyltryptamine, N,N-diallyltryptamine, N-methyl-N-allyltryptamine, N-methyl-N-ethyltryptamine, and N,N-diisopropyltryptamine, wherein the tryptamine is optionally substituted. In some embodiments, the tryptamine is optionally substituted at the 4- or 5-position of the tryptamine ring with a substituent selected from hydroxy, acetoxy, or methoxy. In some embodiments, the tryptamine is 4-hydroxy-N-methyl-N-ethyltryptamine, 5-methoxy-N,N-diisopropyltryptamine, or O-acetylpsilocin (4-acetoxy-N,N-dimethyltryptamine). In some embodiments, the pharmaceutical compound is lysergamid. In some embodiments, the lysergamid is methylisopropyllysergamid, ethylisopropyllysergamid, 6-allyl-6-nor-LSD, 6-ethyl-6-nor-lysergamid, 1-acetyl-LSD, 1-propionyl-6-ethyl-6-nor-lysergamid, 1-propionyl-lysergamid, 1-cyclopropionyl-d-lysergamid, N1-butyryl-lysergamid, or 6-propyl-6-nor-lysergamid. In some embodiments, the pharmaceutical compound is phenethylamine.In some embodiments, the phenethylamine is mescaline, 2,5-dimethoxy-4-bromophenethylamine (2C-B), 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine (2C-I), 2-(4-chloro-2,5-dimethoxyphenyl)ethan-1-amine (2C-C), 2,5-dimethoxy-4-iodoamphetamine, 2-[2,5-dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine, or 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. In some embodiments, the phenethylamine is mescaline.
[0023] In some embodiments, the pharmaceutical compound comprises (i) a pharmaceutical compound containing four or more protonated nitrogen atoms, or an enantiomer, mixture of enantiomers, or isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a conjugate base of a complexing agent containing multiple acidic functional groups, wherein the conjugate base of the complexing agent acts as a counterion of the pharmaceutical compound.
[0024] In embodiments, the pharmaceutical compound is not ketamine or a derivative thereof. In embodiments, the complexing agent acts as a counterion to the pharmaceutical compound between 5 and 10. In embodiments, the complexing agent acts as a counterion to the pharmaceutical compound between 6 and 8. In embodiments, the pKa of the protonated nitrogen atom is about 4 to 12. In embodiments, the pKa of the protonated nitrogen atom is about 8 to 10. In embodiments, the pKa of the protonated nitrogen atom is about 7 to 9. In embodiments, the pKa of the protonated nitrogen atom is about 9 to 11.
[0025] In embodiments, the pharmaceutical compound is an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticridone), 3-methoxyphencyclidine, methoxyeticyclidine, ephenidine, ranismine, dextromethorphan, dextrorphan, methoxyketamine, N,N-dimethyltryptamine, N,N-diethyl ... Tryptamine, N,N-dipropyltryptamine, N-methyl-N-propyltryptamine, N-methyl-N-isopropyltryptamine, N,N-diallyltryptamine, N-methyl-N-allyltryptamine, N-methyl-N-ethyltryptamine, N,N-diisopropyltryptamine, 4-hydroxy-N-methyl-N-ethyltryptamine, 5-methoxy-N,N-diisopropyltryptamine, O-acetylpsilocin, methyl Isopropyllysergic acid diethylamide, ethylisopropyllysergic acid diethylamide, 6-allyl-6-nor-LSD, 6-ethyl-6-nor-lysergic acid diethylamide, 1-acetyl-LSD, 1-propionyl-6-ethyl-6-nor-lysergic acid diethylamide, 1-propionyl-lysergic acid diethylamide, 1-cyclopropionyl-d-lysergic acid diethylamide, N1-butyryl-lysergic acid diethylamide, 6-propyl-6-nor-lysergic acid Gic acid diethylamide, mescaline, 2,5-dimethoxy-4-bromophenethylamine (2C-B), 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine (2C-I), 2-(4-chloro-2,5-dimethoxyphenyl)ethan-1-amine (2C-C), 2,5-dimethoxy-4-iodoamphetamine, 2-[2,5-dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine, 2-(4-iodo-2,5-Dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine, racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, morphine, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl In some embodiments, the complexing agent is selected from the group consisting of cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, 3-methylthiofentanyl, naloxone, naltrexone, cathinone, 3,4-methylenedioxyamphetamine derivatives, aminoalkyl-substituted benzofurans, substituted amphetamines, aminoindan, stimulants, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, and 6-chloro-2-aminotetralin. In some embodiments, the molar ratio of the complexing agent to the pharmaceutical compound is from about 1:4 to about 1:10.
[0026] In embodiments, the complexing agent has formula (I):
[0027] [ka] or a stereoisomer, a mixture of stereoisomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, During the ceremony, R 1 are each independently H or optionally substituted alkyl, wherein at least one R 1 is substituted with an acidic functional group, R 2 are each independently H or optionally substituted alkyl, and n is 6, 7, or 8. In embodiments, R 1is a C substituted with one or more substituents independently selected from halogen, —C(O)OH, —N(H)C(O)OH, —S(O)OH, —OP(O)(OH) and —OC(O)OH; 1-8 In embodiments, R 1 The acidic functional group of C is substituted with one or more inorganic acids. 1-8 In embodiments, R 1 The acidic functional group of C is substituted with one or more organic acids. 1-8 In embodiments, the organic acid is selected from malonic acid, citric acid, tartaric acid, glutamic acid, phthalic acid, benzilic acid, cinnamic acid, fumaric acid, glutaric acid, gluconic acid, hexanoic acid, lactic acid, malic acid, folic acid, propiolic acid, propionic acid, tannic acid, trifluoroacetic acid, uric acid, ascorbic acid, gallic acid, acetylsalicylic acid, and acetic acid. 2 is H. In an embodiment, R 2 is the unsubstituted C 1-6 In embodiments, R 2 are halogens, -CN, -OH, -SH, -NO2, -NH2, =O, =S, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -N(C 1-6 alkyl)2, and -NH(C 1-6 C substituted with a group selected from alkyl 1-6 In an embodiment, n for a compound of Formula (I) is 6. In an embodiment, n for a compound of Formula (I) is 7. In an embodiment, n for a compound of Formula (I) is 8. In an embodiment, the complexing agent is sulfobutylether-β-cyclodextrin.
[0028] In another embodiment, there is provided a method for preparing a pharmaceutical composition, the method comprising the steps of: a) combining in a suitable liquid medium the free base form of a pharmaceutical compound containing at least one basic nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, wherein the pharmaceutical compound contains at least one basic nitrogen atom and is cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin; and b) the free acid form of a complexing agent containing at least one acidic functional group.
[0029] In another aspect is a method of preparing a pharmaceutical composition, the method comprising combining a pharmaceutically acceptable salt disclosed herein with an additional molar equivalent of a pharmaceutical compound disclosed herein, wherein the additional molar equivalent of the pharmaceutical compound is non-ionized.
[0030] In another aspect, a method for preparing a pharmaceutical composition is provided. The method comprises the steps of: (a) mixing in a suitable liquid medium a free base form of a pharmaceutical compound containing at least one nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, wherein the pharmaceutical compound contains at least one nitrogen atom and is cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin; and (b) a free acid form of a complexing agent containing at least one acidic functional group. In embodiments, the molar ratio of the pharmaceutical compound containing at least one basic nitrogen atom to the number of moles of acidic functional groups in the free acid form of the complexing agent is about 1:1 to about 10:1. In embodiments, the method further comprises adding an additional molar equivalent of the free base form of the pharmaceutical compound, hi embodiments, the step of adding an additional molar equivalent of the free base form of the pharmaceutical compound occurs after removing the liquid medium from the pharmaceutical composition.
[0031] Citation by reference All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. [Brief explanation of the drawings]
[0032] [Figure 1] 1 shows an exemplary structure of a compound-complexing agent salt provided herein. The compound-complexing agent salt shown is methoxetamine-SBEBCD salt. [Figure 2] 1 shows an exemplary structure of a methoxetamine-SBEBCD salt that further acts as an inclusion complex for an additional equivalent of free base methoxetamine. [Figure 3] 1 shows an exemplary structure of deschloroketamine-SBEBCD salt. [Figure 4]1 shows an exemplary structure of 3-methoxyphencyclidine-SBEBCD salt. [Figure 5] 1 shows an exemplary structure of a methoxyeticyclidine-SuACD salt. [Figure 6] 1 shows an exemplary structure of dextromethorphan-CMGCD salt. [Figure 7] FIG. 1 shows a schematic diagram of sublingual administration of ketamine-SBEBCD salt formulation. [Figure 8] FIG. 1 shows a schematic diagram of sublingual administration of a ketamine-SBEBCD salt formulation containing an excess of free base ketamine. [Figure 9] shows an exemplary structure of a compound-complexing agent salt provided herein. The compound-complexing agent salt shown is mescaline-SBEBCD salt. [Figure 10] 1 shows an exemplary structure of a mescaline-SBEBCD salt that further acts as an inclusion complex for an additional equivalent of free base mescaline. [Figure 11] 1 shows an exemplary structure of N,N-dimethyltryptamine-SBEBCD salt. [Figure 12] 1 shows an exemplary structure of 4-hydroxy-N-methyl-N-isopropyl-tryptamine-SBEBCD salt. [Figure 13] 1 shows an exemplary structure of 4-acetoxy-N-methyl-N-ethyl-tryptamine-SuACD salt. [Figure 14] 1 shows an exemplary structure of methylisopropyllysergamide-CMGCD salt. [Figure 15] FIG. 1 shows a schematic diagram of sublingual administration of a mescaline-SBEBCD salt formulation. [Figure 16] FIG. 1 shows a schematic diagram of sublingual administration of a mescaline SBEBCD salt formulation containing an excess of free base mescaline. [Figure 17] 1 shows an exemplary structure of an opioid-complexing agent salt provided herein. The opioid-complexing agent salt shown is a racemorphan-SBEBCD salt. [Figure 18] 1 shows an exemplary structure of a racemorphan-SBEBCD salt that further acts as an inclusion complex for an additional equivalent of free base racemorphan. [Figure 19] 1 shows an exemplary structure of levorphanol-SBEBCD salt. [Figure 20] 1 shows an exemplary structure of racemethorphan-SBEBCD salt. [Figure 21] 1 shows an exemplary structure of a fentanyl-SuACD salt. [Figure 22] 1 shows an exemplary structure of a buprenorphine-CMGCD salt. [Figure 23] 1 shows a schematic diagram of sublingual administration of a racemorphan-SBEBCD salt formulation. [Figure 24] FIG. 1 shows a schematic diagram of sublingual administration of a racemorphan-SBEBCD salt formulation containing an excess of free base racemorphan. [Figure 25] 1 shows an exemplary structure of a compound-complexing agent salt provided herein. The compound-complexing agent salt shown is 3-methylmethcathinone-SBEBCD salt. [Figure 26] 1 shows an exemplary structure of 3-methylmethcathinone--SBEBCD salt which further acts as an inclusion complex for an additional equivalent of free base 3-methylmethcathinone. [Figure 27] 1 shows an exemplary structure of diphenhydramine-SBEBCD salt. [Figure 28] 1 shows an exemplary structure of 1-(1,3-benzodioxol-5-yl)-N-methyl-2-butanamine (MBDB)-SBEBCD salt. [Figure 29] 1 shows an exemplary structure of 5-(2-aminopropyl)-benzofuran (5-APB)-SuACD salt. [Figure 30] 1 shows an exemplary structure of 5,6-methylenedioxy-2-aminoindan (MDAI)-CMGCD salt. [Figure 31] FIG. 1 shows a schematic diagram of sublingual administration of a 3-methylmethcathinone-SBEBCD salt formulation. [Figure 32] FIG. 1 shows a schematic diagram of sublingual administration of a 3-methylmethcathinone-SBEBCD salt formulation containing an excess of free base mescaline. [Figure 33]1 shows the appearance of an exemplary captisolic acid (CA)-N,N-dimethyltryptamine (DMT) salt solution at different time points in the absence and presence of light. [Figure 34] 1 shows the phase solubility curves of Captisol and flumazenil. [Figure 35] 1 shows the pH vs. concentration measurement curve of Me-3-MMC formulation (pH 7.0±0.1). [Figure 36] 1 shows the osmolality versus concentration measurement curve of Me-3-MMC formulations (pH 7.0±0.1). [Figure 37] 1 shows the pH vs. concentration measurement curve of Me-3-FMA formulation (pH 7.0±0.1). [Figure 38] 1 shows the osmolality versus concentration measurement curve of Me-3-FMA formulations (pH 7.0±0.1). [Figure 39] 1 shows the pH vs. concentration measurement curve of 5-MAPB formulation (pH 7.0±0.1). [Figure 40] 1 shows the osmolality versus concentration measurement curve of 5-MAPB formulations (pH 7.0±0.1). [Figure 41] 1 shows the pH vs. concentration measurement curves of diluted lidocaine formulations starting from 100 mg / mL lidocaine (FB equivalent) (pH 6.5±0.1). [Figure 42] 1 shows the osmolality versus concentration measurement curves of diluted lidocaine formulations starting from 100 mg / mL lidocaine (FB equivalent) (pH 6.5±0.1). [Figure 43] Representative HPLC traces for concentration determination are shown: 2-F-DCK FB-Cap acid formulation, procaine (2.202 min), 2-F-DCK (2.965 min), mobile phase 80% 10 mM ammonium formate aqueous buffer:20% acetonitrile. [Figure 44] Representative HPLC traces for concentration determination are shown: 3-FMA FB-Cap acid formulation, procaine (2.202 min), 3-FMA (3.460 min), mobile phase 80% 10 mM ammonium formate aqueous buffer:20% acetonitrile. [Figure 45]Representative HPLC traces for concentration determination are shown: 5-IAI FB-Cap acid formulation, procaine (1.745 min), 5-IAI (2.712 min), mobile phase 70% 10 mM ammonium formate aqueous buffer:30% acetonitrile. [Figure 46] Representative HPLC traces for concentration determination are shown: 5-MAPB FB-Cap acid formulation, procaine (2.227 min), 5-MAPB (4.695 min), mobile phase 80% 10 mM ammonium formate aqueous buffer:20% acetonitrile. [Figure 47] Representative HPLC traces for concentration determination are shown: DCK FB-Cap acid formulation, procaine (2.213 min), DCK (2.972 min), mobile phase 80% 10 mM ammonium formate aqueous buffer:20% acetonitrile. [Figure 48] Representative HPLC traces for concentration determination are shown: DXM FB-Cap acid formulation, procaine (1.756 min), DXM (5.859 min), mobile phase 70% 10 mM ammonium formate aqueous buffer:30% acetonitrile. [Figure 49] Representative HPLC traces for concentration determination are shown: Me-3-MMC FB-Cap acid formulation, procaine (2.217 min), Me-3-MMC (3.930 min), mobile phase 80% 10 mM ammonium formate aqueous buffer:20% acetonitrile. [Figure 50] Representative HPLC traces for concentration determination are shown: Morphine FB-Cap acid formulation, procaine (2.226 min), morphine (1.571 min), mobile phase 80% 10 mM ammonium formate aqueous buffer:20% acetonitrile. [Figure 51] A representative three-point calibration curve for concentration determination by HPLC:5-IAI is shown. N=3, error bars are SEM. [Figure 52] A representative three-point calibration curve for concentration determination by HPLC:2-F-DCK is shown. N=3, error bars are SEM. [Figure 53] A representative three-point calibration curve for concentration determination by HPLC:5-MAPB is shown. N=3, error bars are SEM. [Figure 54] A representative three-point calibration curve for concentration determination by HPLC:3-FMA is shown. N=3, error bars are SEM. [Figure 55] A representative three-point calibration curve for concentration determination by HPLC:3-MMC is shown. N=3, error bars are SEM. [Figure 56] A representative three-point calibration curve for concentration determination by HPLC:DCK is shown. N=3, error bars are SEM. [Figure 57] A representative three-point calibration curve for concentration determination by HPLC:Me-3-MMC is shown. N=1. [Figure 58] A representative three-point calibration curve for concentration determination by HPLC:morphine is shown. N=1. [Figure 59] 1 shows the measurement of pH of racemic ketamine HCl and racemic ketamine complex upon dilution. [Figure 60] 1 shows the titration of ketamine HCl and ketamine complexes with 1 M HCl. [Figure 61] 1 shows the measurement of osmolality of ketamine HCl and ketamine complexes upon dilution. DETAILED DESCRIPTION OF THE INVENTION
[0033] For example, provided herein are compositions comprising a salt of a pharmaceutical compound and a complexing agent as a counterion. Such salts are useful in various pharmaceutical compositions, including subcutaneous, intramuscular, intranasal, and sublingual formulations, for reducing irritation to tissue and / or skin tissue. In some aspects, the use of salts provided herein in subcutaneous, intranasal, or sublingual formulations is associated with reduced irritation to tissue at the administration site and increased solubility and bioavailability. In certain aspects, compositions comprising pharmaceutical compounds having a basic nitrogen atom are formulated for subcutaneous, sublingual, or intranasal administration. Also provided herein are methods for treating or preventing pain, or managing depression or opioid overdose, psychiatric disorders, cognitive disorders, neurological disorders, and various other disorders. In some embodiments, microdosing of pharmaceutical compounds with psychedelic properties provided herein is useful for treating various pain and inflammatory disorders.
[0034] I. Definition The abbreviations used herein have their conventional meaning within the chemical and biological arts. The chemical structures and formulas set forth herein are constructed according to the standard rules of chemical valency known in the chemical arts.
[0035] Where substituents are specified by their conventional chemical formula and written from left to right, they equally encompass the chemically identical substituents that result from writing the structure from right to left, e.g., -CH2O- is equivalent to -OCH2-.
[0036] As used herein, the term "about," when referring to a numerical value or range of values, takes into account the variability of the numerical value or range of values, for example, within 10%, or within 5% of the stated value or range of limits stated.
[0037] As used herein, the term "pharmaceutical compound" and similar such terms refer to any compound that can be administered to a subject and can provide any type of therapeutic benefit to the subject (such as treating or preventing a disease, alleviating symptoms of a disease or condition, or any purpose for which a pharmaceutical or drug can be used). Generally, these compounds can be small organic molecules, although other compounds, such as peptides, are also considered pharmaceutical compounds as used herein. In preferred embodiments, the pharmaceutical compound contains a basic nitrogen atom (e.g., an amine group) that can be protonated upon interaction with an acidic functional group, such as a carboxylic acid or sulfonic acid. When referring to pharmaceutical compositions, these compounds may be generally referred to as "active pharmaceutical ingredients" or "APIs." In some cases, the pharmaceutical compounds herein may be simply referred to as "compounds."
[0038] The terms "opioid pharmaceutical compound," "opioid drug," or "opioid," and similar such terms, are all used interchangeably, and the same meaning is intended by each term unless otherwise specified. The term may refer to any naturally occurring opioid or any synthetic homolog or analog. Additionally, any synthetic compound with similar biological activity at the opioid receptor of interest, as well as any compound with opioid antagonist activity (e.g., naltrexone or naloxone), are also intended to be encompassed. When referring to pharmaceutical compositions, these compounds may be commonly referred to as "active pharmaceutical ingredients" or "APIs."
[0039] As used herein, terms such as "comprising," "comprises," and the like are used in their typical sense, leaving any claim or embodiment in which such terms are used to accommodate additional elements, components, or features. However, in each formulation, salt, method, or other disclosure provided herein that uses the term "comprising," it is also contemplated that the formulation, salt, method, or other disclosure may be further limited to other elements, components, or features, as if the term "consisting of" were used in that place. Furthermore, it is also contemplated that the term "comprising" or the like may be similarly substituted for the term "consisting essentially of."
[0040] As used herein, "molar equivalent" refers to a comparison of moles of a substance compared to moles of another substance, reflecting that the comparison should be on a molar or molar basis (e.g., the ratio of moles of one compound to moles of another compound). Molar equivalents need not be integer values. For example, embodiments describing a pharmaceutical composition as comprising a "molar equivalent" of a substance indicate that the amount of substance present is measured in some molar concentration descriptor, e.g., 0.001 to 100 molar equivalents of additional equivalents of the substance, or any other range specified herein.
[0041] All component percentages are given as weight percent unless otherwise specified.
[0042] Average molecular weights of polymers are weight average molecular weights unless otherwise specified.
[0043] As used herein, "individual" (as the subject of treatment) refers to both mammals and non-mammals. Mammals include, for example, humans; non-human primates, such as apes and monkeys; and non-primates, such as dogs, cats, cows, horses, sheep, and goats. Non-mammals include, for example, fish and birds.
[0044] The terms "disease," "disorder," or "condition" refer to a state or condition of a patient or subject that is amenable to treatment with the compounds or methods provided herein. The disease can be a psychiatric disease or disorder. The disease can be a mood disorder. The disease can be an inflammatory disease. The disease can be a brain tumor. The disease can be a neurological disease or disorder. In some further examples, "mental illness or disorder" refers to human psychiatric illness or disorders, including major depressive disorder, treatment-resistant major depressive disorder, suicidal, suicidal disorder, mood disorder, bipolar I disorder, bipolar II disorder, post-traumatic stress disorder (PTSD), complex trauma, anorexia nervosa, bulimia nervosa, eating disorder NOS, obsessive-compulsive disorder, substance-related disorders (e.g., cannabis dependence or withdrawal, barbiturate dependence or withdrawal, benzodiazepine dependence or withdrawal, amphetamine dependence or withdrawal, opioid dependence or withdrawal, alcohol dependence or withdrawal, cocaine dependence or withdrawal), pain disorders, and inflammatory disorders. In some further examples, "neurological disease or disorder" refers to a human neurological disease or disorder, including chronic fatigue syndrome, chronic fatigue and immune deficiency syndrome, neuropathy, fibromyalgia, fibromyalgia syndrome, myoelectric encephalomyelitis, migraine, traumatic brain injury (TBI), stroke, dementia, amyotrophic lateral sclerosis, spinal cord injury, shingles, herpes zoster, radiculopathy, polyneuropathy, dyskinesia, dystonia, tinnitus, postherpetic neuralgia, complex regional pain syndrome, central pain syndrome, chronic pain, acute pain, phantom limb syndrome with pain, phantom limb syndrome without pain, myelitis, mood disorder, complex trauma, anorexia nervosa, bulimia nervosa, eating disorder NOS, obsessive-compulsive disorder, intermittent explosive disorder, sleep disorder, pain disorder, or inflammatory disorder. In some further examples, the brain tumor may be an acoustic neuroma, astrocytoma, brain metastasis, choroid plexus tumor, craniopharyngioma, embryonal tumor, ependymoma, glioblastoma, glioma, medulloblastoma, meningioma, oligodendroglioma, pediatric brain tumor, pinealoma, or pituitary tumor. In some examples, the disease, disorder, or condition is associated with substantial or significant pain. In some embodiments, a salt of a formulation provided herein is administered to a subject to manage pain. The pain may be associated with an appropriate condition for which an opioid pain management regimen is tolerated.In some embodiments, to treat a brain tumor, a subject is administered a salt of the formulations provided herein. In some embodiments, to treat a brain tumor, a subject is administered a salt of the following formulations: a pharmaceutical compound having a basic nitrogen atom, including a dissociative drug compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or a compound that modulates an NMDA receptor, ketamine, a derivative or analog of ketamine, methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticridone), 3-methoxyphencyclidine, methoxyeticlidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine.
[0045] The phrase "effective amount," when used to describe treatment for an individual suffering from a disorder, refers to an amount of a compound described herein that is effective to inhibit or otherwise affect the relevant receptor in the individual's tissue, such inhibition or other effect occurring to a degree sufficient to produce a beneficial therapeutic effect. The effective amount will vary based on the pharmaceutical compound, including but not limited to, an opioid or other API, used in the formulation, and the indication intended to be treated by the compound, including but not limited to, an opioid or other API.
[0046] "Substantially," as used herein, means completely or nearly completely. For example, a composition that is "substantially free" of a component either has none of the component or contains such a small amount that any relevant functional properties of the composition are not affected by the presence of the small amount. For example, a "substantially pure" compound has only trace amounts of impurities present.
[0047] Unless a particular stereochemical or isomeric form is specifically indicated, all chiral, diastereomeric, and / or racemic forms of a structure are intended. The compounds described herein can include enriched or resolved optical isomers at any or all asymmetric atoms, in any degree of enrichment, as is apparent from the description. Both racemic and diastereomeric mixtures, as well as individual optical isomers, can be isolated or synthesized to be substantially free of their enantiomeric or diastereomeric partners, and all are within the scope of this disclosure.
[0048] The inclusion of isotopic forms of one or more atoms in a molecule that differ from the atom's natural isotopic distribution in nature is referred to as an "isotopically labeled form" of the molecule. Unless a specific isotopic form of an atom is indicated, all isotopic forms of the atom are optionally included in the composition of any molecule. For example, any hydrogen atom or set of hydrogen atoms in a molecule may be any of the isotopic forms of hydrogen, i.e., protium ( 1 H), deuterium ( 2 H), tritium ( 3 Similarly, any carbon atom or set of carbon atoms in a molecule can be 11 C. 12 C. 13 C, or 14 C, or any nitrogen atom or set in the molecule. 13 N, 14 N, or 15 N. A molecule can contain any combination of isotopic forms in the component atoms that make up the molecule, and the isotopic forms of all atoms that make up the molecule are independently selected. In a multi-molecular sample of a compound, not all individual molecules necessarily have the same isotopic composition. For example, a sample of a compound may contain radioactive atoms such as tritium or uranium, where only a small fraction of the set of molecules that make up the macroscopic sample contain radioactive atoms. 14Many elements that are artificially isotopically enriched can themselves be isotopically enriched. 14 N and 15 N, 32 S and 34 It is equally understood that the isotopic forms are mixtures of naturally occurring isotopic forms such as S. Molecules listed herein are defined to include all isotopic forms of their constituents at each position in the molecule. As is well known in the art, isotopically labeled compounds can be prepared by conventional methods of chemical synthesis, except for the exchange of isotopically labeled precursor molecules. Radiolabeled or stable isotopes can be obtained by methods known in the art, such as neutron absorption of precursor nuclides in a nuclear reactor, cyclotron reactions, or generation by mass spectrometry. The isotopic forms can be incorporated into precursors as needed for use in any particular synthetic route. For example, 14 C and 3 H can be prepared using neutrons produced in a nuclear reactor. After transmutation, 14 C and 3 H is incorporated into the precursor molecule, followed by further synthesis as needed.
[0049] A "hydrate" is a compound present in a composition that includes water molecules. The composition may include water in a stoichiometric amount, such as a monohydrate or dihydrate, or may include water in any amount. As used herein, "hydrate" refers to a compound in solid form, i.e., in an aqueous solution, but may be hydrated, not a hydrate as used herein.
[0050] A "solvate" is a similar composition except that a solvent other than water replaces the water. For example, methanol or ethanol can form an "alcoholate," which again can be stoichiometric or non-stoichiometric. As the term is used herein, a "solvate" is a compound in solid form, i.e., in solution in a solvent, but which may be solvated, rather than a solvate as used herein.
[0051] A "prodrug," as known to those skilled in the art, is a substance that can be administered to a patient, which is converted in vivo by the action of biochemicals in the patient's body, such as enzymes, on an active pharmaceutical ingredient. Examples of prodrugs include esters of carboxylic acid groups that can be hydrolyzed by endogenous esterases, such as those found in the bloodstream of humans and other mammals. Further examples of prodrugs include boronic acid esters that are hydrolyzable under physiological conditions to provide the corresponding boronic acids. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs," ed. H. Bundgaard, Elsevier, 1985.
[0052] In various embodiments, a compound shown in any of the Examples or in the Exemplary Compounds is provided.
[0053] Conditions may be applied to any of the disclosed categories or embodiments, and any one or more of the other above-disclosed embodiments or species may be excluded from such category or embodiment.
[0054] Isomerism in the compounds described herein optical isomerism When the compounds of the present disclosure contain one or more chiral centers, the compounds may exist in or be isolated as pure enantiomeric or diastereomeric forms or racemic mixtures. Accordingly, the present disclosure includes any possible enantiomers, diastereomers, racemates, or mixtures thereof of the compounds described herein.
[0055] Isomers resulting from the presence of chiral centers comprise a pair of non-superimposable isomers called "enantiomers." Single enantiomers of a pure compound are optically active; that is, they can rotate the plane of plane-polarized light. Single enantiomers are designated according to the Cahn-Ingold-Prelog system. Substituent priorities are ranked based on atomic weight, with higher atomic weights determined by a systematic procedure having higher priority. Once the priority order of the four groups is determined, the molecule is oriented so that the lowest-ranked group is pointed away from the viewer. If the other groups in descending order proceed clockwise, the molecule is designated (R); if the other groups in descending order proceed counterclockwise, the molecule is designated (S). In the following example, the Cahn-Ingold-Prelog ranking is A>B>C>D. The lowest-ranked atom, D, is oriented away from the viewer.
[0056] [ka]
[0057] The present disclosure is intended to encompass diastereomers as well as their racemic and resolved diastereomerically pure, enantiomerically pure forms and salts. Diastereomeric pairs may also be resolved by known separation techniques, including normal phase and reverse phase chromatography, and crystallization.
[0058] "Isolated optical isomer" means a compound that has been substantially purified from the corresponding optical isomer of the same formula. Preferably, the isolated isomer is at least about 80% by weight pure, more preferably at least 90% by weight pure, even more preferably at least 98% by weight pure, and most preferably at least about 99% by weight pure.
[0059] The resolved optical isomers may be purified from the racemic mixture by well-known chiral separation techniques. According to one such method, a racemic mixture of the compounds described herein, or a chiral intermediate thereof, is separated into 99% weight-pure optical isomers by HPLC using a suitable chiral column, such as a member of the DAICEL® CHIRALPAK® family of columns (Daicel Chemical Industries, Ltd., Tokyo, Japan). The column is operated according to the manufacturer's instructions.
[0060] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; enantiomers, racemates, diastereomers, tautomers, geometric isomers, and stereoisomeric forms may be defined, in terms of absolute stereochemistry, as (R)- or (S)-, or (D)- or (L)- for amino acids; and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include those known in the art to be too unstable to synthesize and / or separate. The present disclosure is intended to include compounds in racemic and optically pure form. Optically active (R)- and (S)-, or (D)- and (L)-, isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques. Where the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless otherwise specified, it is intended that the compounds include both E and Z geometric isomers.
[0061] As used herein, the term "isomers" refers to compounds that have the same number and kind of atoms, and hence the same molecular weight, but differ with respect to the structural arrangement or configuration of the atoms.
[0062] The term "tautomer," as used herein, refers to one of two or more structural isomers that exist in equilibrium and are readily converted from one isomeric form to another.
[0063] It will be apparent to one of ordinary skill in the art that certain compounds of the present disclosure exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the present disclosure.
[0064] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure, e.g., R and S configurations of each asymmetric center. Thus, single stereochemical isomers, as well as enantiomeric and diastereomeric forms of the compounds of the invention, are within the scope of the disclosure.
[0065] "Alkyl" refers to a straight or branched hydrocarbon chain radical, consisting solely of carbon and hydrogen atoms, which may optionally be unsaturated with one or more double or triple bonds, and preferably contains from 1 to 15 carbon atoms (e.g., C1-C 15 In certain embodiments, the alkyl group has 1 to 6 carbon atoms (e.g., C1-C6 alkyl). In certain embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), and 1-pentyl (n-pentyl). The alkyl is attached to the remainder of the molecule by a single bond. Unless otherwise specified, the term "alkyl" and its equivalents encompass straight-chain, branched, and / or cyclic alkyl groups. In some examples, "alkyl" includes both cyclic and acyclic (straight-chain and / or branched) alkyl moieties.
[0066] The term "substituted" refers to moieties having substituents replacing a hydrogen on one or more carbon or heteroatoms of the structure. "Substituted" or "substituted with" includes the implicit proviso that such substitution is in accordance with the allowed valences of the substituted atom and substituent, and that the substitution results in a stable compound that does not spontaneously undergo transformation, for example, by rearrangement, cyclization, elimination, and the like. As used herein, the term "substituted" is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds.
[0067] Substituents can include any substituent, such as halogen, hydroxyl, carbonyl (e.g., oxo (=O), carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioxo (=S), thioester, thioacetate, or thioformate), alkoxyl, phosphoryl, phosphate, phosphonate, phosphinate, amino, amido, amidine, imine, oximo, hydrazino, cyano, nitro, azido, sulfhydryl, alkyl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamido, sulfonyl, heterocyclyl, aralkyl, carbocycle, heterocycle, cycloalkyl, heterocycloalkyl, aromatic, and heteroaromatic moieties.
[0068] As used herein, "acidic functional group" or similar terms (e.g., "acidic functionality") refer to a chemical moiety that contains at least one dissociable proton (or isotopic variant thereof) or conjugate base (e.g., a deprotonated anion) of an acidic functional group. In certain embodiments, the dissociable proton dissociates from the chemical moiety at common pHs in aqueous systems (e.g., a pH of about 1 to about 14). In certain preferred embodiments, the dissociable proton dissociates from the chemical moiety in aqueous systems at a pH below 7 (e.g., having a pKa value below 7, such as a pKa below 6, below 5, below 4, below 3, below 2, or below 1). As will be understood by those of skill in the art, whether an acidic functional group contains a dissociable proton depends on the conditions of the system in which the chemical moiety is present (e.g., the pH of the aqueous system containing the molecule with the acidic functional group or the presence of any basic molecules). Thus, as used herein, the term "acidic functional group" (or reference to a particular acidic functional group, such as a carboxylic acid or sulfonic acid) is intended to encompass protonated versions of the moiety, deprotonated versions of the moiety, and any salts of the moiety, unless otherwise specified.
[0069] Unless otherwise stated, structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms (e.g., isotopic variants), such as the replacement of a hydrogen by deuterium or tritium; 13 C or 14 Compounds having the present structures except for the replacement of a carbon with a C-enriched carbon are within the scope of this disclosure.
[0070] The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may contain isotopes of, for example, tritium ( 3 H), iodine-125( 125 I), or carbon-14 ( 14 C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.
[0071] The terms "a" or "an," as used herein, mean one or more. Additionally, the phrase "substituted with one (a[n])...," as used herein, means that the specified group can be substituted with any one or more or all of the specified substituents. For example, when a group such as alkyl or heteroaryl is substituted with an unsubstituted C-C 20 When substituted with alkyl or unsubstituted 2-20 membered heteroalkyl, the group may contain one or more unsubstituted C-C 20 It may contain alkyl, and / or one or more unsubstituted 2-20 membered heteroalkyl.
[0072] As is well known to those skilled in the art, "salts" include organic compounds, such as carboxylic acids, sulfonic acids, or amines, in ionic form in combination with a counterion. For example, such anionic acids can form salts with cations such as metal cations, e.g., sodium, potassium, ammonium salts such as NH4, or cations of various amines, including tetraalkylammonium salts such as tetramethylammonium, or other cations such as trimethylsulfonium. The terms "pharmaceutically acceptable salts" and / or "pharmacologically acceptable salts" are intended to include salts of active compounds prepared with relatively non-toxic acids or bases, depending on the particular substituents found on the compounds described herein. When a compound of the present disclosure contains a relatively acidic functionality, a base addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of the desired base in a neat or suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salts, or similar salts. When a compound of the present disclosure contains a relatively basic functionality, an acid addition salt can be obtained by contacting the neutral form of such a compound with a sufficient amount of the desired acid in a neat or suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, as well as salts derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isobutyric acid, maleic acid, malonic acid, benzoic acid, succinic acid, sublingual acid, fumaric acid, lactic acid, mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, oxalic acid, or methanesulfonic acid.Also included are salts of amino acids such as arginine acid, and salts of organic acids such as glucuronic acid or galacturonic acid (see, e.g., Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0073] Thus, the compounds of the present disclosure may exist as salts with pharmaceutically acceptable acids, etc. The present disclosure includes such salts. Non-limiting examples of such salts include hydrochloride, hydrobromide, phosphate, sulfate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, propionate, tartrate (e.g., (+)-tartrate, (-)-tartrate, or a mixture thereof, including a racemic mixture), succinate, benzoate, and salts with amino acids such as glutamic acid, and quaternary ammonium salts (e.g., methyl iodide, ethyl iodide, etc.). Such salts can be prepared by methods known to those skilled in the art.
[0074] The neutral form of the compound is preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents. In certain embodiments, the compounds of the present disclosure contain both basic and acidic functionality, allowing the compound to be converted to either a base or an acid addition salt. The neutral form of the compound may be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. Although the parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, the salts disclosed herein are equivalent to the parent form of the compound for purposes of this disclosure, unless otherwise indicated.
[0075] In addition to salt forms, the present disclosure provides compounds in prodrug form. Prodrugs of the compounds described herein are compounds that easily undergo chemical changes under physiological conditions to provide the compounds of the present disclosure. Prodrugs of the compounds described herein can be converted in vivo after administration. In addition, prodrugs can be converted to the compounds of the present disclosure by chemical or biochemical methods in an ex vivo environment, for example, when contacted with a suitable enzyme or chemical reagent.
[0076] Certain compounds of the present disclosure can exist in solvated forms as well as unsolvated forms, including hydrated forms. Usually, solvated forms are equivalent to unsolvated forms and are included within the scope of the present disclosure. Certain compounds of the present disclosure can exist in multiple crystalline or amorphous forms. Usually, all physical forms are applicable to the applications contemplated by the present disclosure and are intended to be within the scope of the present disclosure.
[0077] "Pharmaceutically acceptable excipient" and "pharmaceutically acceptable carrier" refer to substances that aid in the administration and absorption of a compound by a subject and that can be included in the compositions of the present disclosure without causing significant adverse toxicological effects to the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, saline, lactated Ringer's solution, standard sucrose, standard glucose, complexing agents (e.g., cyclodextrins), binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavoring agents, salt solutions (such as Ringer's solution), alcohol, oils, gelatin, carbohydrates such as lactose, amylose, or starch, fatty acid esters, hydroxymethylcellulose, polyvinyl pyrrolidine, and coloring agents. Such preparations are sterilized and, if desired, may be mixed with auxiliary substances such as lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure, buffers, coloring agents, and / or flavoring agents that do not deleteriously react with the compounds of the present disclosure. Those skilled in the art will recognize that other pharmaceutical excipients are useful in the present disclosure.
[0078] The term "preparation" is intended to include formulations of active compounds with encapsulating material as a carrier, providing a capsule, in which the active ingredient, with or without other carriers, is surrounded by, and thus associated with, a carrier. Cachets and lozenges are also included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
[0079] The term "treat" or "treatment" refers to any indicia of success in treating or ameliorating an injury, disease, condition, or illness, including any objective or subjective parameter such as relief, remission, a decrease in symptoms or damage, making the condition or illness more tolerable to the patient, slowing the rate of degeneration or decline, making the end point of degeneration less severe, or an improvement in the patient's physical or mental well-being. Treatment or amelioration of symptoms can be based on objective or subjective parameters, including the results of a physical examination, neuropsychiatric examination, and / or psychiatric evaluation. The term "treating" and its conjugations can include prevention of an injury, condition, illness, or illness. In certain embodiments, treatment is prevention. In certain embodiments, treatment does not include prevention.
[0080] As used herein (and as known in the art), "treating" or "treatment" broadly encompasses any approach to achieving a beneficial or desired outcome in a subject's disease, including clinical results. Beneficial or desired clinical results include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, reduction in the extent of disease, stabilization of disease (i.e., a state in which the disease does not worsen), prevention of disease spread or progression, delay or slowing of disease progression, improvement or alleviation of disease status, reduction in disease recurrence, and remission, whether partial or total, and whether detectable or undetectable. In other words, "treatment" as used herein includes any cure, amelioration, or prevention of disease. Treatment can prevent disease from occurring, inhibit the spread of disease, relieve symptoms of disease (e.g., eye pain, seeing halos around lights, red eyes, very high intraocular pressure), completely or partially eliminate the underlying cause of disease, shorten the duration of disease, or a combination thereof. Associated symptoms vary depending on the intended indication for a particular API.
[0081] As used herein, "treating" and "treatment" may also include preventive treatment. A treatment method includes administering a therapeutically effective amount of a compound described herein to a subject. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on various factors, such as the severity of the disease, the age of the patient, the concentration of the compound, the activity of the composition used in the treatment, or a combination thereof. It will also be understood that the effective amount of an agent used for treatment or prevention may be increased or decreased during a particular treatment or prevention regimen. Changes in dosage may occur and be evident using standard diagnostic assays known in the art. In some instances, long-term administration may be required. For example, a composition is administered to a subject for a period sufficient to treat the patient with a certain amount.
[0082] The term "preventing" refers to a reduction in the occurrence of disease symptoms in a patient. As noted above, prevention can be complete (no detectable symptoms) or partial, such that fewer symptoms are observed than would occur without treatment. In certain embodiments, prevention refers to slowing the progression of a disease, disorder, or condition or inhibiting its progression to an adverse or otherwise undesirable state.
[0083] "Patient" or "subject in need" refers to a living organism suffering from or susceptible to a disease or disorder that can be treated by administration of a pharmaceutical composition as provided herein. Non-limiting examples include humans, other mammals, cattle, rats, mice, dogs, monkeys, goats, sheep, cows, deer, and other non-mammals. In some embodiments, the patient is a human.
[0084] An "effective amount" is an amount of a compound sufficient to achieve its stated purpose compared to the absence of the compound (e.g., achieve the effect for which the compound is administered, treat a disease, reduce enzyme activity, increase enzyme activity, decrease a signaling pathway, or reduce one or more symptoms of a disease or disorder). An example of an "effective amount" is an amount sufficient to cause the treatment, prevention, or reduction of a symptom of a disease, which may also be referred to as a "therapeutically effective amount." A "reduction" of a symptom (and grammatical equivalents of this phrase) refers to a decrease in the severity or frequency of the symptom, or the elimination of the symptom. A "prophylactically effective amount" of a drug is an amount of drug that, when administered to a subject, has an intended prophylactic effect, such as preventing or delaying the onset (or recurrence) of an injury, disease, condition, or disorder, or reducing the likelihood of the onset (or recurrence) of an injury, disease, condition, or disorder, or a symptom thereof. A complete prophylactic effect does not necessarily occur with the administration of a single dose, but may occur only after the administration of a series of doses. Thus, a prophylactically effective amount may be administered in one or more administrations. As used herein, an "activity-reducing amount" refers to the amount of antagonist required to reduce the activity of an enzyme relative to the absence of the antagonist. A "function-interfering amount" refers to the amount of antagonist required to interfere with the function of an enzyme or protein relative to the absence of the antagonist. The exact amount will depend on the purpose of the treatment and can be determined by those skilled in the art using known techniques (see, for example, Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins).A therapeutically effective amount can be ascertained by measuring relevant physiological effects, and can be adjusted in conjunction with dosing regimens and diagnostic analyses of a subject's condition, etc. By way of example, measurement of serum levels of an inhibitor (or, e.g., a metabolite thereof) at a particular time after administration can indicate whether a therapeutically effective amount has been administered.
[0085] For any compound described herein, the therapeutically effective amount can be initially determined from cell culture assays. The target concentration is the concentration of active compound that is capable of achieving the methods described herein, as measured using methods described herein or known in the art.
[0086] As is well known in the art, therapeutically effective amounts for human use can also be determined from animal models.For example, the dosage for humans can be formulated to achieve the concentration found to be effective in animals.The dosage in humans can be adjusted by monitoring the effect of the compound and adjusting the dosage upward or downward, as described above.Based on the above-mentioned methods and other methods, it is within the ability of a person skilled in the art to adjust the dosage to achieve maximum efficacy in humans.Based on the above-mentioned methods and other methods, it is within the ability of a person skilled in the art to adjust the dosage to achieve maximum therapeutic efficacy or toxicity in humans.
[0087] As used herein, the term "therapeutically effective amount" refers to an amount of a therapeutic agent sufficient to ameliorate a disorder described herein. For example, for a given parameter, a therapeutically effective amount may exhibit at least a 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or 100% increase or decrease. The effectiveness of a therapeutic agent may also be expressed as a "-fold" increase or decrease. For example, a therapeutically effective amount may have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or greater effect relative to a control.
[0088] Dosage may vary depending on the requirements of the patient and the compound being utilized. The dose administered to a patient must be sufficient to achieve a beneficial therapeutic response in the patient over time, in the context of the present disclosure. The size of the dose is also determined by the existence, nature, and extent of any side effects. Determining the appropriate dosage for a particular situation is within the skill of the practitioner. Generally, treatment is initiated with a low dosage that is less than the optimal amount of the compound. Thereafter, the dosage is increased by small increments until the optimal effect under the circumstances is reached. The amount and interval of administration can be individually adjusted to provide a level of the administered compound that is effective for the particular clinical indication being treated. This results in a treatment regimen commensurate with the severity of the individual's condition.
[0089] As used herein, the term "administration" refers to subcutaneous (i.e., "SC," "subQ," or "SQ") administration, oral administration, administration as a suppository, topical contact or administration, intravenous, parenteral, intraperitoneal, intramuscular, intraosseous, intralesional, intrathecal, intracranial, intranasal, epidural, or implantation of a sustained-release device, e.g., a mini-osmotic pump, into a subject. Administration is by any route, including parenteral and oral mucosa (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal). Parenteral administration includes, for example, intravenous, intramuscular, intraarteriolar, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other delivery methods include, but are not limited to, the use of liposomal formulations, intravenous injection, transdermal patches, and the like. "Concurrent administration" means that the compositions described herein are administered simultaneously with, immediately before, or immediately after the administration of one or more additional therapies (e.g., anti-cancer agents, chemotherapeutic agents, or treatments for neurodegenerative diseases). The compounds of the present disclosure can be administered singly or simultaneously to a patient. Simultaneous administration is intended to include simultaneous or sequential administration of compounds, individually or in combination (more than one compound or agent). Thus, preparations can be combined with other agents, if desired (e.g., to reduce metabolic degradation). Compositions of the present disclosure can be formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, pigments, powders, and aerosols for transdermal topical delivery. Oral preparations include tablets, pills, powders, dragees, capsules, liquids, lozenges, cachets, gels, syrups, slurries, suspensions, and the like, suitable for ingestion by a patient. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. Liquid preparations include solutions, suspensions, and emulsions, such as water or water / propylene glycol solutions. The compositions of the present disclosure may further comprise ingredients for sustained release and / or comfort. Such ingredients include high molecular weight anionic mucomimetic polymers, gelling polysaccharides, and finely divided drug carrier matrices.These components are discussed in more detail in U.S. Patent Nos. 4,911,920, 5,403,841, 5,212,162, and 4,861,760. The entire contents of these patents are incorporated herein by reference in their entirety for all purposes. The compositions of the present disclosure can also be delivered as microspheres for sustained release in the body. For example, the microspheres can be administered via intradermal injection of drug-containing microspheres that slowly release subcutaneously (see Rao, J. Biomater Sci. Polym. Ed. 7:623-645, 1995), as biodegradable and injectable gel formulations (see, e.g., Gao Pharm. Res. 12:857-863, 1995), or as microspheres for oral administration (see, e.g., Eyles, J. Pharm. Pharmacol. 49:669-674, 1997). In another embodiment, formulations of the compositions of the present disclosure can be delivered using liposomes that fuse with cell membranes or undergo endocytosis, for example, by using liposome-bound receptor ligands that bind to cell surface membrane protein receptors that result in endocytosis. The use of liposomes can focus delivery of the compositions of the present disclosure to target cells in vivo, particularly if the liposome surface carries receptor ligands specific to the target cells or is otherwise preferentially oriented to a particular organ. (See, for example, Al-Muhammed, J. Microencapsul. 13:293-306, 1996; Chonn, Curr. Opin. Biotechnol. 6:698-708, 1995; Ostro, Am. J. Hosp. Pharm. 46:1576-1587, 1989). The compositions of the present disclosure can also be delivered as nanoparticles.
[0090] As used herein, "co-administering" means that the compositions described herein are administered simultaneously with, immediately before, or immediately after the administration of one or more additional therapeutic agents. The compounds of the present disclosure can be administered alone or simultaneously to a patient. Co-administration is intended to include simultaneous or sequential administration of compounds, individually or in combination (more than one compound). The compositions of the present disclosure can be delivered transdermally, topically, or formulated as applicator sticks, solutions, suspensions, emulsions, gels, creams, ointments, pastes, jellies, pigments, powders, and aerosols.
[0091] The teachings provided herein can be used to design effective prophylactic or therapeutic treatment regimens that do not cause substantial toxicity and are effective in treating the clinical symptoms exhibited by a particular patient. This plan should involve careful selection of active compounds by considering factors such as the potency of the compound, relative bioavailability, the patient's weight, the presence and severity of adverse side effects, the preferred mode of administration, and the toxicity profile of the selected agent.
[0092] The compounds described herein can be used in combination with each other and with other active agents known to be useful in treating psychiatric diseases or disorders, mood disorders, neurological diseases or disorders, metabolic disorders (e.g., type 2 diabetes and / or its complications), endometriosis, glaucoma, pain, or inflammatory disorders.
[0093] In some embodiments, simultaneous administration includes administering one active agent within 0.5, 1, 2, 4, 6, 8, 10, 12, 16, 20, 24 hours, 2 days, 4 days, 1 week, or 1 month of a second active agent. Simultaneous administration includes administering two active agents simultaneously, nearly simultaneously (e.g., within about 1, 5, 10, 15, 20, or 30 minutes of each other), or sequentially in any order. In some embodiments, simultaneous administration can be achieved by co-formulation, e.g., preparing a single pharmaceutical composition containing both active agents. In other embodiments, the active agents can be formulated separately. In another embodiment, the active agents and / or adjuncts can be linked or conjugated to each other. In some embodiments, the compounds described herein may be combined with treatments for infection (e.g., bacterial infection), inflammation, and / or vasodilation.
[0094] The compounds described herein can be administered to treat metabolic diseases or disorders (e.g., type 2 diabetes and / or its complications), psychiatric diseases or disorders, mood disorders, neurological conditions or disorders, endometriosis, glaucoma, pain, or inflammatory disorders.In this regard, the compounds disclosed herein can be administered alone to treat such diseases or disorders, or can be administered together with another therapeutic agent to treat such diseases or disorders.
[0095] The compounds disclosed herein may be co-administered with other active agents, including, but not limited to, antidepressants, antipsychotics, anti-inflammatory agents, anxiolytic agents, and / or analgesics.
[0096] The APIs disclosed herein (e.g., ketamine, methoxetamine, deschloroketamine, tryptamine, phenethylamine, lysergamide compounds, opioids, cathinone compounds, 3,4-methylenedioxyamphetamine compound derivatives, aminoalkyl-substituted benzofurans, substituted amphetamines, aminoindan, stimulants, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin) may be administered once daily until the study endpoint is reached. The inhibitors disclosed herein may be administered at least three times, although in some studies, four or more times may be administered depending on the length and / or design of the study.
[0097] The term "bioavailability (F)" as used herein refers to the fraction of a dose of a drug (e.g., epinephrine) that is absorbed from its site of administration and reaches the systemic circulation in an unchanged form. The term "absolute bioavailability" is used when the fraction of a drug absorbed is related to its IV bioavailability. This can be calculated using the following formula:
[0098]
number
[0099] Relative bioavailability (F rel The term ) is used to compare two different extravascular routes of drug administration and can be calculated using the following formula:
[0100]
number
[0101] The term "clearance (CL)," as used herein, refers to the rate at which a drug is eliminated divided by its plasma concentration, giving the plasma volume from which the drug is completely removed per unit time. CL is calculated by multiplying the elimination rate constant (λ) by the volume of distribution (V d ) is equal to "V d " is the fluid volume required to contain the amount of drug present in the body at the same concentration as in plasma. As used herein, the term "apparent clearance (CL / F)" refers to the clearance without taking into account the bioavailability of the drug. It is the ratio of dose to AUC.
[0102] "Control" or "control experiment" is used according to its simple and ordinary meaning and refers to an experiment in which an experimental subject or reagent is treated in parallel with the experiment except for the omission of an experimental procedure, reagent, or variable. In some instances, a control is used as a standard of comparison in evaluating experimental efficacy. In some embodiments, a control is a measurement of protein activity in the absence of a compound as described herein (including in the embodiments and examples).
[0103] Generally, dosage levels of the pharmaceutical compound (API) in the composition can range from about 5 μg / kg to about 10 mg / kg, about 0.5 mg / kg to about 5 mg / kg, about 1 mg / kg to about 3 mg / kg, or a fixed dose of about 10-100 mg, or 20-75 mg, or 3-60 mg, or 10-250 mg, or 10-400 mg, or an amount greater than 400 mg.
[0104] "Substantially pure" indicates that a component constitutes more than about 50% of the total content of the composition, typically more than about 60% of the total content. More typically, "substantially pure" refers to a composition in which the component of interest constitutes at least 75%, at least 85%, at least 90% or more of the total composition. In some cases, the polypeptide constitutes more than about 90%, or more than about 95% (percentage on a weight / weight basis) of the total content of the composition.
[0105] It should be noted that throughout this application, alternatives are written as Markush groups, e.g., at each amino acid position containing more than one possible amino acid. It is specifically contemplated that each member of a Markush group is considered separately, thereby comprising alternative embodiments, and that a Markush group is not to be read as a single unit.
[0106] "Contacting" is used according to its simple ordinary meaning and refers to a process that allows at least two distinct species (e.g., chemical compounds, including biological molecules or cells) to be in sufficient proximity to react, interact, or come into physical contact. It will be understood, however, that the resulting reaction product may be produced directly from the reaction between the added reagents or from an intermediate from one or more of the added reagents that may be produced in the reaction mixture.
[0107] The term "contacting" includes allowing two species to react, interact, or come into physical contact, where the two species can be a compound as described herein and a protein or enzyme. In some embodiments, contacting includes allowing a compound described herein to interact with a protein or enzyme involved in a signaling pathway (e.g., a MAP kinase pathway).
[0108] As defined herein, the terms "activation," "activate," "activating," and the like, with respect to proteins, refer to the conversion of a protein from an initial inactive or inactivated state to a biologically active derivative. These terms refer to activation, or activating, sensitizing, or upregulating signal transduction, enzyme activity, or the amount of protein reduction in disease.
[0109] The terms "agonist," "activator," "upregulator," and the like refer to a substance capable of detectably increasing the expression or activity of a given gene or protein. An agonist can increase expression or activity by 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or more compared to a control in the absence of the agonist. In particular examples, expression or activity is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold or more greater than expression or activity in the absence of the agonist. In embodiments, an agonist is a molecule that interacts with a target to cause or promote increased activation of the target. In embodiments, an activator is a molecule that increases, activates, promotes, enhances, sensitizes, or upregulates, for example, a gene, protein, ligand, receptor, or cell.
[0110] The "activity" of a molecule can describe or refer to the binding of the molecule to a ligand or receptor, catalytic activity, ability to stimulate gene expression or cell signaling, differentiation, or maturation, antigenic activity, modulation of the activity of other molecules, etc.
[0111] As used herein, the term "osmolality" is defined as the number of osmolalities (Osm) of solute per kilogram of solvent (osmol / kg or Osm / kg).
[0112] As used herein, the term "osmolality" is defined as the number of osmolalities of a solute per liter (L) of solution (osmol / L or Osm / L).
[0113] Osmolality can be calculated from osmolality as follows: Osmolality = Osmolality x (ρ sol -c a ), where ρ sol is the density of the solution in g / mL, and c ais the (anhydrous) solute concentration in g / mL. Unless otherwise specified, osmolality is calculated using osmolality according to the formula above. Alternatively, osmolality can be calculated experimentally.
[0114] II. Composition Complexing agent salts of pharmaceutical compounds Provided herein are salts of the conjugate acid form of a pharmaceutical compound containing at least one basic nitrogen and the conjugate base form of a complexing agent. Such salts have advantages over other salts of the compound because they are more soluble than many other salt forms due to the properties of the complexing agent and its ability to solubilize the compound. Furthermore, in some embodiments, the preparation of such complexing agent / pharmaceutical compound salts produces compositions with lower molar concentrations in solution or in solution than the combination of each component or the individual salts of each component individually.
[0115] In one aspect, provided herein is a pharmaceutically acceptable salt of a pharmaceutical compound, the pharmaceutically acceptable salt comprising: (i) a pharmaceutical compound comprising a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a conjugate base of a complexing agent comprising a plurality of acidic functional groups, wherein the conjugate base of the complexing agent acts as a counterion for the pharmaceutical compound, and the pharmaceutical compound is selected from the group consisting of a dissociative drug, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diamino-2-methyl-2-propanol ... diarylethylamines, beta-keto-arylcyclohexylamines, compounds that modulate NMDA receptors, tryptamines, phenethylamines, lysergamide compounds, opioids containing a protonated nitrogen atom, cathinones, 3,4-methylenedioxyamphetamine derivatives, benzofurans, substituted amphetamines, aminoindans, stimulants, diphenhydramine, hydroxazines, phenylephrine, dopamine adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin. In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, 3-methylthiofentanyl, naloxone, or naltrexone. In some embodiments, the opioid is an opioid receptor antagonist. In some embodiments, the opioid receptor antagonist is naloxone or naltrexone.
[0116] In some embodiments, the plurality of acidic functional groups comprises an acidic group that acts as a counterion to a protonated nitrogen atom of the pharmaceutical compound. In some embodiments, the acidic group is a conjugate base of the acidic group. In some embodiments, the acidic group is a carboxylic acid or a carboxylate. In some embodiments, the acidic group is a carboxylate. In some embodiments, the acidic group is a sulfonic acid or a sulfonate. In some embodiments, the acidic group is a sulfonate. In some embodiments, the conjugate base of the complexing agent acts as a counterion to the plurality of pharmaceutical compounds. Each acidic group of the plurality of acidic functional groups acts as a counterion to the plurality of pharmaceutical compounds. In some embodiments, each acidic group of the plurality of acidic functional groups acts as a counterion to a protonated amine of the plurality of pharmaceutical compounds. In some embodiments, each acidic functional group acts as a counterion to a protonated amine.
[0117] In some embodiments, the complexing agent is a cyclodextrin substituted with multiple acidic functional groups. In some embodiments, the multiple acidic functional groups are carboxylic acids, sulfonic acids, sulfinic acids, phosphonic acids, or phosphinic acids, or any combination thereof. In some embodiments, the cyclodextrin is substituted with at least one, at least two, at least three, at least four, at least five, or at least six acidic functional groups. In some embodiments, the cyclodextrin is substituted with 3 to 8 acidic functional groups, 3 to 7 acidic functional groups, 4 to 8 acidic functional groups, 4 to 7 acidic functional groups, 5 to 8 acidic functional groups, 6 to 8 acidic functional groups, or 7 to 8 acidic functional groups.
[0118] In some embodiments, the complexing agent is a substituted cyclodextrin. In some cases, the substituted cyclodextrins provided herein are complex mixtures in which individual cyclodextrin molecules may contain a different number of substituents than other individual cyclodextrin molecules. In such cases, the number of substituents (e.g., the number of acidic functional groups) described as being present on a cyclodextrin provided herein may refer to the average degree of substitution of the mixture. For example, if a cyclodextrin is described as being substituted with 3 to 8 acidic functional groups, it is intended to encompass a complex mixture of cyclodextrins having an average degree of substitution of 3 to 8 acidic functional groups. The average degree of substitution need not be an integer value and is often a decimal value. For example, commercially available SBEBCD has an average degree of substitution of about 6.5.
[0119] In some embodiments, the complexing agent is a substituted cyclodextrin. In some embodiments, the substituted cyclodextrin is substituted with one or more acidic functional groups, or pharmaceutically acceptable salts thereof. In some embodiments, the substituted cyclodextrin is substituted with multiple carboxylic, sulfonic, sulfinic, phosphonic, or phosphinic acid functional groups. In some embodiments, the cyclodextrin is substituted with at least one, at least two, at least three, at least four, at least five, or at least six acidic functional groups. In some embodiments, the cyclodextrin is substituted with 3 to 8 acidic functional groups, 3 to 7 acidic functional groups, 4 to 8 acidic functional groups, 4 to 7 acidic functional groups, 5 to 8 acidic functional groups, 6 to 8 acidic functional groups, or 7 to 8 acidic functional groups.
[0120] In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:8. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:10. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:5 to about 1:7. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:4. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:5. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:6. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:7. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:8. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:9. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:10.
[0121] In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 2:1 to about 1:2. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.75:1 to about 1:1.75. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.5:1 to about 1:1.5. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.4:1 to about 1:1.4. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is 1.3:1 to about 1:1.3. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.25:1 to about 1:1.25. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.2:1 to about 1:1.2. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.15:1 to about 1:1.15. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.1:1 to about 1:1.1. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.05:1 to about 1:1.05. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:1.
[0122] In some embodiments, the cyclodextrin has the formula (I):
[0123] [ka] or a stereoisomer, a mixture of stereoisomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; During the ceremony, R1 are each independently H or optionally substituted alkyl; R 2 are each independently H or optionally substituted alkyl; and n is 6, 7, or 8.
[0124] In some embodiments, R 1 are each independently H or an alkyl optionally substituted with a polar functional group. In some embodiments, the polar functional group is an amide functional group, an acid functional group, an ester functional group, a hydroxyl functional group, an alkoxy functional group, or a poly(alkylene oxide) functional group. In some embodiments, R 1 are each independently H or alkyl optionally substituted with an acidic or hydroxyl functional group.
[0125] In some embodiments, R 1 are each independently H or alkyl optionally substituted with an acidic functional group. In some embodiments, R 1 are each independently H or alkyl substituted with an acidic functional group. In some embodiments, R 1 are each independently H or a C1-C6 alkyl substituted with an acidic functional group. In some embodiments, R 1 are each independently H or a C1-C6 alkyl substituted with an acidic functional group selected from carboxylic acid, sulfonic acid, sulfinic acid, phosphonic acid, or phosphinic acid. In some embodiments, R 1 are each independently H,
[0126] [ka] In some embodiments, R 1 are each independently H,
[0127] [ka] R 1 In some embodiments, R 2 are H or acetyl. 1 In some embodiments, R 2 are H respectively.
[0128] In some embodiments, R 1 are each independently H or alkyl optionally substituted with a hydroxyl functional group. In some embodiments, R 1 are each independently H or alkyl substituted with a hydroxyl functional group. In some embodiments, R 1 are each independently H or a C1-C6 alkyl substituted with a hydroxyl functional group. In some embodiments, R 1 are each independently H, or hydroxypropyl, hydroxybutyl, hydroxypentyl, or hydroxyhexyl. In some embodiments, R 1 and R 2 are each independently H, or hydroxypropyl, hydroxybutyl, hydroxypentyl, or hydroxyhexyl.
[0129] In some embodiments, R 2 are each independently H or alkyl optionally substituted with a polar functional group. In some embodiments, R 2 are each independently H or alkyl optionally substituted with a hydroxyl functional group. In some embodiments, R 2 are each independently H or alkyl substituted with a hydroxyl functional group. In some embodiments, R 2 are each independently H or a C1-C6 alkyl substituted with a hydroxyl functional group. In some embodiments, R 2 are each independently H, or hydroxypropyl, hydroxybutyl, hydroxypentyl, or hydroxyhexyl. In some embodiments, each R 2 is H. In some embodiments, each R2 is H or acetyl.
[0130] In some embodiments, R 2 are each independently H or alkyl optionally substituted with an acidic functional group. In some embodiments, R 2 are each independently H or a C1-C6 alkyl optionally substituted with an acidic functional group. In some embodiments, R 2 are each independently H or a C1-C6 alkyl optionally substituted with a sulfonic acid or carboxylic acid functional group.
[0131] In some embodiments, n is 6 or 7. In some embodiments, n is 7 or 8. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8.
[0132] In some embodiments, the cyclorodextrin is SBEBCD.
[0133] In one aspect, the present specification provides a compound of the formula: [A] a [B] There is provided a pharmaceutically acceptable salt of a pharmaceutical compound having the formula: During the ceremony, A is a pharmaceutical compound containing at least one basic nitrogen atom, the pharmaceutical compound being a dissociative drug, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, a compound that modulates an NMDA receptor, a tryptamine, a phenethylamine, a lysergamide compound, a compound that converts a protonated nitrogen atom into an opioid, a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, a hydroxazine, a phenylephrine, a dopamine, an adrenaline, a lidocaine, an oxymetazoline, a clemastine, a chlorpheniramine, or a 6-chloro-2-aminotetralin; B is a complexing agent containing multiple acidic functional groups; and a is a number from 1 to 8, selected such that the total number of basic nitrogen atoms in A is equal to the number of acidic functional groups in B.
[0134] In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, morphine, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanyl, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, or 3-methylthiofentanyl. In some embodiments, the opioid is an opioid receptor antagonist such as naloxone or naltrexone.
[0135] B can be any of the complexing agents provided herein, including but not limited to, any of the cyclodextrins or compounds of formula (I) provided herein, and the number of acidic groups in such compounds affects the value of a.
[0136] A can be any of the pharmaceutical compounds provided herein, whose properties (e.g., the number of basic nitrogen atoms) affect the value of a. A pharmaceutical compound may contain multiple basic nitrogen atoms, one or more (but not necessarily all) of which may be considered basic. However, depending on the difference in pKa values between multiple basic nitrogen atoms, not all nitrogen atoms need to be protonated. In some embodiments, only basic nitrogen atoms with pKa values above a threshold pKa (e.g., a pKa of 3, 4, 5, 6, 7, 8, 9, 10, or 11) are actually protonated in the salts provided herein, and any nitrogen atoms with a pKa below the threshold are not protonated. Thus, in some embodiments, at least one basic nitrogen atom includes any nitrogen in a pharmaceutical compound having a pKa of at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or at least 11.
[0137] In some embodiments, a is a number selected such that the total number of basic nitrogen atoms in A equals the number of acidic functional groups in B, thus resulting in a neutrally charged compound, where the acidic functional groups in B are deprotonated (and thus anionic) and the basic nitrogen atom or atoms in A are protonated (and thus cationic). The result is a complexing agent / pharmaceutical compound salt with an overall neutral charge. For example, if complexing agent B contains six acidic functional groups and the pharmaceutical compound contains only a single basic nitrogen atom, a is 6. Furthermore, if complexing agent B contains six acidic functional groups and the pharmaceutical compound contains two basic nitrogen atoms that are both ionized at the product pH, a is 3.
[0138] The value of a need not be an integer value. For example, if complexing agent B contains five acidic functional groups and pharmaceutical compound A contains two basic nitrogen atoms, then a is 2.5 and the overall structure of the salt complex results in a charged molecule of A being effectively "shared" between two molecules of B.
[0139] Furthermore, any complexing agent B need not be a uniform species of identical substitution of acidic functional groups, and it is expressly contemplated by the present disclosure that this is often not the case. For example, commercially available SBEBCD has an average degree of substitution of acidic functional groups of about 6.5. In such cases, the formula [A] a Compounds having [B] are intended to encompass heterogeneous mixtures of such complexing agents, and for pharmaceutical compounds having one basic nitrogen atom, a is 6.5.
[0140] In some embodiments, the pharmaceutical compound of A contains 1, 2, or 3 basic nitrogen atoms. In some embodiments, the pharmaceutical compound of A contains 1 basic nitrogen atom. In some embodiments, the pharmaceutical compound of A contains 2 basic nitrogen atoms. In some embodiments, the pharmaceutical compound of A contains 3 basic nitrogen atoms.
[0141] In some embodiments, B comprises from about 1 to about 8 acidic functional groups. In some embodiments, B comprises from about 1 to about 2, from about 1 to about 3, from about 1 to about 4, from about 1 to about 5, from about 1 to about 6, from about 1 to about 7, from about 1 to about 8, from about 2 to about 3, from about 2 to about 4, from about 2 to about 5, from about 2 to about 6, from about 2 to about 7, from about 2 to about 8, from about 3 to about 4, from about 3 to about 5, from about 3 to about 6, from about 3 to about 7, from about 3 to about 8, from about 4 to about 5, from about 4 to about 6, from about 4 to about 7, from about 4 to about 8, from about 5 to about 6, from about 5 to about 7, from about 5 to about 8, from about 6 to about 7, from about 6 to about 8, or from about 7 to about 8 acidic functional groups. In some embodiments, B comprises about 1, about 2, about 3, about 4, about 5, about 6, about 7, or about 8 acidic functional groups. In some embodiments, B comprises at least about 1, about 2, about 3, about 4, about 5, about 6, or about 7 acidic functional groups. In some embodiments, B comprises at most about 2, about 3, about 4, about 5, about 6, about 7, or about 8 acidic functional groups. In some embodiments, the acidic functional groups are strongly acidic (e.g., pKa less than 2). In some embodiments, the acidic functional groups are sulfonic acid functional groups, phosphoric acid functional groups, or carboxylic acid functional groups. In some embodiments, the acidic functional groups are sulfonic acid functional groups.
[0142] In embodiments, the pKa of the basic nitrogen atom is about 4 to about 12. In some embodiments, the pKa of the basic nitrogen atom is about 4 to about 5, about 4 to about 6, about 4 to about 7, about 4 to about 8, about 4 to about 9, about 4 to about 10, about 4 to about 11, about 4 to about 12, about 5 to about 6, about 5 to about 7, about 5 to about 8, about 5 to about 9, about 5 to about 10, about 5 to about 11, about 5 to about 12, about 6 to about 7, about 6 to about 8, about 6 to about 9, about 6 to about 10, about 6 to about 11, about 6 to about 12, about 7 to about 8, about 7 to about 9, about 7 to about 10, about 7 to about 11, about 7 to about 12, about 8 to about 9, about 8 to about 10, about 8 to about 11, about 8 to about 12, about 9 to about 10, about 9 to about 11, about 9 to about 12, about 10 to about 11, about 10 to about 12, or about 11 to about 12. In embodiments, the pKa of the basic nitrogen atom is about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12. In some embodiments, the pKa of the basic nitrogen atom is at least about 4, about 5, about 6, about 7, about 8, about 9, about 10, or about 11. In some embodiments, the pKa of the basic nitrogen atom is at most about 5, about 6, about 7, about 8, about 9, about 10, about 11, or about 12.
[0143] In embodiments, the pKa of the basic nitrogen atom is about 4 to about 7. In some embodiments, the pKa of the basic nitrogen atom is about 4 to about 4.5, about 4 to about 5, about 4 to about 5.5, about 4 to about 6, about 4 to about 6.5, about 4 to about 7, about 4.5 to about 5, about 4.5 to about 5.5, about 4.5 to about 6, about 4.5 to about 6.5, about 4.5 to about 7, about 5 to about 5.5, about 5 to about 6, about 5 to about 6.5, about 5 to about 7, about 5.5 to about 6, about 5.5 to about 6.5, about 5.5 to about 7, about 6 to about 6.5, about 6 to about 7, or about 6.5 to about 7. In some embodiments, the pKa of the basic nitrogen atom is about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, or about 7. In some embodiments, the pKa of the basic nitrogen atom is at least about 4, about 4.5, about 5, about 5.5, about 6, or about 6.5. In some embodiments, the pKa of the basic nitrogen atom is at most about 4.5, about 5, about 5.5, about 6, about 6.5, or about 7.
[0144] In embodiments, the pKa of the basic nitrogen atom is about 7 to about 11. In some embodiments, the pKa of the basic nitrogen atom is about 7 to about 7.5, about 7 to about 8, about 7 to about 8.5, about 7 to about 9, about 7 to about 9.5, about 7 to about 10, about 7 to about 10.5, about 7 to about 11, about 7.5 to about 8, about 7.5 to about 8.5, about 7.5 to about 9, about 7.5 to about 9.5, about 7.5 to about 10, about 7.5 to about 10.5, about 7.5 to about 11, about 8 to about 8.5, about 8 to about 9, about 8 to about 9.5, about 8 to about 10, about 8 to about 10.5, about 8 to about 11, about 8.5 to about 9, about 8.5 to about 9.5, about 8.5 to about 10, about 8.5 to about 10.5, about 8.5 to about 11, about 9 to about 9.5, about 9 to about 10, about 9 to about 10.5, about 9 to about 11, about 9.5 to about 10, about 9.5 to about 10.5, about 9.5 to about 11, about 10 to about 10.5, about 10 to about 11, or about 10.5 to about 11. In some embodiments, the pKa of the basic nitrogen atom is about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, or about 11. In some embodiments, the pKa of the basic nitrogen atom is at least about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, or about 10.5. In some embodiments, the pKa of the basic nitrogen atom is at most about 7.5, about 8, about 8.5, about 9, about 9.5, about 10, about 10.5, or about 11.
[0145] In some embodiments, the pKa of the basic nitrogen atom is such that the compound is partially protonated at a physiologically acceptable pH. In some embodiments, the pKa is about 4 to about 11. In some embodiments, the pKa is about 4 to about 10. In some embodiments, the pKa is about 4 to about 9. In some embodiments, the pKa is about 5 to about 11. In some embodiments, the pKa is about 5 to about 10. In some embodiments, the pKa is about 5 to about 9. In some embodiments, the pKa is about 6 to about 11. In some embodiments, the pKa is about 6 to about 10. In some embodiments, the pKa is about 6 to about 9. In some embodiments, the pKa is about 7 to about 11. In some embodiments, the pKa is about 7 to about 10. In some embodiments, the pKa is about 7 to about 9. In some embodiments, the pKa is about 8 to about 11. In some embodiments, the pKa is about 8 to about 10. In some embodiments, the pKa is about 8 to about 10.
[0146] In some embodiments, the basic nitrogen atom is an amine. In some embodiments, the amine is a primary amine, a secondary amine, or a tertiary amine. In some embodiments, the amine is an alkyl amine. In some embodiments, the amine is an aryl amine (e.g., aniline).
[0147] In some embodiments, the basic nitrogen atom is contained in a heterocyclic ring. In some embodiments, the amine is contained in a heteroaromatic ring. Non-limiting examples of such heteroaromatic rings include pyrrole, pyrazole, imidazole, azaindole, indazole, benzoxazole, benzimidazole, quinoline, isoquinoline, quinazoline, pyridine, pyrimidine, pyrazine, naphthyridine, quinoxaline, phenazine, and the like, each of which may be substituted.
[0148] In one aspect, provided herein is a pharmaceutically acceptable salt of a pharmaceutical compound, the pharmaceutically acceptable salt comprising (i) a pharmaceutical compound comprising a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a conjugate base of SBEBCD, wherein the conjugate base of SBEBCD acts as a counterion to the pharmaceutical compound comprising a protonated nitrogen atom, and the pharmaceutical compound is selected from the group consisting of a dissociative drug, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-dimethyl-2-(2-methyl-2-propanol), a 1,2-dimethyl-2-propanol, ... - diarylethylamines, beta-keto-arylcyclohexylamines, compounds that modulate NMDA receptors, tryptamines, phenethylamines, lysergamide compounds, opioids containing a protonated nitrogen atom, cathinones, 3,4-methylenedioxyamphetamine derivatives, aminoalkyl-substituted benzofurans, substituted amphetamines, aminoindans, stimulants, diphenhydramine, hydroxazines, phenylephrine, dopamine adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin. In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanyl, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanyl, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, or 3-methylthiofentanyl, naloxone, or naltrexone. In some embodiments, the opioid is an opioid receptor antagonist. In some embodiments, the opioid receptor antagonist is naloxone or naltrexone.
[0149] In some embodiments, the pharmaceutically acceptable salts provided herein consist essentially of a complexing agent and a pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salts provided herein consist of a complexing agent and a pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salts provided herein consist of a protonated pharmaceutical compound and a deprotonated complexing agent.
[0150] In some embodiments, the pharmaceutically acceptable salt is in a solid form. In some embodiments, the solid form is a crystalline form or an amorphous form. In some embodiments, the solid form is an amorphous powder. In some embodiments, the solid form is a lyophilized powder. In some embodiments, the solid form is a crystalline form.
[0151] In some embodiments, the pharmaceutically acceptable salts provided herein consist essentially of a complexing agent and an opioid. In some embodiments, the pharmaceutically acceptable salts provided herein consist of a complexing agent and an opioid. In some embodiments, the pharmaceutically acceptable salts provided herein consist of a protonated opioid and a deprotonated complexing agent.
[0152] In some embodiments, the pharmaceutically acceptable salt is dissolved or suspended in a liquid medium. In some embodiments, the liquid medium is an aqueous medium, an organic solvent, or a combination thereof. In some embodiments, the liquid medium is an aqueous medium. In some embodiments, the liquid medium is an organic solvent. In some embodiments, the organic solvent comprises acetic acid, acetone, acetonitrile, benzene, tert-butyl alcohol, tert-butyl methyl ether, carbon tetrachloride, chloroform, cyclohexane, 1,2-dichloroethane, dichloromethane, diethyl ether, diglyme, 1,2-dimethoxyethane, dimethylacetamide, dimethylformamide, dimethyl sulfoxide, dioxane, ethanol, ethyl acetate, ethyl methyl ketone, ethylene glycol, hexane, hexamethylphosphoramide, methanol, nitromethane, pentane, 2-proponal, pyridine, tetrahydrofuran, toluene, xylene, or any combination thereof. In some embodiments, the pharmaceutically acceptable salt is dissolved or suspended in a liquid medium as an intermediate step in the preparation of the salt or a pharmaceutical composition comprising the salt.
[0153] In some embodiments, the pharmaceutically acceptable salt is substantially free of excess ions. Examples of such ions include other salts that may remain from the salt preparation or by-products of salt production (e.g., sodium chloride, lithium chloride, potassium chloride, sodium bromide, etc.). In some embodiments, the excess ions are counterions to excess complexing agents or pharmaceutical compounds in the salt preparation, such as excess sodium ions occupying deprotonated acidic sites or chloride ions associated with excess protonated pharmaceutical compounds.
[0154] In some embodiments, a pharmaceutically acceptable salt may contain an excess of pharmaceutical compound, where the excess pharmaceutical compound is non-ionized. The presence of an excess pharmaceutical compound can have numerous benefits in certain situations, including increasing the dosage per unit weight or volume of the salt when used in a pharmaceutical composition. Furthermore, when used in a pharmaceutical composition, the presence of a free base or non-ionized pharmaceutical compound can be used to increase the pH of the composition when it is administered, thus potentially promoting both bioavailability and tolerability in certain situations (e.g., when the pKa of the pharmaceutical compound is lower than the pH at which the compound can be comfortably administered to the target tissue). Furthermore, many of the complexing agents contemplated herein have additional coordination sites for non-ionized APIs (e.g., the central complexing site of cyclodextrins). Thus, in some embodiments, the complexing agents used herein can provide additional solubilization of pharmaceutical compounds beyond that achieved simply by acid / base chemistry and ion exchange / ion pairing.
[0155] In some embodiments, the pharmaceutically acceptable salt comprises an additional molar equivalent of the pharmaceutical compound. In some embodiments, the additional equivalent is measured relative to the number of moles of complexing agent. In some embodiments, the pharmaceutically acceptable salt comprises an additional molar equivalent of the pharmaceutical compound. In some embodiments, the additional molar equivalent is measured relative to the number of moles of complexing agent. In some embodiments, the additional equivalent is measured relative to the number of moles of pharmaceutical compound (e.g., protonated pharmaceutical compound) that forms a salt with the complexing agent.
[0156] In some embodiments, the pharmaceutically acceptable salt comprises an additional molar equivalent of the non-ionized pharmaceutical compound relative to the protonated pharmaceutical compound of the complexing agent / protonated pharmaceutical compound salt. In some embodiments, the pharmaceutically acceptable salt comprises from about 0.01 molar equivalent to about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises from about 0.1 molar equivalent to about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises from about 0.1 molar equivalent to about 10 molar equivalents of the non-ionized opioid. In some embodiments, the pharmaceutically acceptable salt comprises about 0.1 molar equivalents to about 0.2 molar equivalents, about 0.1 molar equivalents to about 0.5 molar equivalents, about 0.1 molar equivalents to about 0.75 molar equivalents, about 0.1 molar equivalents to about 1 molar equivalent, about 0.2 molar equivalents to about 0.5 molar equivalents, about 0.2 molar equivalents to about 0.75 molar equivalents, about 0.2 molar equivalents to about 1 molar equivalent, about 0.5 molar equivalents to about 0.75 molar equivalents, about 0.5 molar equivalents to about 1 molar equivalent, or about 0.75 molar equivalents to about 1 molar equivalent. In some embodiments, the pharmaceutically acceptable salt comprises about 0.1 molar equivalent, about 0.2 molar equivalent, about 0.5 molar equivalent, about 0.75 molar equivalent, or about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises at least about 0.1 molar equivalent, about 0.2 molar equivalent, about 0.5 molar equivalent, or about 0.75 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises up to about 0.2 molar equivalent, about 0.5 molar equivalent, about 0.75 molar equivalent, or about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises from about 0.5 molar equivalent to about 5 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises about 0.5 equivalents to about 1 equivalent, about 0.5 equivalents to about 2 equivalents, about 0.5 equivalents to about 3 equivalents, about 0.5 equivalents to about 4 equivalents, about 0.5 equivalents to about 5 equivalents, about 1 equivalent to about 2 equivalents, about 1 equivalent to about 3 equivalents, about 1 equivalent to about 4 equivalents, about 1 equivalent to about 5 equivalents, about 2 equivalents to about 3 equivalents, about 2 equivalents to about 4 equivalents, about 2 equivalents to about 5 equivalents, about 3 equivalents to about 4 equivalents, about 3 equivalents to about 5 equivalents, or about 4 equivalents to about 5 equivalents of the non-ionized pharmaceutical compound.In some embodiments, the pharmaceutically acceptable salt comprises about 0.5 molar equivalents, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 4 molar equivalents, or about 5 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises at least about 0.5 molar equivalents, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, or about 4 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises up to about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 4 molar equivalents, or about 5 molar equivalents of the non-ionized pharmaceutical compound.
[0157] In some embodiments, the pharmaceutically acceptable salt comprises an additional molar equivalent of the non-ionized pharmaceutical compound relative to the complexing agent of the complexing agent / protonated pharmaceutical compound salt. In some embodiments, the pharmaceutically acceptable salt comprises from about 0.01 molar equivalent to about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises from about 0.1 molar equivalent to about 10 molar equivalents of the non-ionized opioid. In some embodiments, the pharmaceutically acceptable salt is from about 0.1 molar equivalents to about 0.5 molar equivalents, about 0.1 molar equivalents to about 1 molar equivalent, about 0.1 molar equivalents to about 2 molar equivalents, about 0.1 molar equivalents to about 3 molar equivalents, about 0.1 molar equivalents to about 5 molar equivalents, about 0.1 molar equivalents to about 7 molar equivalents, about 0.1 molar equivalents to about 10 molar equivalents, about 0.5 molar equivalents to about 1 molar equivalent, about 0.5 molar equivalents to about 2 molar equivalents, about 0.5 molar equivalents to about 3 molar equivalents, about 0.5 molar equivalents to about 5 molar equivalents, about 0.5 molar equivalents to about 7 molar equivalents, about 0. The range includes 5 molar equivalents to about 10 molar equivalents, about 1 molar equivalent to about 2 molar equivalents, about 1 molar equivalent to about 3 molar equivalents, about 1 molar equivalent to about 5 molar equivalents, about 1 molar equivalent to about 7 molar equivalents, about 1 molar equivalent to about 10 molar equivalents, about 2 molar equivalents to about 3 molar equivalents, about 2 molar equivalents to about 5 molar equivalents, about 2 molar equivalents to about 7 molar equivalents, about 2 molar equivalents to about 10 molar equivalents, about 3 molar equivalents to about 5 molar equivalents, about 3 molar equivalents to about 7 molar equivalents, about 3 molar equivalents to about 10 molar equivalents, about 5 molar equivalents to about 7 molar equivalents, about 5 molar equivalents to about 10 molar equivalents, or about 7 molar equivalents to about 10 molar equivalents. In some embodiments, the pharmaceutically acceptable salt comprises about 0.1 molar equivalent, about 0.5 molar equivalent, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, about 7 molar equivalents, or about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises at least about 0.1 molar equivalent, about 0.5 molar equivalent, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, or about 7 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salt comprises up to about 0.5 molar equivalent, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, about 7 molar equivalents, or about 10 molar equivalents of the non-ionized pharmaceutical compound.In some embodiments, the pharmaceutically acceptable salt comprises about 0.01 molar equivalents to about 20 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent. In some embodiments, the pharmaceutically acceptable salt comprises about 0.1 molar equivalents to about 20 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent. In some embodiments, the pharmaceutical composition comprises about 1 molar equivalent to about 20 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent. In some embodiments, at least a portion of these additional equivalents of the non-ionized pharmaceutical compound relative to the complexing agent is complexed to the complexing agent (e.g., up to about 1 molar equivalent of the non-ionized pharmaceutical compound relative to the moles of the complexing agent).
[0158] In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or a compound that modulates the NMDA receptor. In some embodiments, the pharmaceutical compound is not ketamine.
[0159] In some embodiments, the pharmaceutical compound modulates NMDA receptor. In some embodiments, the pharmaceutical compound is an NMDA receptor antagonist, an NMDA receptor agonist, a mixed NMDA receptor agonist-antagonist, or an NMDA receptor inverse agonist. In some embodiments, the pharmaceutical compound modulates NMDA receptor at polyamine site, glycine binding site, glutamate binding site, PCP binding site, ketamine binding site, allosteric modulation site, zinc binding site, or magnesium binding site. In some embodiments, the pharmaceutical compound is not ketamine.
[0160] In some embodiments, the pharmaceutical compound does not modulate NMDA receptors. In some embodiments, the pharmaceutical compound is not an NMDA receptor agonist. In some embodiments, the pharmaceutical compound is not ketamine.
[0161] In some embodiments, the pharmaceutical compound is methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticidone), 3-methoxyphencyclidine, methoxyeticyclidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound is methoxetamine or deschloroketamine. In some embodiments, the pharmaceutical compound is methoxetamine. In some embodiments, the pharmaceutical compound is deschloroketamine.
[0162] In some embodiments, the pharmaceutical compound is ketamine, methoxetamine, deschloroketamine, N-ethyldeschloroketamine (eticidone), 3-methoxyphencyclidine, methoxyeticyclidine, ephenidine, lanicemine, dextromethorphan, dextrorphan, or methoxyketamine. In some embodiments, the pharmaceutical compound is methoxetamine or deschloroketamine. In some embodiments, the pharmaceutical compound is ketamine. In some embodiments, the ketamine is racemic ketamine. In some embodiments, the ketamine is stereopure or stereoenhanced ketamine. In some embodiments, the ketamine is (R)-ketamine. In some embodiments, the ketamine is (S)-ketamine.
[0163] In some embodiments, the pharmaceutical compound is a tryptamine, phenethylamine, or lysergamide compound. In some embodiments, the pharmaceutical compound is tryptamine, phenethylamine, or lysergamide. In some embodiments, the pharmaceutical compound is N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine, N-methyl-N-propyltryptamine, N-methyl-N-isopropyltryptamine, N,N-diallyltryptamine, N-methyl-N-allyltryptamine, N-methyl-N-ethyltryptamine, N,N-diisopropyltryptamine, α-ethyltryptamine, or lysergamide.
[0164] In some embodiments, the pharmaceutical compound is N,N-dimethylpropionamide. In some embodiments, the pharmaceutical compound is a tryptamine selected from N,N-dimethyltryptamine, N,N-diethyltryptamine, N,N-dipropyltryptamine, N-methyl-N-propyltryptamine, N-methyl-N-isopropyltryptamine, N,N-diallyltryptamine, N-methyl-N-allyltryptamine, N-methyl-N-ethyltryptamine, and N,N-diisopropyltryptamine, wherein the tryptamine is optionally substituted. In some embodiments, the tryptamine is optionally substituted on the tryptamine ring. In some embodiments, the tryptamine is optionally substituted on the tryptamine ring with a substituent selected from hydroxy, acetoxy, alkoxy, halogen, or alkyl. In some embodiments, the tryptamine is optionally substituted at the 4- or 5-position of the tryptamine ring. In some embodiments, the tryptamine is optionally substituted at the 4- or 5-position of the tryptamine ring with a substituent selected from hydroxy, acetoxy, or methoxy.
[0165] In some embodiments, the pharmaceutical compound is N-methyl-N-ethyltryptamine.
[0166] In some embodiments, the pharmaceutical compound is N,N-dimethyltryptamine. In some embodiments, the pharmaceutical compound is psilocin, O-acetylpsilocin, or 5-methoxy-N,N-dimethyltryptamine.
[0167] In some embodiments, the pharmaceutical compound is N,N-diethyltryptamine. In some embodiments, the pharmaceutical compound is N,N-diethyltryptamine, 4-hydroxy-diethyl-tryptamine, 4-acetoxy-N,N-diethyltryptamine, or 5-methoxy-N,N-diethyltryptamine.
[0168] In some embodiments, the pharmaceutical compound is N,N-dipropyltryptamine, 4-hydroxy-dipropyltryptamine, 4-acetoxy-N,N-dipropyltryptamine, or 5-methoxy-N,N-dipropyltryptamine.
[0169] In some embodiments, the pharmaceutical compound is N-methyl-N-propyltryptamine. In some embodiments, the pharmaceutical compound is N-methyl-N-propyltryptamine, 4-hydroxy-N-methyl-N-propyltryptamine, 4-acetoxy-N-methyl-N-propyltryptamine, or 5-methoxy-N-methyl-N-propyltryptamine.
[0170] In some embodiments, the pharmaceutical compound is N-methyl-N-ethyltryptamine. In some embodiments, the pharmaceutical compound is N-methyl-N-ethyltryptamine, 4-hydroxy-N-methyl-N-ethyltryptamine, 4-acetoxy-N-methyl-N-ethyltryptamine, or 5-methoxy-N-methyl-N-ethyltryptamine.
[0171] In some embodiments, the pharmaceutical compound is N-methyl-N-isopropyltryptamine. In some embodiments, the pharmaceutical compound is N-methyl-N-isopropyltryptamine, 4-hydroxy-N-methyl-N-isopropyltryptamine, 4-acetoxy-N-methyl-N-isopropyltryptamine, or 5-methoxy-N-methyl-N-isopropyltryptamine.
[0172] In some embodiments, the pharmaceutical compound is N,N-diallyltryptamine, hi some embodiments, the pharmaceutical compound is N,N-diallyltryptamine, 4-hydroxy-diallyltryptamine, 4-acetoxy-N,N-diallyltryptamine, or 5-methoxy-N,N-diallyltryptamine.
[0173] In some embodiments, the pharmaceutical compound is N-methyl-N-allyl-tryptamine. In some embodiments, the pharmaceutical compound is N-methyl-N-allyl-tryptamine, 4-hydroxy-N-methyl-N-allyl-tryptamine, 4-acetoxy-N-methyl-N-allyl-tryptamine, or 5-methoxy-N-methyl-N-allyl-tryptamine.
[0174] In some embodiments, the pharmaceutical compound is N,N-diisopropyltryptamine. In some embodiments, the pharmaceutical compound is N,N-diisopropyltryptamine, 4-hydroxy-N,N-diisopropyltryptamine, 4-acetoxy-N,N-diisopropyltryptamine, or 5-methoxy-N,N-diisopropyltryptamine. In some embodiments, the pharmaceutical compound is α-ethyltryptamine.
[0175] In some embodiments, the pharmaceutical compound is lysergamide. In some embodiments, the pharmaceutical compound is methylisopropyllysergamide, ethylisopropyllysergamide, 6-allyl-6-nor-LSD, 6-ethyl-6-nor-lysergic acid diethylamide, 1-acetyl-LSD, 1-propionyl-6-ethyl-6-nor-lysergic acid diethylamide, 1-propionyl-lysergic acid diethylamide, 1-cyclopropionyl-d-lysergic acid diethylamide, N1-butyryl-lysergic acid diethylamide, or 6-propyl-6-nor-lysergic acid diethylamide.
[0176] In some embodiments, the pharmaceutical compound is phenethylamine. In some embodiments, the pharmaceutical compound is mescaline, 2,5-dimethoxy-4-bromophenethylamine (2C-B), 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine (2C-I), 2-(4-chloro-2,5-dimethoxyphenyl)ethan-1-amine (2C-C), 2,5-dimethoxy-4-iodoamphetamine, or 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine. In some embodiments, the pharmaceutical compound is mescaline. In some embodiments, the pharmaceutical compound is 2,5-dimethoxy-4-bromophenethylamine (2C-B). In some embodiments, the pharmaceutical compound is 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine (2C-I). In some embodiments, the pharmaceutical compound is 2-[2,5-dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine.
[0177] In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the opioid is a naturally occurring opioid. In some embodiments, the opioid is a synthetic opioid. In some embodiments, the opioid is an opioid derivative. In some embodiments, the opioid is a morphine derivative. In some embodiments, the opioid is a fentanyl derivative. In some embodiments, the opioid is a semi-synthetic opioid.
[0178] In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, or 3-methylthiofentanyl. In some embodiments, the opioid is racemorphan, levorphanol, or racemethorphan. In some embodiments, the opioid is racemorphan. In some embodiments, the opioid is levorphanol. In some embodiments, the opioid is racemethorphan.
[0179] In some embodiments, the opioid has a pKa of about 7 to about 11. In some embodiments, the opioid is morphine, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, or 3-methylthiofentanyl.
[0180] In some embodiments, the opioid is an opioid receptor antagonist. In some embodiments, the opioid receptor antagonist is naloxone or naltrexone.
[0181] In some embodiments, the pharmaceutical compound is a 3-substituted methcathinone, a 3-substituted ethcathinone, a 4-substituted methcathinone, a 4-substituted ethcathinone, a methylone, an ethylone, or a butylone.
[0182] In some embodiments, the pharmaceutical compound is a 3-substituted methcathinone. In some embodiments, the pharmaceutical compound is 3-methylmethcathinone, 3-ethylmethcathinone, 3-fluoromethcathinone, 3-chloromethcathinone, or 3-bromomethcathinone. In some embodiments, the pharmaceutical compound is 3-methylmethcathinone.
[0183] In some embodiments, the pharmaceutical compound is a 3-substituted ethcathinone. In some embodiments, the pharmaceutical compound is 3-methylethcathinone, 3-ethylethcathinone, 3-fluoroethcathinone, 3-chloroethcathinone, or 3-bromoethcathinone.
[0184] In some embodiments, the pharmaceutical compound is a 4-substituted methcathinone, hi some embodiments, the pharmaceutical compound is 4-methylmethcathinone, 4-ethylmethcathinone, 4-fluoromethcathinone, 4-chloromethcathinone, or 4-bromomethcathinone.
[0185] In some embodiments, the pharmaceutical compound is a 4-substituted ethcathinone, hi some embodiments, the pharmaceutical compound is 4-methylethcathinone, 4-ethylethcathinone, 4-fluoroethcathinone, 4-chloroethcathinone, or 4-bromoethcathinone.
[0186] In some embodiments, the pharmaceutical compound is methylone, ethylone, or butylone. In some embodiments, the pharmaceutical compound is methylone. In some embodiments, the pharmaceutical compound is ethylone. In some embodiments, the pharmaceutical compound is butylone.
[0187] In some embodiments, the pharmaceutical compound is a 3,4-methylenedioxyamphetamine derivative. In some embodiments, the pharmaceutical compound is 1-(1,3-benzodioxol-5-yl)-2-butanamine, 1-(1,3-benzodioxol-5-yl)-N-methyl-2-butanamine, 1-(1,3-benzodioxol-5-yl)-N-ethyl-2-butanamine, 3,4-methylenedioxyamphetamine, 3,4-methylene-dioxy-N-ethyl-amphetamine, S-3,4-methylene-dioxy-N-ethyl-amphetamine, 3,4-methylenedioxy-N-methylamphetamine, 5,6-methylenedioxy-2-aminoindan, 2-amino-(3,4-methylenedioxy)propiophenone, or methylenedioxypyrovalerone.
[0188] In some embodiments, the pharmaceutical compound is an aminoalkyl-substituted benzofuran. In some embodiments, the pharmaceutical compound is 5-(2-aminopropyl)-benzofuran, the 2,3-dihydro isomer of 5-APB, 1-(benzofuran-5-yl)-N-methylpropan-2-amine, 6-(2-aminopropyl)-benzofuran, the 2,3-dihydro isomer of 6-APB, or 1-(benzofuran-6-yl)-N-methylpropan-2-amine.
[0189] In some embodiments, the pharmaceutical compound is a substituted amphetamine. In some embodiments, the pharmaceutical compound is 4-fluoroamphetamine, 4-fluoromethamphetamine, 3-fluoroamphetamine, 3-fluoromethamphetamine, 2-fluoroamphetamine, or 2-fluoromethamphetamine.
[0190] In some embodiments, the pharmaceutical compound is aminoindan, hi some embodiments, the pharmaceutical compound is 5-iodo-2-aminoindan, 5,6-methylenedioxy-2-aminoindan, 5-methoxy-2-aminoindan (MEA1), N-acetyl-MEA1, 5-hydroxy-N-acetyl-A1, or 5-methoxy-6-methyl-2-aminoindan.
[0191] In some embodiments, the pharmaceutical compound is a stimulant. In some embodiments, the pharmaceutical compound is ephedrine, pseudoephedrine, amphetamine, (R)-1-phenyl-N-propylpentan-2-amine, benzofuranylpropylaminopentane, or methylphenidate.
[0192] In some embodiments, the pharmaceutical compound is diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin. In some embodiments, the pharmaceutical compound is diphenhydramine.
[0193] Pharmaceutical Composition Provided herein are pharmaceutical formulations of pharmaceutical compounds suitable for administration by various routes, including subcutaneous injection, intranasal administration, and / or sublingual administration. These pharmaceutical compositions utilize the complexing agent / pharmaceutical compound salts provided herein. Such salts offer numerous advantages in each type of pharmaceutical composition, some of which are specific to the route of administration.
[0194] In one aspect, provided herein is a pharmaceutical composition comprising: (i) a compound containing a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof; and (ii) a complexing agent that is an acid-substituted cyclodextrin containing multiple acidic functional groups, wherein the multiple acidic functional groups include acidic groups that act as counterions to the protonated nitrogen atom of the pharmaceutical compound. In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound. In some embodiments, the pharmaceutical compound is a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the pharmaceutical compound is a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin.
[0195] In another aspect, provided herein is a pharmaceutical composition, the pharmaceutical composition comprising: (i) a pharmaceutical compound that is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclo-hexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound, or an enantiomer, mixture of enantiomers, or isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent that comprises a plurality of acidic functional groups.
[0196] In another aspect, provided herein are pharmaceutical compositions comprising: (i) a pharmaceutical compound that is a tryptamine, phenethylamine, or lysergamide compound, or an enantiomer, mixture of enantiomers, or isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent that comprises a plurality of acidic functional groups.
[0197] In another aspect, provided herein is (i) an opioid, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof, and (ii) a complexing agent comprising multiple acidic functional groups.
[0198] In another aspect, provided herein is a pharmaceutical composition comprising: (i) a pharmaceutical compound that is a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; and (ii) a complexing agent that comprises a plurality of acidic functional groups.
[0199] In another aspect, provided herein are pharmaceutical compositions comprising: (i) a compound containing a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof; (ii) a complexing agent containing a plurality of acidic functional groups, wherein the plurality of acidic functional groups comprises a conjugate base of an acid that acts as a counterion to the protonated nitrogen atom of the pharmaceutical compound; and (iii) an additional molar equivalent of a non-ionized pharmaceutical compound. In some embodiments, the additional molar equivalent of the pharmaceutical compound is 0.01 to 20 molar equivalents. In some embodiments, the pharmaceutical compound is a dissociative pharmaceutical compound, a dissociative hallucinogen compound, a dissociative anesthetic compound, an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, or an NMDA receptor modulating compound. In some embodiments, the pharmaceutical compound is a tryptamine, a phenethylamine, or a lysergamide compound. In some embodiments, the pharmaceutical compound is an opioid. In some embodiments, the opioid is racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetylfentanyl, alfentanil, butyrylfentanyl, butylfentanyl, carfentanil, 3-methylcarfentanil, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylfentanyl, β-hydroxy-3-methylfentanyl, remifentanil, sufentanil, 3-methylthiofentanyl, naloxone, or naltrexone. In some embodiments, the opioid is racemorphan, levorphanol, or racemethorphan. In some embodiments, the opioid is racemorphan. In some embodiments, the opioid is levorphanol. In some embodiments, the opioid is racemethorphan. In some embodiments, the opioid is an opioid receptor antagonist. In some embodiments, the opioid receptor antagonist is naloxone or naltrexone.In some embodiments, the pharmaceutical compound is a cathinone, a 3,4-methylenedioxyamphetamine derivative, an aminoalkyl-substituted benzofuran, a substituted amphetamine, an aminoindan, a stimulant, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, or 6-chloro-2-aminotetralin.
[0200] In some embodiments, the plurality of acidic functional groups comprises an acidic group that acts as a counterion to the protonated amine of the pharmaceutical compound. In some embodiments, the acidic group is the conjugate base of the acidic group. In some embodiments, the acidic group is a carboxylic acid or a carboxylate. In some embodiments, the acidic group is a carboxylate. In some embodiments, the acidic group is a sulfonic acid or a sulfonate. In some embodiments, the acidic group is a sulfonate. In some embodiments, the conjugate base of the complexing agent acts as a counterion to the plurality of pharmaceutical compounds. Each acidic group of the plurality of acidic functional groups acts as a counterion to the plurality of pharmaceutical compounds. In some embodiments, each acidic group of the plurality of acidic functional groups acts as a counterion to the protonated amine of the plurality of pharmaceutical compounds. In some embodiments, each acidic functional group acts as a counterion to the protonated amine and / or protonated nitrogen atom.
[0201] In some embodiments, the pharmaceutical composition comprises a cyclodextrin substituted with at least one acidic functional group. In some embodiments, the at least one acidic functional group is a carboxylic acid, sulfonic acid, sulfinic acid, phosphonic acid, or phosphinic acid, or any combination thereof. In some embodiments, the cyclodextrin is substituted with at least one, at least two, at least three, at least four, at least five, or at least six acidic functional groups. In some embodiments, the cyclodextrin is substituted with 3 to 8 acidic functional groups, 3 to 7 acidic functional groups, 4 to 8 acidic functional groups, 4 to 7 acidic functional groups, 5 to 8 acidic functional groups, 6 to 8 acidic functional groups, or 7 to 8 acidic functional groups.
[0202] In some embodiments, the pharmaceutical composition further comprises a complexing agent.
[0203] In some embodiments, the complexing agent is a substituted or unsubstituted cyclodextrin. In some cases, the substituted cyclodextrins provided herein are complex mixtures in which individual cyclodextrin molecules may contain a different number of substituents than other individual cyclodextrin molecules. In such cases, the number of substituents (e.g., the number of acidic functional groups) described as being present on a cyclodextrin provided herein may refer to the average degree of substitution of the mixture. For example, if a cyclodextrin is described as being substituted with 3 to 8 acidic functional groups, it is intended to encompass a complex mixture of cyclodextrins having an average degree of substitution of 3 to 8 acidic functional groups. The average degree of substitution need not be an integer value and is often a decimal value. For example, commercially available SBEBCD has an average degree of substitution of about 6.5.
[0204] In some embodiments, the complexing agent is a substituted cyclodextrin. In some embodiments, the substituted cyclodextrin is substituted with one or more acidic functional groups, or pharmaceutically acceptable salts thereof. In some embodiments, the substituted cyclodextrin is substituted with one or more carboxylic, sulfonic, sulfinic, phosphonic, or phosphinic acids. In some embodiments, the cyclodextrin is substituted with at least one, at least two, at least three, at least four, at least five, or at least six acidic functional groups. In some embodiments, the cyclodextrin is substituted with 3 to 8 acidic functional groups, 3 to 7 acidic functional groups, 4 to 8 acidic functional groups, 4 to 7 acidic functional groups, 5 to 8 acidic functional groups, 6 to 8 acidic functional groups, or 7 to 8 acidic functional groups.
[0205] In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:8. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:10. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:5 to about 1:7. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:4. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:5. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:6. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:7. In some embodiments, the molar ratio of cyclodextrin to pharmaceutical compound comprising a protonated nitrogen atom is about 1:8. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:9. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:10. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:10. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:5 to about 1:7. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:5. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:6. In some embodiments, the molar ratio of the cyclodextrin to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:7.
[0206] In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 2:1 to about 1:2. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.75:1 to about 1:1.75. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.5:1 to about 1:1.5. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.4:1 to about 1:1.4. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is 1.3:1 to about 1:1.3. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.25:1 to about 1:1.25. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.2:1 to about 1:1.2. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.15:1 to about 1:1.15. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.1:1 to about 1:1.1. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.05:1 to about 1:1.05. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:1.
[0207] In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 2:1 to about 1:2. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.75:1 to about 1:1.75. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.5:1 to about 1:1.5. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.4:1 to about 1:1.4. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.3:1 to about 1:1.3. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.25:1 to about 1:1.25. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.2:1 to about 1:1.2. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.15:1 to about 1:1.15. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.1:1 to about 1:1.1. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1.05:1 to about 1:1.05. In some embodiments, the molar ratio of the acidic functional group of the complexing agent to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:1.
[0208] In some embodiments, the cyclodextrin has the formula (I):
[0209] [ka] or a stereoisomer, a mixture of stereoisomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof; During the ceremony, R1 are each independently H or optionally substituted alkyl; R 2 are each independently H or optionally substituted alkyl; and n is 6, 7, or 8.
[0210] In some embodiments, R 1 are each independently H or an alkyl optionally substituted with a polar functional group. In some embodiments, the polar functional group is an amide functional group, an acid functional group, an ester functional group, a hydroxyl functional group, an alkoxy functional group, or a poly(alkylene oxide) functional group. In some embodiments, R 1 are each independently H or alkyl optionally substituted with an acidic or hydroxyl functional group.
[0211] In some embodiments, R 1 are each independently H or alkyl optionally substituted with an acidic functional group. In some embodiments, R 1 are each independently H or alkyl substituted with an acidic functional group. In some embodiments, R 1 are each independently H or a C1-C6 alkyl substituted with an acidic functional group. In some embodiments, R 1 are each independently H or a C1-C6 alkyl substituted with an acidic functional group selected from carboxylic acid, sulfonic acid, sulfinic acid, phosphonic acid, or phosphinic acid. In some embodiments, R 1 are each independently H,
[0212] [ka] In some embodiments, R 1 are each independently H,
[0213] [ka] R 1 In some embodiments, R 2 are H or acetyl. 1 In some embodiments, R 2 are H respectively.
[0214] In some embodiments, R 1 are each independently H or alkyl optionally substituted with a hydroxyl functional group. In some embodiments, R 1 are each independently H or alkyl substituted with a hydroxyl functional group. In some embodiments, R 1 are each independently H or a C1-C6 alkyl substituted with a hydroxyl functional group. In some embodiments, R 1 are each independently H, or hydroxypropyl, hydroxybutyl, hydroxypentyl, or hydroxyhexyl. In some embodiments, R 1 and R 2 are each independently H, or hydroxypropyl, hydroxybutyl, hydroxypentyl, or hydroxyhexyl.
[0215] In some embodiments, R 2 are each independently H or alkyl optionally substituted with a polar functional group. In some embodiments, R 2 are each independently H or alkyl optionally substituted with a hydroxyl functional group. In some embodiments, R 2 are each independently H or alkyl substituted with a hydroxyl functional group. In some embodiments, R 2 are each independently H or a C1-C6 alkyl substituted with a hydroxyl functional group. In some embodiments, R 2 are each independently H, or hydroxypropyl, hydroxybutyl, hydroxypentyl, or hydroxyhexyl. In some embodiments, each R 2 is H. In some embodiments, each R2 is H or acetyl.
[0216] In some embodiments, R 2 are each independently H or alkyl optionally substituted with an acidic functional group. In some embodiments, R 2 are each independently H or a C1-C6 alkyl optionally substituted with an acidic functional group. In some embodiments, R 2 are each independently H or a C1-C6 alkyl optionally substituted with a sulfonic acid or carboxylic acid functional group.
[0217] In some embodiments, n is 6 or 7. In some embodiments, n is 7 or 8. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8.
[0218] In some embodiments, the cyclodextrin is sulfobutyl-ether-β-cyclodextrin (SBEBCD) or hydroxypropyl-β-cyclodextrin (HPBCD).
[0219] In some embodiments, the cyclorodextrin is SBEBCD. In some embodiments, the SBEBCD is the free acid form of SBEBCD.
[0220] In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:8. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:10. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:8. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4 to about 1:10. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:5 to about 1:7. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:4. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:5. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:6. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:7. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:8. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:9. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:10. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:2 to about 1:10.In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:2 to about 1:3, about 1:2 to about 1:4, about 1:2 to about 1:5, about 1:2 to about 1:6, about 1:2 to about 1:7, about 1:2 to about 1:8, about 1:2 to about 1:9, about 1:2 to about 1:10, about 1:3 to about 1:4, about 1:3 to about 1:5, about 1:3 to about 1:6, about 1:3 to about 1:7, about 1:3 to about 1:8, about 1:3 to about 1:9, about 1:3 to about 1:10, about 1:4 to about 1:5, about 1:4 to about 1:5, about 1:4 to about 1:6, about 1:4 to about 1:7, about 1:4 to about 1:8, about 1:4 to about 1:9, about 1:3 to about 1:10, about 1:4 to about 1:5, about 1:4 to about 1:5, about 1:4 to about 1:5, about 1:4 to about 1:6, about 1:4 to about 1:5, about 1:4 to about 1:6, about 1:4 to about 1:6, about 1:4 to about 1:7, about 1:4 to about 1:8, about 1:4 to about 1:9, about 1:4 to about 1:10, about 1:4 to about 1:5, about 1:4 to about 1:5, about 1:4 to about 1:5, about 1:4 to about 1:6, about 1:4 to about 1:6, about 1:4 to about 1:7, about 1:4 to about 1:8, about 1:4 to about 1:6, about 1:4 to about 1:7, about 1:4 to about 1:8, about 1:4 to about 1:9, about 1:4 to about 1:10, about 1:5 to about 1:6, about 1:5 to about 1:7, about 1:5 to about 1:8, about 1:5 to about 1:9, about 1:5 to about 1:10, about 1:6 to about 1:7, about 1:6 to about 1:8, about 1:6 to about 1:9, about 1:6 to about 1:10, about 1:7 to about 1:8, about 1:7 to about 1:9, about 1:7 to about 1:10, about 1:8 to about 1:9, about 1:8 to about 1:10, or about 1:9 to about 1:10. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, or about 1:10. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is at least about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, or about 1:9. In some embodiments, the molar ratio of SBEBCD to the pharmaceutical compound comprising a protonated nitrogen atom is at most about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, or about 1:10.
[0221] In some embodiments, the pharmaceutically acceptable salts or pharmaceutical compositions provided herein consist essentially of a complexing agent and a pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salts or pharmaceutical compositions provided herein consist of a complexing agent and a pharmaceutical compound. In some embodiments, the pharmaceutically acceptable salts or pharmaceutical compositions provided herein consist of a protonated pharmaceutical compound and a deprotonated complexing agent.
[0222] In some embodiments, the pharmaceutical composition further comprises a base, a buffering agent, or a combination thereof.
[0223] In some embodiments, the pharmaceutical composition does not include a base, a buffer, or a combination thereof.
[0224] In some embodiments, the co-solvent is ethanol, propylene glycol, tween 20, tween 80, glycerin, or a combination thereof.
[0225] In some embodiments, the complexing agent is a substituted or unsubstituted cyclodextrin. In some cases, the substituted cyclodextrins provided herein are complex mixtures in which individual cyclodextrin molecules may contain a different number of substituents than other individual cyclodextrin molecules. In such cases, the number of substituents (e.g., the number of acidic functional groups) described as being present on a cyclodextrin provided herein may refer to the average degree of substitution of the mixture. For example, if a cyclodextrin is described as being substituted with 3 to 8 acidic functional groups, it is intended to encompass a complex mixture of cyclodextrins having an average degree of substitution of 3 to 8 acidic functional groups.
[0226] In some embodiments, the complexing agent is a substituted cyclodextrin. In some embodiments, the substituted cyclodextrin is substituted with one or more acidic functional groups, or pharmaceutically acceptable salts thereof. In some embodiments, the substituted cyclodextrin is substituted with one or more carboxylic, sulfonic, sulfinic, phosphoric, or phosphonic acids. In some embodiments, the cyclodextrin is substituted with at least one, at least two, at least three, at least four, at least five, or at least six acidic functional groups. In some embodiments, the cyclodextrin is substituted with 3 to 8 acidic functional groups, 3 to 7 acidic functional groups, 4 to 8 acidic functional groups, 4 to 7 acidic functional groups, 5 to 8 acidic functional groups, 6 to 8 acidic functional groups, or 7 to 8 acidic functional groups.
[0227] In some embodiments, the cyclodextrin is a compound of formula (I).
[0228] In some embodiments, the cyclodextrin is sulfobutyl-ether-β-cyclodextrin (SBEBCD).
[0229] In some embodiments, SBEBCD is the free acid form of SBEBCD.
[0230] In some embodiments, the pharmaceutically acceptable salt is formulated in an aqueous medium as either a solution or a suspension. Such a solution or suspension can be used in various formulations, such as for subcutaneous administration, intranasal administration, or sublingual administration. In some embodiments, when formulated in an aqueous medium, the pharmaceutical compositions provided herein have a lower molality than other formulations that utilize salts of the complexing agent, the pharmaceutical compound, or both, and have the same concentration of the complexing agent and the pharmaceutical compound.
[0231] In some embodiments, the pharmaceutical composition has a lower osmolality than a composition comprising a salt of the pharmaceutical compound and a salt of a complexing agent. In some embodiments, the pharmaceutical composition has a lower osmolality than a composition comprising a salt of the pharmaceutical compound. In some embodiments, the pharmaceutical composition has a lower osmolality than a composition comprising a salt of the complexing agent (e.g., a sodium salt). The pharmaceutical composition has substantially the same osmolality as a solution of the same concentration of salt of the complexing agent. In some embodiments, the pharmaceutical composition has substantially the same osmolality as a solution of the same concentration of sodium salt of the complexing agent. In some embodiments, the osmolality of pharmaceutical compositions is compared to those in which the concentrations of the pharmaceutical compound and complexing agent are the same. In some embodiments, the salt of the complexing agent used in the comparison is the sodium salt. In some embodiments, the salt of the pharmaceutical compound is the HCl salt.
[0232] In some embodiments, the pharmaceutical composition has an osmolality that is about 10% to about 50% lower than a corresponding pharmaceutical composition prepared from a salt of a complexing agent. In some embodiments, the pharmaceutical composition has an osmolality that is about 10% to about 20%, about 10% to about 30%, about 10% to about 40%, about 10% to about 50%, about 20% to about 30%, about 20% to about 40%, about 20% to about 50%, about 30% to about 40%, about 30% to about 50%, or about 40% to about 50% lower than a corresponding pharmaceutical composition prepared from a salt of a complexing agent. In some embodiments, the pharmaceutical composition has an osmolality that is about 10%, about 20%, about 30%, about 40%, or about 50% lower than a corresponding pharmaceutical composition prepared from a salt of a complexing agent. In some embodiments, the pharmaceutical composition has an osmolality that is at least about 10%, about 20%, about 30%, or about 40% lower than a corresponding pharmaceutical composition prepared from a salt of the complexing agent.
[0233] In some embodiments, the pharmaceutical composition has an osmolality that is about 10% to about 50% lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound. In some embodiments, the pharmaceutical composition has an osmolality that is about 10% to about 20%, about 10% to about 30%, about 10% to about 40%, about 10% to about 50%, about 20% to about 30%, about 20% to about 40%, about 20% to about 50%, about 30% to about 40%, about 30% to about 50%, or about 40% to about 50% lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound. In some embodiments, the pharmaceutical composition has an osmolality that is about 10%, about 20%, about 30%, about 40%, or about 50% lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound. In some embodiments, the pharmaceutical composition has an osmolality that is at least about 10%, about 20%, about 30%, or about 40% lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound.
[0234] In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg to about 500 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of a complexing agent. In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg to about 100 mOsm / kg, about 50 mOsm / kg to about 150 mOsm / kg, about 50 mOsm / kg to about 200 mOsm / kg, about 50 mOsm / kg to about 250 mOsm / kg, about 50 mOsm / kg to about 300 mOsm / kg, about 50 mOsm / kg to about 400 mOsm / kg, or about 50 mOsm / kg to about 600 mOsm / kg. Approx. 50mOsm / kg~Approx. 500mOsm / kg, Approx. 100mOsm / kg~Approx. 150mOsm / kg, Approx. 100mOsm / kg~Approx. 200mOsm / kg, Approx. 100mOsm / kg~Approx. 250mOs m / kg, about 100mOsm / kg to about 300mOsm / kg, about 100mOsm / kg to about 400mOsm / kg, about 100mOsm / kg to about 500mOsm / kg, about 150mOsm / kg to about 2 00mOsm / kg, about 150mOsm / kg to about 250mOsm / kg, about 150mOsm / kg to about 300mOsm / kg, about 150mOsm / kg to about 400mOsm / kg, about 150mOsm / kg~about 500mOsm / kg, about 200mOsm / kg~about 250mOsm / kg, about 200mOsm / kg~about 300mOsm / kg, about 200mOsm / kg~about 400mOsm / kg, about 20 The osmolality may be as low as 0 mOsm / kg to about 500 mOsm / kg, about 250 mOsm / kg to about 300 mOsm / kg, about 250 mOsm / kg to about 400 mOsm / kg, about 250 mOsm / kg to about 500 mOsm / kg, about 300 mOsm / kg to about 400 mOsm / kg, about 300 mOsm / kg to about 500 mOsm / kg, or about 400 mOsm / kg to about 500 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg, about 100 mOsm / kg, about 150 mOsm / kg, about 200 mOsm / kg, about 250 mOsm / kg, about 300 mOsm / kg, about 400 mOsm / kg, or about 500 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of a complexing agent.In some embodiments, the pharmaceutical composition has an osmolality that is at least about 50 mOsm / kg, about 100 mOsm / kg, about 150 mOsm / kg, about 200 mOsm / kg, about 250 mOsm / kg, about 300 mOsm / kg, or about 400 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of the complexing agent.
[0235] In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg to about 500 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound. In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg to about 100 mOsm / kg, about 50 mOsm / kg to about 150 mOsm / kg, about 50 mOsm / kg to about 200 mOsm / kg, about 50 mOsm / kg to about 250 mOsm / kg, about 50 mOsm / kg to about 300 mOsm / kg, or about 50 mOsm / kg to about 400 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound. g, about 50mOsm / kg to about 500mOsm / kg, about 100mOsm / kg to about 150mOsm / kg, about 100mOsm / kg to about 200mOsm / kg, about 100mOsm / kg to about 250mO sm / kg, about 100mOsm / kg to about 300mOsm / kg, about 100mOsm / kg to about 400mOsm / kg, about 100mOsm / kg to about 500mOsm / kg, about 150mOsm / kg to about 200mOsm / kg, about 150mOsm / kg to about 250mOsm / kg, about 150mOsm / kg to about 300mOsm / kg, about 150mOsm / kg to about 400mOsm / kg, about 150mOsm / kg~about 500mOsm / kg, about 200mOsm / kg~about 250mOsm / kg, about 200mOsm / kg~about 300mOsm / kg, about 200mOsm / kg~about 400mOsm / kg, about 20 The osmolality may be as low as 0 mOsm / kg to about 500 mOsm / kg, about 250 mOsm / kg to about 300 mOsm / kg, about 250 mOsm / kg to about 400 mOsm / kg, about 250 mOsm / kg to about 500 mOsm / kg, about 300 mOsm / kg to about 400 mOsm / kg, about 300 mOsm / kg to about 500 mOsm / kg, or about 400 mOsm / kg to about 500 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg, about 100 mOsm / kg, about 150 mOsm / kg, about 200 mOsm / kg, about 250 mOsm / kg, about 300 mOsm / kg, about 400 mOsm / kg, or about 500 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound.In some embodiments, the pharmaceutical composition has an osmolality that is at least about 50 mOsm / kg, about 100 mOsm / kg, about 150 mOsm / kg, about 200 mOsm / kg, about 250 mOsm / kg, about 300 mOsm / kg, or about 400 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of the pharmaceutical compound.
[0236] In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg to about 500 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of a pharmaceutical compound and a salt of a complexing agent. In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg to about 100 mOsm / kg, about 50 mOsm / kg to about 150 mOsm / kg, about 50 mOsm / kg to about 200 mOsm / kg, about 50 mOsm / kg to about 250 mOsm / kg, about 50 mOsm / kg to about 300 mOsm / kg, or about 50 mOsm / kg to about 400 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of a pharmaceutical compound and a salt of a complexing agent. mOsm / kg, about 50mOsm / kg to about 500mOsm / kg, about 100mOsm / kg to about 150mOsm / kg, about 100mOsm / kg to about 200mOsm / kg, about 100mOsm / kg to about 250mOsm / kg, about 100mOsm / kg to about 300mOsm / kg, about 100mOsm / kg to about 400mOsm / kg, about 100mOsm / kg to about 500mOsm / kg, about 150mOsm / kg ~ approx. 200mOsm / kg, approx. 150mOsm / kg ~ approx. 250mOsm / kg, approx. 150mOsm / kg ~ approx. 300mOsm / kg, approx. 150mOsm / kg ~ approx. 400mOsm / kg, approx. 150m Osm / kg~about 500mOsm / kg, about 200mOsm / kg~about 250mOsm / kg, about 200mOsm / kg~about 300mOsm / kg, about 200mOsm / kg~about 400mOsm / kg, about The osmolality may be as low as 200 mOsm / kg to about 500 mOsm / kg, about 250 mOsm / kg to about 300 mOsm / kg, about 250 mOsm / kg to about 400 mOsm / kg, about 250 mOsm / kg to about 500 mOsm / kg, about 300 mOsm / kg to about 400 mOsm / kg, about 300 mOsm / kg to about 500 mOsm / kg, or about 400 mOsm / kg to about 500 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality that is about 50 mOsm / kg, about 100 mOsm / kg, about 150 mOsm / kg, about 200 mOsm / kg, about 250 mOsm / kg, about 300 mOsm / kg, about 400 mOsm / kg, or about 500 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of a pharmaceutical compound and a salt of a complexing agent.In some embodiments, the pharmaceutical composition has an osmolality that is at least about 50 mOsm / kg, about 100 mOsm / kg, about 150 mOsm / kg, about 200 mOsm / kg, about 250 mOsm / kg, about 300 mOsm / kg, or about 400 mOsm / kg lower than a corresponding pharmaceutical composition prepared from a salt of a pharmaceutical compound and a salt of a complexing agent.
[0237] In some embodiments, the pharmaceutical compositions provided herein are formulated for subcutaneous administration. Subcutaneously deliverable compounds have the advantage over other forms of compounds (e.g., IV or IM delivery), in that they can be used outside of hospitals or clinical settings, such as by patients using them at home. Other formulations of compounds suitable for home use, such as oral or nasal delivery formulations, tend to require higher doses to achieve the same clinical effect, which carries risks including bladder dysfunction due to higher doses and dissociation effects. In addition, oral or sublingual administration is sometimes unreliable due to the presence of food or chyme in the stomach or proximal small intestine and substantial first-pass metabolism. Intranasal administration can, in certain circumstances, cause allergic or irritant rhinitis, epistaxis (nosebleeds), or bacterial or viral sinusitis.
[0238] In some embodiments, the pharmaceutical formulations provided herein can combine high concentrations of compound (e.g., >20 mg / mL) with additional features of formulations ideally suited for subcutaneous injection. These additional features may include osmolality and pH closer to physiological levels than is possible with compositions prepared exclusively or partially with salts of the compound and / or complexing agent, while still maintaining formulation stability and compound solubility. In some embodiments, these desired properties are achieved through the use of complexing agents, particularly cyclodextrins, that act to enhance compound solubility at high pH (e.g., as high as about 5.5, or another pH near the lower limit of the buffering capacity of the particular compound of interest). In some embodiments, these attributes are further enhanced through the use of modified cyclodextrins, particularly cyclodextrins modified with sulfonate functional groups (e.g., sulfobutyl-ether-β-cyclodextrin (SBEBCD)). In some embodiments, the use of cyclodextrins (e.g., SBEBCD) modified to replace sodium in the sulfonate sodium salt functional group to form a sulfonic acid functional group is particularly advantageous because the sulfonic acid functional group can act as a counteranion to protonate the unionized or free base form of the compound. In such embodiments, low osmolality in high-concentration pharmaceutical compound formulations is achieved because additional salts and counterions can be omitted from the formulation. Thus, high concentrations of compounds at pH levels compatible with subcutaneous injection can be achieved with osmolalities comparable to physiological levels (~300 mOsm / kg), thus enabling subcutaneous administration of compounds without side effects such as pain or injection site irritation.
[0239] In some embodiments, the pharmaceutical composition is a solution. In some embodiments, the pharmaceutical composition is a solid. In some embodiments, the pharmaceutical composition has a pH greater than about 4.
[0240] In some embodiments, the pharmaceutical composition has a pH of about 4 to about 7. In some embodiments, the pharmaceutical composition has a pH of about 4 to about 7. In some embodiments, the pharmaceutical composition has a pH of about 4 to about 4.5, about 4 to about 5, about 4 to about 5.5, about 4 to about 6, about 4 to about 6.5, about 4 to about 7, about 4.5 to about 5, about 4.5 to about 5.5, about 4.5 to about 6, about 4.5 to about 6.5, about 4.5 to about 7, about 5 to about 5.5, about 5 to about 6, about 5 to about 6.5, about 5 to about 7, about 5.5 to about 6, about 5.5 to about 6.5, about 5.5 to about 7, about 6 to about 6.5, about 6 to about 7, or about 6.5 to about 7. In some embodiments, the pharmaceutical composition has a pH of about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, or about 7. In some embodiments, the pharmaceutical composition has a pH of at least about 4, about 4.5, about 5, about 5.5, about 6, or about 6.5. In some embodiments, the pharmaceutical composition has a pH of at most about 4.5, about 5, about 5.5, about 6, about 6.5, or about 7.
[0241] In some embodiments, the pharmaceutical composition has a pH of about 4.5 to about 6.5.
[0242] In some embodiments, the pharmaceutical composition has an osmolality of about 250 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 275 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 300 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 325 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 350 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 375 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 400 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 300 mOsm / kg to about 450 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 475 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 500 mOsm / kg to about 850 mOsm / kg.
[0243] In some embodiments, the pharmaceutical composition has an osmolality of at least about 250 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 275 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 300 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 325 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 350 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 375 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 400 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 425 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 450 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 475 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of at least about 500 mOsm / kg.
[0244] In some embodiments, the pharmaceutical composition has an osmolality of less than about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 825 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 800 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 775 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 750 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 725 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 700 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 675 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 650 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 625 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 600 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 575 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 550 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 525 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 500 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 450 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 400 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of less than about 350 mOsm / kg.
[0245] In some embodiments, the pharmaceutical composition has an osmolality of about 300 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 300 mOsm / kg to about 350 mOsm / kg, about 300 mOsm / kg to about 400 mOsm / kg, about 300 mOsm / kg to about 450 mOsm / kg, about 300 mOsm / kg to about 500 mOsm / kg, about 300 mOsm / kg to about 550 mOsm / kg, about 300 mOsm / kg to about 600 mOsm / kg, about 300 mOsm / kg to about 650 mOsm / kg, about 300 mOsm / kg to about 700 mOsm / kg, or about 300 mOsm / kg to about 750 mOsm / kg. kg, about 300mOsm / kg to about 800mOsm / kg, about 300mOsm / kg to about 850mOsm / kg, about 350mOsm / kg to about 400mOsm / kg, about 350mOsm / kg to about 450mOsm / kg, about 350mOsm / kg to about 500m Osm / kg, about 350mOsm / kg to about 550mOsm / kg, about 350mOsm / kg to about 600mOsm / kg, about 350mOsm / kg to about 650mOsm / kg, about 350mOsm / kg to about 700mOsm / kg, about 350mOsm / kg to about 7 50mOsm / kg, about 350mOsm / kg to about 800mOsm / kg, about 350mOsm / kg to about 850mOsm / kg, about 400mOsm / kg to about 450mOsm / kg, about 400mOsm / kg to about 500mOsm / kg, about 400mOsm / k g ~ about 550mOsm / kg, about 400mOsm / kg - about 600mOsm / kg, about 400mOsm / kg - about 650mOsm / kg, about 400mOsm / kg - about 700mOsm / kg, about 400mOsm / kg - about 750mOsm / kg, about 400mOs m / kg~about 800mOsm / kg, about 400mOsm / kg~about 850mOsm / kg, about 450mOsm / kg~about 500mOsm / kg, about 450mOsm / kg~about 550mOsm / kg, about 450mOsm / kg~about 600mOsm / kg, about 45 0mOsm / kg~about 650mOsm / kg, about 450mOsm / kg~about 700mOsm / kg, about 450mOsm / kg~about 750mOsm / kg, about 450mOsm / kg~about 800mOsm / kg, about 450mOsm / kg~about 850mOsm / kg,Approximately 500mOsm / kg to approximately 550mOsm / kg, approximately 500mOsm / kg to approximately 600mOsm / kg, approximately 500mOsm / kg to approximately 650mOsm / kg, approximately 500mOsm / kg to approximately 7 00mOsm / kg, about 500mOsm / kg to about 750mOsm / kg, about 500mOsm / kg to about 800mOsm / kg, about 500mOsm / kg to about 850mOsm / kg, about 550 mOsm / kg ~ approx. 600mOsm / kg, approx. 550mOsm / kg ~ approx. 650mOsm / kg, approx. 550mOsm / kg ~ approx. 700mOsm / kg, approx. 550mOsm / kg ~ approx. 750mO sm / kg, about 550mOsm / kg to about 800mOsm / kg, about 550mOsm / kg to about 850mOsm / kg, about 600mOsm / kg to about 650mOsm / kg, about 600mOsm / kg ~ approx. 700mOsm / kg, approx. 600mOsm / kg ~ approx. 750mOsm / kg, approx. 600mOsm / kg ~ approx. 800mOsm / kg, approx. 600mOsm / kg ~ approx. 850mOsm / k g, about 650mOsm / kg to about 700mOsm / kg, about 650mOsm / kg to about 750mOsm / kg, about 650mOsm / kg to about 800mOsm / kg, about 650mOsm / kg to The osmolality is about 850 mOsm / kg, about 700 mOsm / kg to about 750 mOsm / kg, about 700 mOsm / kg to about 800 mOsm / kg, about 700 mOsm / kg to about 850 mOsm / kg, about 750 mOsm / kg to about 800 mOsm / kg, about 750 mOsm / kg to about 850 mOsm / kg, or about 800 mOsm / kg to about 850 mOsm / kg. In some embodiments, the pharmaceutical composition has an osmolality of about 300 mOsm / kg, about 350 mOsm / kg, about 400 mOsm / kg, about 450 mOsm / kg, about 500 mOsm / kg, about 550 mOsm / kg, about 600 mOsm / kg, about 650 mOsm / kg, about 700 mOsm / kg, about 750 mOsm / kg, about 800 mOsm / kg, or about 850 mOsm / kg. In some embodiments, the pharmaceutical composition provides a concentration of at least about 300 mOsm / kg, about 350 mOsm / kg, about 400 mOsm / kg, about 450 mOsm / kg, about 500 mOsm / kg, about 550 mOsm / kg, about 600 mOsm / kg, about 650 mOsm / kg, about 700 mOsm / kg,In some embodiments, the pharmaceutical composition has an osmolality of at most about 350 mOsm / kg, about 400 mOsm / kg, about 450 mOsm / kg, about 500 mOsm / kg, about 550 mOsm / kg, about 600 mOsm / kg, about 650 mOsm / kg, about 700 mOsm / kg, about 750 mOsm / kg, about 800 mOsm / kg, or about 850 mOsm / kg.
[0246] In some embodiments, the pharmaceutical composition is isotonic
[0247] In some embodiments, the pharmaceutical composition has an osmolality of about 500 mOsm / kg.
[0248] In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 20 mg / mL to about 150 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of up to about 150 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of at least about 20 mg / mL.
[0249] In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 80 mg / mL to about 120 mg / mL.
[0250] In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 95 mg / mL to about 105 mg / mL.
[0251] In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 20 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 25 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 30 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 35 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 40 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 45 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 50 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 55 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 60 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 65 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 70 mg / mL.In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 75 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 80 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 85 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 90 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 95 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 100 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 105 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 110 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 115 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 120 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 125 mg / mL.In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 130 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 135 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 140 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 145 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate, has a concentration of about 150 mg / mL.
[0252] In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 95 mg / mL, about 96 mg / mL, about 97 mg / mL, about 98 mg / mL, about 99 mg / mL, about 100 mg / mL, about 101 mg / mL, 102 mg / mL, about 103 mg / mL, about 104 mg / mL, or about 105 mg / mL.
[0253] In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 20 mg / mL to about 150 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of from about 20 mg / mL to about 40 mg / mL, from about 20 mg / mL to about 60 mg / mL, from about 20 mg / mL to about 80 mg / mL, from about 20 mg / mL to about 100 mg / mL, from about 20 mg / mL to about 120 mg / mL, from about 20 mg / mL to about 140 mg / mL, from about 20 mg / mL to about 150 mg / mL, from about 40 mg / mL to about 60 mg / mL, from about 40 mg / mL to about 80 mg / mL, from about 40 mg / mL to about 100 mg / mL, from about 40 mg / mL to about 120 mg / mL, from about 40 mg / mL to about 140 mg / mL, from about 40 mg / mL to about 15 The concentration is about 0 mg / mL, about 60 mg / mL to about 80 mg / mL, about 60 mg / mL to about 100 mg / mL, about 60 mg / mL to about 120 mg / mL, about 60 mg / mL to about 140 mg / mL, about 60 mg / mL to about 150 mg / mL, about 80 mg / mL to about 100 mg / mL, about 80 mg / mL to about 120 mg / mL, about 80 mg / mL to about 140 mg / mL, about 80 mg / mL to about 150 mg / mL, about 100 mg / mL to about 120 mg / mL, about 100 mg / mL to about 140 mg / mL, about 100 mg / mL to about 150 mg / mL, about 120 mg / mL to about 140 mg / mL, about 120 mg / mL to about 150 mg / mL, or about 140 mg / mL to about 150 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of about 20 mg / mL, about 40 mg / mL, about 60 mg / mL, about 80 mg / mL, about 100 mg / mL, about 120 mg / mL, about 140 mg / mL, or about 150 mg / mL.In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of at least about 20 mg / mL, about 40 mg / mL, about 60 mg / mL, about 80 mg / mL, about 100 mg / mL, about 120 mg / mL, or about 140 mg / mL. In some embodiments, the pharmaceutical compound, or its enantiomer, mixture of enantiomers, or isotopic variant, or solvate or hydrate thereof, has a concentration of at most about 40 mg / mL, about 60 mg / mL, about 80 mg / mL, about 100 mg / mL, about 120 mg / mL, about 140 mg / mL, or about 150 mg / mL.
[0254] In some embodiments, the cyclodextrin is present in an amount of about 50 mg / mL to about 600 mg / mL. In some embodiments, the cyclodextrin is present in an amount of about 10 mg / mL to about 600 mg / mL. In some embodiments, the cyclodextrin is present in an amount of about 50 mg / mL to about 600 mg / mL. In some embodiments, the cyclodextrin is from about 50 mg / mL to about 100 mg / mL, from about 50 mg / mL to about 200 mg / mL, from about 50 mg / mL to about 300 mg / mL, from about 50 mg / mL to about 400 mg / mL, from about 50 mg / mL to about 500 mg / mL, from about 50 mg / mL to about 600 mg / mL, from about 100 mg / mL to about 200 mg / mL, from about 100 mg / mL to about 300 mg / mL, from about 100 mg / mL to about 400 mg / mL, from about 100 mg / mL to about 500 mg / mL, or from about 100 mg / mL to about 150 mg / mL. In some embodiments, the cyclodextrin is present in an amount of about 50 mg / mL, about 100 mg / mL, about 200 mg / mL, about 300 mg / mL, about 400 mg / mL, about 500 mg / mL, or about 600 mg / mL. In some embodiments, the cyclodextrin is present in an amount of at least about 50 mg / mL, about 100 mg / mL, about 200 mg / mL, about 300 mg / mL, about 400 mg / mL, or about 500 mg / mL, hi some embodiments, the cyclodextrin is present in an amount of at most about 100 mg / mL, about 200 mg / mL, about 300 mg / mL, about 400 mg / mL, about 500 mg / mL, or about 600 mg / mL.
[0255] In some embodiments, the pharmaceutical composition further comprises a preservative. In some embodiments, the preservative is benzethonium chloride. In some embodiments, the benzethonium chloride is present in an amount of about 0.1 mg / mL to about 0.5 mg / mL. In some embodiments, the preservative is benzethonium chloride, benzalkonium chloride, or chloroxylenol. Other preservatives include benzyl alcohol, methylparaben, ethyl or n-propyl, and p-hydroxybenzoate. In some embodiments, the preservative is an antimicrobial agent, including, but not limited to, phenol, meta-cresol, benzyl alcohol, paraben (methyl, propyl, or butyl), benzalkonium chloride, benzethonium chloride, chlorobutanol, myristyl gamma picolinium chloride, 2-phenoxyethanol, phenylethyl alcohol, sorbates (sorbic acid, sodium sorbate), ethanol, and / or propylene glycol. In some embodiments, the preservative is present in an amount of about 0.1 mg / mL to about 1 mg / mL.In some embodiments, the preservative is from about 0.1 mg / mL to about 0.2 mg / mL, from about 0.1 mg / mL to about 0.3 mg / mL, from about 0.1 mg / mL to about 0.4 mg / mL, from about 0.1 mg / mL to about 0.5 mg / mL, from about 0.1 mg / mL to about 0.6 mg / mL, from about 0.1 mg / mL to about 0.7 mg / mL, from about 0.1 mg / mL to about 0.8 mg / mL, from about 0.1 mg / mL to about 0.9 mg / mL, from about 0.1 mg / mL to about 1 mg / mL, from about 0.2 mg / mL to about 0.3 mg / mL, from about 0.2 mg / mL to about 0.0 mg / mL, .4mg / mL, about 0.2mg / mL to about 0.5mg / mL, about 0.2mg / mL to about 0.6mg / mL, about 0.2mg / mL to about 0.7mg / mL, about 0.2mg / mL to about 0.8mg / mL, about 0.2mg / mL to about 0.9mg / mL, about 0.2m g / mL~about 1mg / mL, about 0.3mg / mL~about 0.4mg / mL, about 0.3mg / mL~about 0.5mg / mL, about 0.3mg / mL~about 0.6mg / mL, about 0.3mg / mL~about 0.7mg / mL, about 0.3mg / mL~about 0.8mg / mL, about 0.3mg / mL~about 0.9mg / mL, about 0.3mg / mL~about 1mg / mL, about 0.4mg / mL~about 0.5mg / mL, about 0.4mg / mL~about 0.6mg / mL, about 0.4mg / mL~about 0.7mg / mL, about 0.4mg / mL~about 0.8mg / mL, approximately 0.4 mg / mL to approximately 0.9 mg / mL, approximately 0.4 mg / mL to approximately 1 mg / mL, approximately 0.5 mg / mL to approximately 0.6 mg / mL, approximately 0.5 mg / mL to approximately 0.7 mg / mL, approximately 0.5 mg / mL to approximately 0.8 mg / mL, approximately 0.5 mg / mL to approximately 0 The compound is present in an amount of about 0.9 mg / mL, about 0.5 mg / mL to about 1 mg / mL, about 0.6 mg / mL to about 0.7 mg / mL, about 0.6 mg / mL to about 0.8 mg / mL, about 0.6 mg / mL to about 0.9 mg / mL, about 0.6 mg / mL to about 1 mg / mL, about 0.7 mg / mL to about 0.8 mg / mL, about 0.7 mg / mL to about 0.9 mg / mL, about 0.7 mg / mL to about 1 mg / mL, about 0.8 mg / mL to about 0.9 mg / mL, about 0.8 mg / mL to about 1 mg / mL, or about 0.9 mg / mL to about 1 mg / mL.In some embodiments, the preservative is present in an amount of about 0.1 mg / mL, about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, about 0.8 mg / mL, about 0.9 mg / mL, or about 1 mg / mL. In some embodiments, the preservative is present in an amount of at least about 0.1 mg / mL, about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, about 0.8 mg / mL, or about 0.9 mg / mL. In some embodiments, the preservative is present in an amount of up to about 0.2 mg / mL, about 0.3 mg / mL, about 0.4 mg / mL, about 0.5 mg / mL, about 0.6 mg / mL, about 0.7 mg / mL, about 0.8 mg / mL, about 0.9 mg / mL, or about 1 mg / mL.
[0256] In some embodiments of the pharmaceutical compositions disclosed herein, the formulation is a subcutaneous (e.g., injection or bolus) dosage form. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 3.0 to about 7.0. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 4.0 to about 5.0. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 4.5 to about 5.5. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 5.0 to about 6.0. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 5.5 to about 6.5. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 6.0 to about 7.0. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 3.0. In some embodiments of the pharmaceutical composition, the formulation is a subcutaneous dosage form, the pH is about 3.5. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 4.0. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 4.5. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.0. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.1. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.2. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.3. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.4. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.5. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.6. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.7. In some embodiments of the pharmaceutical composition, the form is a subcutaneous dosage form, the pH is about 5.8. In some embodiments of the pharmaceutical composition in a subcutaneous dosage form, the pH is about 5.9. In some embodiments of the pharmaceutical composition in a subcutaneous dosage form, the pH is about 6.0. In some embodiments of the pharmaceutical composition in a subcutaneous dosage form, the pH is about 6.5. In some embodiments of the pharmaceutical composition in a subcutaneous dosage form, the pH is about 7.0.
[0257] Intranasal preparations In some embodiments, pharmaceutical compositions containing the pharmaceutical compounds provided herein are formulated for intranasal administration. While many traditional approaches to intranasal administration of pharmaceutical compounds face distinct challenges due to poor tissue tolerance (e.g., burning sensation, nosebleeds, infections), bioavailability, and tissue uptake rate, pharmaceutical compositions containing complexing agent salts provided herein overcome many of these difficulties. In some cases, the complexing agent / pharmaceutical compound salt allows delivery of the selected compound at a target pH compatible with native tissue conditions while maintaining an osmolality compatible with nasal tissue. Furthermore, in some cases, the presence of a complexing agent ionically associated with the pharmaceutical compound helps solubilize non-ionized compound components as the pharmaceutical composition is deposited in the nasal tissue, where ions and other compounds exchange with components of the nasal mucosa to enable compound uptake. In some cases, the presence of a complexing agent in the formulation further allows for enhanced solubility of the pharmaceutical compound at the pH of the surrounding nasal mucosa after delivery.
[0258] Furthermore, in some embodiments, pharmaceutical compositions comprising a complexing agent / pharmaceutical compound salt provided herein contain additional equivalents of the pharmaceutical compound that are not ionically bonded to the complexing agent, such as a non-ionized pharmaceutical compound or one ionized with a different counterion. When an additional non-ionized pharmaceutical compound is used, the complexing agent (e.g., a cyclodextrin such as SBEBCD) can complex with this additional pharmaceutical compound through non-ionic interactions. Furthermore, the pharmaceutical composition may further contain additional equivalents of the non-ionized pharmaceutical compound relative to the amount of complexing agent present (e.g., up to 20 molar equivalents of the free base pharmaceutical compound). When a substantial excess of the pharmaceutical compound is present, the cyclodextrin can deliver and solubilize one equivalent of the pharmaceutical compound at a time through complexing interactions with the cyclodextrin core and, further, can act in a shuttle-like mechanism to further solubilize additional molar equivalents of the free base pharmaceutical compound that may be present. When such formulations are administered, bioavailability and tolerability may be increased due to the presence of a certain amount of the non-ionized pharmaceutical compound. This can occur for several reasons, including that the free base (non-ionized) pharmaceutical compound is more easily taken up by relevant cells and distributed (e.g., by passive diffusion) to target tissues in the body. Furthermore, the presence of additional non-ionized pharmaceutical compound can act as a buffer to help achieve the desired pH of the localized tissue (which depends on the amount of non-ionized pharmaceutical compound added and the pKa of the pharmaceutical compound). Thus, in some embodiments, the desired pH can be achieved without the presence of an additional base or buffer.
[0259] In some embodiments, the pharmaceutical composition comprising the complexing agent / pharmaceutical compound salt is formulated for intranasal administration. In some embodiments, the pharmaceutical composition is formulated as an inhalable powder for intranasal administration. In some embodiments, the pharmaceutical composition is formulated as a liquid suspension for intranasal administration. In some embodiments, the pharmaceutical composition is formulated as a liquid solution for intranasal administration. In some embodiments, the liquid suspension is an aqueous suspension. In some embodiments, the liquid solution is an aqueous solution.
[0260] In some embodiments, the pharmaceutical composition comprises an additional equivalent of a pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises an additional molar equivalent of a pharmaceutical compound. In some embodiments, the additional equivalent is measured relative to the number of moles of complexing agent. In some embodiments, the additional equivalent is measured relative to the number of moles of a pharmaceutical compound that forms a salt with the complexing agent.
[0261] In some embodiments, the pharmaceutical composition comprises an additional equivalent of the non-ionized pharmaceutical compound compared to the protonated pharmaceutical compound of the complexing agent / protonated pharmaceutical compound salt. In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalent to about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.1 molar equivalent to about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalent to about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises about 0.1 molar equivalents to about 0.2 molar equivalents, about 0.1 molar equivalents to about 0.5 molar equivalents, about 0.1 molar equivalents to about 0.75 molar equivalents, about 0.1 molar equivalents to about 1 molar equivalent, about 0.2 molar equivalents to about 0.5 molar equivalents, about 0.2 molar equivalents to about 0.75 molar equivalents, about 0.2 molar equivalents to about 1 molar equivalent, about 0.5 molar equivalents to about 0.75 molar equivalents, about 0.5 molar equivalents to about 1 molar equivalent, or about 0.75 molar equivalents to about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises about 0.1 molar equivalent, about 0.2 molar equivalent, about 0.5 molar equivalent, about 0.75 molar equivalent, or about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises at least about 0.1 molar equivalent, about 0.2 molar equivalent, about 0.5 molar equivalent, or about 0.75 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises up to about 0.2 molar equivalent, about 0.5 molar equivalent, about 0.75 molar equivalent, or about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.5 equivalent to about 5 equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises about 0.5 equivalents to about 1 equivalent, about 0.5 equivalents to about 2 equivalents, about 0.5 equivalents to about 3 equivalents, about 0.5 equivalents to about 4 equivalents, about 0.5 equivalents to about 5 equivalents, about 1 equivalent to about 2 equivalents, about 1 equivalent to about 3 equivalents, about 1 equivalent to about 4 equivalents, about 1 equivalent to about 5 equivalents, about 2 equivalents to about 3 equivalents, about 2 equivalents to about 4 equivalents, about 2 equivalents to about 5 equivalents, about 3 equivalents to about 4 equivalents, about 3 equivalents to about 5 equivalents, or about 4 equivalents to about 5 equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises about 0.5 equivalents, about 1 equivalent, about 2 equivalents, about 3 equivalents, about 4 equivalents, or about 5 equivalents of the non-ionized pharmaceutical compound.In some embodiments, the pharmaceutical composition comprises at least about 0.5 equivalents, about 1 equivalent, about 2 equivalents, about 3 equivalents, or about 4 equivalents of the non-ionized pharmaceutical compound, hi some embodiments, the pharmaceutical composition comprises at most about 1 equivalent, about 2 equivalents, about 3 equivalents, about 4 equivalents, or about 5 equivalents of the non-ionized pharmaceutical compound.
[0262] In some embodiments, the pharmaceutical composition comprises a sufficient amount of a non-ionized pharmaceutical compound to form a buffer system with the ionized pharmaceutical compound in the composition. In some embodiments, the buffer system is at a desired pH. In some embodiments, the buffer system provides a desired pH upon administration to nasal tissue.
[0263] In some embodiments, the buffer system provides a pH within a target range of the pKa value of the pharmaceutical compound. In some embodiments, the target pH is within about 0.2 pH units to about 2 pH units of the pKa value. In some embodiments, the target pH is within about 0.2 pH units to about 0.5 pH units, about 0.2 pH units to about 1 pH unit, about 0.2 pH units to about 1.5 pH units, about 0.2 pH units to about 2 pH units, about 0.5 pH units to about 1 pH unit, about 0.5 pH units to about 1.5 pH units, about 0.5 pH units to about 2 pH units, about 1 pH units to about 1.5 pH units, about 1 pH units to about 2 pH units, or about 1.5 pH units to about 2 pH units of the pKa value. In some embodiments, the target pH is within about 0.2 pH units, about 0.5 pH units, about 1 pH unit, about 1.5 pH units, or about 2 pH units of the pKa value. In some embodiments, the target pH is within at least about 0.2 pH units, about 0.5 pH units, about 1 pH unit, or about 1.5 pH units of the pKa value, hi some embodiments, the target pH is within at most about 0.5 pH units, about 1 pH units, about 1.5 pH units, or about 2 pH units of the pKa value.
[0264] In some embodiments, the buffer system provides a pH at which a specific percentage of the pharmaceutical compound is ionized upon administration. In some embodiments, the buffer system provides a pH at which about 1% to about 99% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which about 1% to about 5%, about 1% to about 10%, about 1% to about 25%, about 1% to about 50%, about 1% to about 70%, about 1% to about 90%, about 1% to about 95%, about 1% to about 99%, about 5% to about 10%, about 5% to about 25%, about 5% to about 50%, about 5% to about 70%, about 5% to about 90%, about 5% to about 95%, about 5% to about 99%, about 10% to about 25%, about 10% to about 50%, or about 10% to about 70%. The pH may be such that about 10% to about 90%, about 10% to about 95%, about 10% to about 99%, about 25% to about 50%, about 25% to about 70%, about 25% to about 90%, about 25% to about 95%, about 25% to about 99%, about 50% to about 70%, about 50% to about 90%, about 50% to about 95%, about 50% to about 99%, about 70% to about 90%, about 70% to about 95%, about 70% to about 99%, about 90% to about 95%, about 90% to about 99%, or about 95% to about 99% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which about 1%, about 5%, about 10%, about 25%, about 50%, about 70%, about 90%, about 95%, or about 99% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which at least about 1%, about 5%, about 10%, about 25%, about 50%, about 70%, about 90%, or about 95% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which up to about 5%, about 10%, about 25%, about 50%, about 70%, about 90%, about 95%, or about 99% of the pharmaceutical compound is ionized. In some embodiments, percent ionization is measured immediately after administration.
[0265] In some embodiments, the pharmaceutical composition comprises an additional molar equivalent of the non-ionized pharmaceutical compound relative to the complexing agent of the complexing agent / protonated pharmaceutical compound salt. In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalent to about 10 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent. In some embodiments, the pharmaceutical composition comprises from about 0.1 molar equivalent to about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalent to about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition is in an amount of about 0.1 molar equivalents to about 0.5 molar equivalents, about 0.1 molar equivalents to about 1 molar equivalent, about 0.1 molar equivalents to about 2 molar equivalents, about 0.1 molar equivalents to about 3 molar equivalents, about 0.1 molar equivalents to about 5 molar equivalents, about 0.1 molar equivalents to about 7 molar equivalents, about 0.1 molar equivalents to about 10 molar equivalents, about 0.5 molar equivalents to about 1 molar equivalent, about 0.5 molar equivalents to about 2 molar equivalents, about 0.5 molar equivalents to about 3 molar equivalents, about 0.5 molar equivalents to about 5 molar equivalents, about 0.5 molar equivalents to about 7 molar equivalents, about 0.5 molar equivalents to about 10 molar equivalents, The non-ionized pharmaceutical compound may comprise about 1 molar equivalent to about 2 molar equivalents, about 1 molar equivalent to about 3 molar equivalents, about 1 molar equivalent to about 5 molar equivalents, about 1 molar equivalent to about 7 molar equivalents, about 1 molar equivalent to about 10 molar equivalents, about 2 molar equivalents to about 3 molar equivalents, about 2 molar equivalents to about 5 molar equivalents, about 2 molar equivalents to about 7 molar equivalents, about 2 molar equivalents to about 10 molar equivalents, about 3 molar equivalents to about 5 molar equivalents, about 3 molar equivalents to about 7 molar equivalents, about 3 molar equivalents to about 10 molar equivalents, about 5 molar equivalents to about 7 molar equivalents, about 5 molar equivalents to about 10 molar equivalents, or about 7 molar equivalents to about 10 molar equivalents. In some embodiments, the pharmaceutical composition comprises about 0.1 molar equivalents, about 0.5 molar equivalents, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, about 7 molar equivalents, or about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises at least about 0.1 molar equivalents, about 0.5 molar equivalents, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, or about 7 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises at most about 0.5 molar equivalents, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, about 7 molar equivalents, or about 10 molar equivalents of the non-ionized pharmaceutical compound.In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalents to about 20 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent. In some embodiments, the pharmaceutical composition comprises from about 1 molar equivalent to about 20 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent. In some embodiments, at least a portion of these additional equivalents of the non-ionized pharmaceutical compound relative to the complexing agent is complexed to the complexing agent (e.g., up to about 1 molar equivalent of the non-ionized pharmaceutical compound).
[0266] In some embodiments, the pharmaceutical composition comprises a carrier suitable for intranasal administration. The carrier is usually inert and often serves as a diluent for dispensing the therapeutic agent into a storage container or device such as a capsule, or to assist in the intranasal administration of the pharmaceutical compound. In some embodiments, the pharmaceutically acceptable carrier for the composition includes, but is not limited to, amino acids, peptides, proteins, non-biological polymers, biological polymers, monosaccharides, carbohydrates, gums, inorganic salts, and metal compounds, which may be present alone or in combination. In some embodiments, the pharmaceutically acceptable carrier comprises a natural form, a derivatized form, a modified form, or a combination thereof.
[0267] In some embodiments, useful proteins include, but are not limited to, gelatin or albumin. In some embodiments, useful sugars that can serve as pharmaceutically acceptable carriers include, but are not limited to, fructose, galactose, glucose, lactitol, lactose, maltitol, maltose, mannitol, melezitose, myo-inositol, palatinite, raffinose, stachyose, sucrose, trehalose, xylitol, hydrates thereof, and combinations thereof.
[0268] In some embodiments, useful carbohydrates that can serve as pharmaceutically acceptable carriers include, but are not limited to, starches such as corn starch, potato starch, amylose, amylopectin, pectin, hydroxypropyl starch, carboxymethyl starch, and cross-linked starch. In other embodiments, useful carbohydrates that can function as pharmaceutically acceptable carriers include, but are not limited to, cellulose, crystalline cellulose, microcrystalline cellulose, α-cellulose, methylcellulose, hydroxypropyl cellulose, carboxymethylcellulose, ethylcellulose, hydroxypropylmethylcellulose, and cellulose acetate.
[0269] In another embodiment, useful inorganic salts or metal compounds include, but are not limited to, aluminum, calcium, magnesium, silicon, and zinc salts. In some embodiments, aluminum salts include, for example, aluminum hydroxychloride, aluminum magnesium hydroxide, aluminum hydroxide, aluminum sulfate, aluminum stearate, aluminum monostearate, and potassium aluminum sulfate. In other embodiments, calcium salts include, for example, apatite, hydroxyapatite, calcium carbonate, calcium chloride, calcium citrate, calcium silicate, calcium oxide, calcium hydroxide, calcium stearate, tribasic calcium phosphate, calcium lactate, calcium oleate, calcium palmitate, calcium hydrogen phosphate, primary calcium phosphate, calcium acetate, and calcium sulfate. In some embodiments, magnesium compounds include, for example, magnesium chloride, magnesium aluminate silicate, magnesium silicate, magnesium oxide, magnesium hydroxide, magnesium stearate, magnesium carbonate, magnesium sulfate, and sodium magnesium silicate.
[0270] In some embodiments, the carrier is substantially water-insoluble. In further embodiments, the substantially water-insoluble carrier is selected from the group consisting of peptides, proteins, non-biological polymers, biological polymers, carbohydrates, gums, inorganic salts, and metal compounds. In some embodiments, the substantially water-insoluble carbohydrate comprises cellulose, crystalline cellulose, and microcrystalline cellulose.
[0271] In some embodiments, the carrier is substantially water-soluble. In further embodiments, the substantially water-soluble carrier is selected from the group consisting of polysaccharides, sugars, salts, peptides, proteins, carbohydrates, non-biological polymers, biological polymers, gums, inorganic salts, and metal compounds. In some embodiments, the substantially water-soluble polysaccharide is cellulose. In some embodiments, the cellulose is hydroxypropyl cellulose, carboxymethyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, or cellulose acetate. In other embodiments, the substantially water-soluble polysaccharide is starch. In some embodiments, the substantially water-soluble starch is hydroxypropyl starch, carboxymethyl starch, cross-linked starch, amylose, amylopectin, or pectin, and combinations thereof. In some embodiments, the substantially water-soluble sugar comprises fructose, galactose, glucose, lactitol, lactose, maltitol, maltose, mannitol, melezitose, myo-inositol, palatinite, raffinose, stachyose, sucrose, trehalose, xylitol, hydrates thereof, and combinations thereof.
[0272] Typically, the carrier has a mean particle size and / or particle size distribution substantially larger than that of the drug. Small particle size therapeutic agents often exhibit very poor flow characteristics, impairing the accuracy of the dispensed drug when filled into a storage container or device, such as a capsule. The same poor flow characteristics also interfere with aerosolization or atomization characteristics, impairing the intended amount of therapeutic agent to be delivered to the patient. By blending a microcrystalline therapeutic agent with an excess of a carrier having a substantially larger median particle size, the flow characteristics of the composition essentially determine the characteristics of the carrier, thereby improving the handling characteristics necessary for accurate dispensing and administration.
[0273] For some formulations herein, the carrier particles have an average particle size of at least 1 μm, at least 2 μm, at least 3 μm, at least 4 μm, at least 5 μm, at least 10 μm, at least 15 μm, at least 20 μm, at least 25 μm, at least 30 μm, at least 40 μm, at least 50 μm, at least 60 μm, at least 70 μm, at least 80 μm, at least 90 μm, at least 100 μm, at least 150 μm, at least 200 μm, or at least 250 μm.
[0274] The intranasal pharmaceutical composition may also include any of the other excipients provided herein, including, but not limited to, any lubricant, glidant, surfactant, buffer, preservative, antioxidant, humectant, or any other such suitable excipient that is compatible with intranasal formulations.
[0275] Sublingual preparations In some aspects, the pharmaceutical compositions provided herein are formulated for sublingual administration. In some embodiments, pharmaceutical compounds with low bioavailability, slow onset of physiological effects, and compounds with substantial non-target effects on the gastrointestinal tract or liver are ideal compounds for use in sublingual formulations comprising the complexing agent / pharmaceutical compound salts provided herein. Similar to the intranasal formulations provided herein, traditional sublingual approaches to pharmaceutical compound formulations suffer from poor bioavailability (in some cases, at least in part, due to low solubility) and oral tissue irritation (e.g., burning or stinging sensations). The present salts improve this by enhancing the solubility of relatively high doses of the compound at tolerable pH and concentrations without a substantial increase in osmolality compared to formulations made with complexing agents or compound salts, thus maximizing bioavailability and absorption while minimizing tissue irritation.
[0276] Furthermore, in some embodiments, pharmaceutical compositions comprising a complexing agent / pharmaceutical compound salt provided herein include an additional equivalent of the pharmaceutical compound that is not ionically bonded to the complexing agent, such as a non-ionized pharmaceutical compound or one ionized with a different counterion. When an additional non-ionized pharmaceutical compound is used, the complexing agent (e.g., a cyclodextrin such as SBEBCD) can complex with this additional pharmaceutical compound through non-ionic interactions. When such a formulation is administered, bioavailability and tolerability may be increased due to the presence of a certain amount of the non-ionized pharmaceutical compound. This can occur for several reasons, including that the free base (non-ionized) pharmaceutical compound is more easily taken up by relevant cells and distributed to target tissues in the body (e.g., by passive diffusion). Furthermore, the presence of the additional non-ionized pharmaceutical compound can act to improve the sublingual formulation even beyond a 1:1 molar ratio of pharmaceutical compound to complexing agent (e.g., up to 20:1 or even higher) that is expected to be complexed within the complexing agent (e.g., a cyclodextrin such as SBEBCD). For example, an additional equivalent of free base compound can simultaneously act as a buffer, as an aid in achieving a desired pH in the localized tissue (which depends on the amount of non-ionized pharmaceutical compound added and the pKa of the pharmaceutical compound), and as a source of non-ionized or free base drug product for absorption and renewal by the tissue (e.g., via mucosal absorption). Thus, in some embodiments, the desired pH can be achieved without the presence of an additional base or buffer.
[0277] In some embodiments, the pharmaceutical composition comprising the complexing agent / pharmaceutical compound salt is formulated for sublingual administration, hi some embodiments, the pharmaceutical composition is formulated as a sublingual tablet, sublingual strip, sublingual drop, sublingual spray, sublingual troche, or lozenge.
[0278] In some embodiments, the pharmaceutical composition comprises an additional equivalent of the non-ionized pharmaceutical compound relative to the protonated pharmaceutical compound of the complexing agent / protonated pharmaceutical compound salt. In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalent to about 5 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.1 molar equivalent to about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises about 0.1 molar equivalents to about 0.2 molar equivalents, about 0.1 molar equivalents to about 0.5 molar equivalents, about 0.1 molar equivalents to about 0.75 molar equivalents, about 0.1 molar equivalents to about 1 molar equivalent, about 0.2 molar equivalents to about 0.5 molar equivalents, about 0.2 molar equivalents to about 0.75 molar equivalents, about 0.2 molar equivalents to about 1 molar equivalent, about 0.5 molar equivalents to about 0.75 molar equivalents, about 0.5 molar equivalents to about 1 molar equivalent, or about 0.75 molar equivalents to about 1 molar equivalent. In some embodiments, the pharmaceutical composition comprises about 0.1 molar equivalent, about 0.2 molar equivalent, about 0.5 molar equivalent, about 0.75 molar equivalent, or about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises at least about 0.1 molar equivalent, about 0.2 molar equivalent, about 0.5 molar equivalent, or about 0.75 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises up to about 0.2 molar equivalent, about 0.5 molar equivalent, about 0.75 molar equivalent, or about 1 molar equivalent of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.5 equivalent to about 5 equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises about 0.5 equivalents to about 1 equivalent, about 0.5 equivalents to about 2 equivalents, about 0.5 equivalents to about 3 equivalents, about 0.5 equivalents to about 4 equivalents, about 0.5 equivalents to about 5 equivalents, about 1 equivalent to about 2 equivalents, about 1 equivalent to about 3 equivalents, about 1 equivalent to about 4 equivalents, about 1 equivalent to about 5 equivalents, about 2 equivalents to about 3 equivalents, about 2 equivalents to about 4 equivalents, about 2 equivalents to about 5 equivalents, about 3 equivalents to about 4 equivalents, about 3 equivalents to about 5 equivalents, or about 4 equivalents to about 5 equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises about 0.5 equivalents, about 1 equivalent, about 2 equivalents, about 3 equivalents, about 4 equivalents, or about 5 equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises at least about 0.5 equivalents, about 1 equivalent, about 2 equivalents, about 3 equivalents, or about 4 equivalents of the non-ionized pharmaceutical compound.In some embodiments, the pharmaceutical composition comprises up to about 1 equivalent, about 2 equivalents, about 3 equivalents, about 4 equivalents, or about 5 equivalents of the non-ionized pharmaceutical compound.
[0279] In some embodiments, the pharmaceutical composition includes a sufficient amount of a non-ionized pharmaceutical compound to form a buffer system with the ionized pharmaceutical compound in the composition. In some embodiments, the buffer system is at a desired pH. In some embodiments, the buffer system provides a desired pH when administered to the sublingual tissue.
[0280] In some embodiments, the buffer system provides a pH within a target range of the pKa value of the pharmaceutical compound. In some embodiments, the target pH is within about 0.2 pH units to about 2 pH units of the pKa value. In some embodiments, the target pH is within about 0.2 pH units to about 0.5 pH units, about 0.2 pH units to about 1 pH unit, about 0.2 pH units to about 1.5 pH units, about 0.2 pH units to about 2 pH units, about 0.5 pH units to about 1 pH unit, about 0.5 pH units to about 1.5 pH units, about 0.5 pH units to about 2 pH units, about 1 pH units to about 1.5 pH units, about 1 pH units to about 2 pH units, or about 1.5 pH units to about 2 pH units of the pKa value. In some embodiments, the target pH is within about 0.2 pH units, about 0.5 pH units, about 1 pH unit, about 1.5 pH units, or about 2 pH units of the pKa value. In some embodiments, the target pH is within at least about 0.2 pH units, about 0.5 pH units, about 1 pH unit, or about 1.5 pH units of the pKa value, hi some embodiments, the target pH is within at most about 0.5 pH units, about 1 pH units, about 1.5 pH units, or about 2 pH units of the pKa value.
[0281]
[0330] In some embodiments, the buffer system provides a pH at which a specific percentage of the pharmaceutical compound is ionized upon administration. In some embodiments, the buffer system provides a pH at which about 1% to about 99% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which about 1% to about 5%, about 1% to about 10%, about 1% to about 25%, about 1% to about 50%, about 1% to about 70%, about 1% to about 90%, about 1% to about 95%, about 1% to about 99%, about 5% to about 10%, about 5% to about 25%, about 5% to about 50%, about 5% to about 70%, about 5% to about 90%, about 5% to about 95%, about 5% to about 99%, about 10% to about 25%, about 10% to about 50%, about 10% to about 70%, about 10% to about 90%, about The buffer system provides a pH at which about 10% to about 95%, about 10% to about 99%, about 25% to about 50%, about 25% to about 70%, about 25% to about 90%, about 25% to about 95%, about 25% to about 99%, about 50% to about 70%, about 50% to about 90%, about 50% to about 95%, about 50% to about 99%, about 70% to about 90%, about 70% to about 95%, about 70% to about 99%, about 90% to about 95%, about 90% to about 99%, or about 95% to about 99% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which about 1%, about 5%, about 10%, about 25%, about 50%, about 70%, about 90%, about 95%, or about 99% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which at least about 1%, about 5%, about 10%, about 25%, about 50%, about 70%, about 90%, or about 95% of the pharmaceutical compound is ionized. In some embodiments, the buffer system provides a pH at which up to about 5%, about 10%, about 25%, about 50%, about 70%, about 90%, about 95%, or about 99% of the pharmaceutical compound is ionized. In some embodiments, percent ionization is measured immediately after administration.
[0282] In some embodiments, the pharmaceutical composition comprises an additional molar equivalent of the non-ionized pharmaceutical compound relative to the complexing agent of the complexing agent / protonated pharmaceutical compound salt. In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalent to about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.1 molar equivalent to about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition is in an amount of about 0.1 molar equivalents to about 0.5 molar equivalents, about 0.1 molar equivalents to about 1 molar equivalent, about 0.1 molar equivalents to about 2 molar equivalents, about 0.1 molar equivalents to about 3 molar equivalents, about 0.1 molar equivalents to about 5 molar equivalents, about 0.1 molar equivalents to about 7 molar equivalents, about 0.1 molar equivalents to about 10 molar equivalents, about 0.5 molar equivalents to about 1 molar equivalent, about 0.5 molar equivalents to about 2 molar equivalents, about 0.5 molar equivalents to about 3 molar equivalents, about 0.5 molar equivalents to about 5 molar equivalents, about 0.5 molar equivalents to about 7 molar equivalents, about 0.5 molar equivalents to about 10 molar equivalents, The non-ionized pharmaceutical compound may comprise about 1 molar equivalent to about 2 molar equivalents, about 1 molar equivalent to about 3 molar equivalents, about 1 molar equivalent to about 5 molar equivalents, about 1 molar equivalent to about 7 molar equivalents, about 1 molar equivalent to about 10 molar equivalents, about 2 molar equivalents to about 3 molar equivalents, about 2 molar equivalents to about 5 molar equivalents, about 2 molar equivalents to about 7 molar equivalents, about 2 molar equivalents to about 10 molar equivalents, about 3 molar equivalents to about 5 molar equivalents, about 3 molar equivalents to about 7 molar equivalents, about 3 molar equivalents to about 10 molar equivalents, about 5 molar equivalents to about 7 molar equivalents, about 5 molar equivalents to about 10 molar equivalents, or about 7 molar equivalents to about 10 molar equivalents. In some embodiments, the pharmaceutical composition comprises about 0.1 molar equivalent, about 0.5 molar equivalent, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, about 7 molar equivalents, or about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises at least about 0.1 molar equivalent, about 0.5 molar equivalent, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, or about 7 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises up to about 0.5 molar equivalent, about 1 molar equivalent, about 2 molar equivalents, about 3 molar equivalents, about 5 molar equivalents, about 7 molar equivalents, or about 10 molar equivalents of the non-ionized pharmaceutical compound. In some embodiments, the pharmaceutical composition comprises from about 0.01 molar equivalent to about 20 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent.In some embodiments, the pharmaceutical composition comprises about 1 molar equivalent to about 20 molar equivalents of the non-ionized pharmaceutical compound relative to the complexing agent, and in some embodiments, at least a portion of these additional equivalents of the non-ionized pharmaceutical compound relative to the complexing agent is complexed to the complexing agent (e.g., up to about 1 molar equivalent of the non-ionized pharmaceutical compound).
[0283] In some embodiments, the pharmaceutical composition comprises additional ingredients to improve properties specific to sublingual administration. Non-limiting examples of such additional excipients or ingredients include permeation enhancers, stabilizers, lyophilization excipients, disintegrants, masking agents, flavoring agents, binders, sweetening agents, bittering agents, texturing agents, wetting agents, dispersing agents, additional buffering agents, and other such excipients.
[0284] Additional formulation ingredients The compounds of the present disclosure (e.g., ketamine, methoxetamine, deschloroketamine, mescaline, tryptamine, phenethylamine, lysergamide, racemorphan, levorphanol, racemethorphan, 3-methylmethcathinone, ethylone, diphenhydramine, etc.) may be in the form of compositions suitable for administration to a subject. Generally, such compositions are "pharmaceutical compositions" comprising the compound (e.g., ketamine, methoxetamine, deschloroketamine, mescaline, tryptamine, phenethylamine, lysergamide, racemorphan, levorphanol, racemethorphan, 3-methylmethcathinone, ethylone, diphenhydramine, etc.) and one or more pharmaceutically or physiologically acceptable diluents, carriers, or excipients. In some embodiments, the compound (e.g., ketamine, methoxetamine, deschloroketamine, mescaline, tryptamine, phenethylamine, lysergamide, racemorphan, levorphanol, racemethorphan, 3-methylmethcathinone, ethylone, diphenhydramine, etc.) is present in a therapeutically acceptable amount. Pharmaceutical compositions can be used in the methods of the disclosure; thus, for example, pharmaceutical compositions can be administered to a subject ex vivo or in vivo to practice the treatment and prevention methods and uses described herein.
[0285] Pharmaceutical compositions of the present disclosure can be formulated to be compatible with the intended method or route of administration, exemplary routes of administration are described herein.
[0286] In certain embodiments of the pharmaceutical compositions described herein, the co-solvent comprises PEG200, PEG300, PEG400, PEG600, propylene glycol, ethanol, polysorbate 20, polysorbate 80, cremefol, glycerin, benzyl alcohol, dimethylacetamide (DMA), N-methyl-2-pyrrolidone (NMP), tert-butanol, or a combination thereof.
[0287] In certain embodiments, the dosage form or pharmaceutical composition comprises a surfactant.
[0288] In certain embodiments of the pharmaceutical compositions described herein, the surfactant comprises polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monooleate, polyoxyethylene sorbitan monolaurate (Tween 20), lecithin, polyoxyethylene-polyoxypropylene copolymer (Pluronics 1), or a combination thereof.
[0289] In certain embodiments, the dosage form or pharmaceutical composition comprises a non-ionic surfactant.
[0290] In certain embodiments of the pharmaceutical compositions described herein, the non-ionic surfactant comprises Cremophor RH40, Cremophor RH60, d-alpha-tocopherol polyethylene glycol 1000 succinate, polysorbate 20, polysorbate 80, Solutol HS 15, sorbitan monooleate, poloxamer 407, Labrafil M-1944CS, Labrafil M-2125CS, Labrasol, Gellucire 44 / 14, Softigen 767, or a combination thereof.
[0291] In some embodiments, the pharmaceutical composition comprises one or more co-solvents, solubilizing / solubilizing agents, stabilizers, antioxidants, preservatives, cryoprotectants, bulking agents, tonicity agents, or antimicrobial agents. In some embodiments, the pharmaceutical composition comprises at least one co-solvent. In some embodiments, the pharmaceutical composition comprises at least one solubilizing agent. In some embodiments, the pharmaceutical composition comprises at least one stabilizer. In some embodiments, the pharmaceutical composition comprises at least one antioxidant. In some embodiments, the pharmaceutical composition comprises at least one preservative. In some embodiments, the pharmaceutical composition comprises at least one cryoprotectant. In some embodiments, the pharmaceutical composition comprises at least one lyoprotectant. In some embodiments, the pharmaceutical composition comprises at least one bulking agent. In some embodiments, the pharmaceutical composition comprises at least one tonicity agent. In some embodiments, the pharmaceutical composition comprises at least one antimicrobial agent.
[0292] In some embodiments, the formulation or pharmaceutical composition is a pharmaceutical composition. In some embodiments, the formulation is in the form of a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents as mentioned herein. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example, a solution in 1,3-butanediol. Acceptable diluents, solvents, and dispersion media that can be used include water, Ringer's solution, isotonic sodium chloride solution, Cremophor® EL (BASF, Parsippany, NJ) or phosphate-buffered saline (PBS), ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol), and suitable mixtures thereof. Additionally, sterile, fixed oils are conventionally used as solvents or suspending media. For this purpose, any bland, fixed oil, including synthetic mono- or diglycerides, can be used. Additionally, fatty acids such as oleic acid are useful in the preparation of injectables. Prolonged absorption of certain injectable formulations can be achieved by including an agent that delays absorption (e.g., aluminum monostearate or gelatin). In some embodiments, the formulation contains a cosolvent. In some embodiments, suitable cosolvents are propylene glycol, glycerin, ethanol, polyethylene glycol (300 and 400), sorbitol, dimethylacetamide, Cremophor EL, or N-methyl-2-pyrrolidone, or dimethyl sulfoxide.
[0293] In some embodiments, the formulation or pharmaceutical composition is an aqueous suspension. Aqueous suspensions contain the active substance mixed with excipients suitable for its manufacture. Such excipients can be suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, and gum acacia, dispersing agents, or wetting agents, such as naturally occurring phosphatides (e.g., lecithin), or condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearate), or condensation products of ethylene oxide with long-chain aliphatic alcohols (e.g., heptadecaethyleneoxycetanol), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitols (e.g., polyoxyethylene sorbitol monooleate), or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). Aqueous suspensions can also contain one or more preservatives (e.g., benzethonium chloride).
[0294] In some embodiments, the formulation or pharmaceutical composition comprises a stabilizer. In some embodiments, the formulation comprises a surfactant solubilizer. Surfactant solubilizers include, but are not limited to, polyoxyethylene sorbitan monooleate (Tween 80), sorbitan monooleate, polyoxyethylene sorbitan monolaurate (Tween 20), lecithin, and polyoxyethylene-polyoxypropylene copolymer (Pluronics 1). In some embodiments, the formulation comprises a non-ionic surfactant solubilizer. Nonionic surfactants include, but are not limited to, Cremophor RH 40, Cremophor RH 60, d-α-tocopherol polyethylene glycol 1000 succinate, polysorbate 20, polysorbate 80, Solutol HS 1, sorbitan monooleate, poloxamer 407, Labrafil M-1944CS, Labrafil M-2125CS, Labrasol, Gellucire 44 / 14, Softigen 767, and mono- and di-fatty acid esters of PEG 300, 400, and 1750. In some embodiments, the formulation comprises a phospholipid solubilizer such as hydrogenated soy phosphatidylcholine, phosphatidylcholine, distearoylphosphatidylglycerol, L-α-dimyristoylphosphatidylcholine, or L-α-dimyristoylphosphatidylglycerol.
[0295] In some embodiments, the formulation or pharmaceutical composition includes a complexing agent. In some embodiments, the complexing agent is hydroxypropyl-β-cyclodextrin, bromobutylether-β-cyclodextrin (Captisol 1), or polyvinylpyrrolidone. In some embodiments, the complexing agent is an amino acid such as arginine, lysine, or histidine. In some embodiments, the formulation or pharmaceutical composition includes a cyclodextrin excipient. Cyclodextrin excipients are used to enhance the stability, tolerability, and absorption of the compound in parenteral aqueous solutions. Common cyclodextrin excipients include, but are not limited to, α-cyclodextrin (α-CD), β-cyclodextrin (β-CD), γ-cyclodextrin (γ-CD), diethyl-ethyl-β-cyclodextrin (DE-β-CD), dimethyl-ethyl-β-cyclodextrin (DM-β-CD), hydroxypropyl-β-cyclodextrin (HP-β-CD), hydroxypropyl-γ-cyclodextrin (HP-γ-CD), methyl-β-cyclodextrin (M-β-CD), sulfobutylether-β-cyclodextrin (SBE-β-CD), randomly methylated-β-CD (RM-β-CD), maltosyl-β-CD (mal-β-CD), hydroxypropyl-α-CD, and the like.
[0296] The formulation or pharmaceutical composition of the present disclosure can also be in the form of oil-in-water emulsion.Oil phase can be vegetable oil, such as olive oil or peanut oil, or mineral oil, such as liquid paraffin, or their mixture.Suitable emulsifier can be naturally occurring gum, such as gum acacia or gum tragacanth, naturally occurring phosphatides, such as soybean, lecithin, and esters or partial esters derived from fatty acids, hexitol anhydrides, such as sorbitan monooleate, and condensation products of partial esters and ethylene oxide, such as polyoxyethylene sorbitan monooleate.
[0297] Formulations or pharmaceutical compositions typically contain a therapeutically effective amount of an active compound (e.g., ketamine, methoxetamine, deschloroketamine, mescaline, tryptamine, phenethylamine, lysergamide, racemorphan, levorphanol, or racemetorphan, 3-methylmethcathinone, ethylone, diphenhydramine, etc.), or a hydrate, solvate, tautomer, or pharmaceutically acceptable salt thereof, and one or more pharmaceutically and physiologically acceptable formulating agents. Suitable pharmaceutically or physiologically acceptable diluents, carriers, or excipients include, but are not limited to, antioxidants (e.g., ascorbic acid and sodium bisulfate), preservatives (e.g., benzyl alcohol, methylparaben, ethyl or n-propyl p-hydroxybenzoate), emulsifiers, suspending agents, dispersing agents, solvents, fillers, extenders, surfactants, buffers, vehicles, diluents, and / or adjuvants. For example, a suitable vehicle may be saline or citrate buffered saline, possibly supplemented with other materials common to pharmaceutical compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Those skilled in the art will readily recognize various buffers that can be used in the pharmaceutical compositions and dosage forms contemplated herein. Typical buffers include, but are not limited to, pharmaceutically acceptable weak acids, weak bases, or mixtures thereof. For example, buffer components may be water-soluble materials such as phosphoric acid, tartaric acid, lactic acid, succinic acid, citric acid, acetic acid, ascorbic acid, aspartic acid, glutamic acid, and their salts. Acceptable buffers include, for example, triethanolamine (Tris) buffer, histidine, bicarbonate, N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulfonic acid) (HEPES), 2-(N-morpholino)ethanesulfonic acid (MES), 2-(N-morpholino)ethanesulfonic acid sodium salt (MES), 3-(N-morpholino)propanesulfonic acid) (MOPS), and N-tris[hydroxymethyl]methyl-3-aminopropanesulfonic acid (TAPS).
[0298] Many active pharmaceutical ingredients (APIs), including pharmaceutical compounds, are weak acids or weak bases. Weak acids and bases can exist in a non-ionized form or as an ionized complex prepared by the addition of a base or acid, respectively. The resulting complex, stabilized by ionic interactions, is known as a salt. This complex exists through ionic bonding between the ionized API and an oppositely charged counterion. Salts offer several advantages over their non-ionized counterparts. The choice of counterion can significantly affect the properties of the salt, and the use of a given salt form of a given API in a pharmaceutical product is influenced and guided by several factors, such as stability (light, hydrolysis, and heat), solubility, physicochemical properties, solid-state properties (crystallinity, polymorphism, particle size, crystalline morphology, melting point, compressibility), manufacturing considerations (e.g., ease of handling and processing), dissolution rate, drug release modulation, compatibility with excipients and containers, ease and consistency of manufacture, desired route of administration, and organoleptic factors (e.g., taste). Additionally, with regard to injections, salts can contribute to pain and irritation at the injection site.
[0299] APIs that are weak acids or bases can act as their own buffers at pHs close to the API's pKa. For example, a compound containing an amino functional group with a pKa of about 7.5 can therefore serve as a buffer in the region of about ±2 pH units from the pKa (e.g., a pH of about 5.5 to about 9.5). If the formulation has a target pH within this range, an additional buffer may not be necessary. In some embodiments, the pharmaceutical compositions provided herein do not contain an additional buffering agent.
[0300] With regard to cyclodextrin solubilization, certain salts of various APIs have been found to form multicomponent complexes or ternary systems that may have different desirable properties compared to their standard binary complexes or ternary systems prepared between cyclodextrin and non-ionized APIs, as well as compared to other multicomponent ternary complexes or systems containing different salt forms of the API. Thus, these multicomponent complexes or systems can dramatically affect the solubility and dissolution rate of the API in aqueous solution, affecting the product stability and pharmacokinetic properties of the pharmaceutical formulation.
[0301] After the pharmaceutical composition is formulated, it can be stored in a sterile vial as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder. Such formulations can be stored in a ready-to-use form, a lyophilized form that requires reconstitution before use, a liquid form that requires dilution before use, or other acceptable form. In some embodiments, the pharmaceutical composition is provided in a single-use container (e.g., a single-use vial, an ampoule, a syringe, or an auto-injector (e.g., similar to EpiPen®)), while in other embodiments, a multi-use container (e.g., a multi-use vial) is provided.
[0302] Formulations or pharmaceutical compositions can also contain carriers to protect the composition from rapid degradation or disappearance from the body, such as controlled-release formulations, including liposomes, hydrogels, prodrugs, and microencapsulated delivery systems.For example, time-delay materials such as glyceryl monostearate or glyceryl stearate can be used alone or in combination with wax.To deliver pharmaceutical compounds, any drug delivery device can be used, including implants (e.g., implantable pumps) and catheter systems, slow infusion pumps, and devices, all of which are well known to those skilled in the art.
[0303] In some embodiments, the formulation or pharmaceutical composition is stored in a reservoir of a drug delivery device. In some embodiments, the formulation is stored in a cartridge that is insertable into and / or attachable to the drug delivery device. In some embodiments, the cartridge and / or drug delivery device includes a product label for intramuscular injection. In some embodiments, the cartridge and / or drug delivery device includes a product label for subcutaneous injection. In some embodiments, the cartridge and / or drug delivery device includes a product label for intravenous injection. In some embodiments, disclosed herein are kits that include a product label for intramuscular injection. In some embodiments, disclosed herein are kits that include a product label for subcutaneous injection. In some embodiments, disclosed herein are kits that include a product label for intravenous injection.
[0304] In some embodiments, the formulation or pharmaceutical composition is a liquid formulation comprising a pharmaceutical compound.
[0305] It is often beneficial to improve one or more physical properties of the therapeutic modalities disclosed herein and / or the manner in which they are administered. Improvements in physical properties include, for example, methods to increase water solubility, bioavailability, serum half-life, and / or therapeutic half-life, and / or modulating biological activity. Modifications known in the art include pegylation, Fc fusion, and albumin fusion. While generally associated with large molecule drugs (e.g., polypeptides), such modifications have recently been evaluated for certain small molecules. For example, Chiang, M. et al. (J. Am. Chem. Soc., 2014, 136(9):3370-73) describe a small molecule agonist of the adenosine 2a receptor conjugated to an immunoglobulin Fc domain. The small molecule-Fc conjugate retains strong Fc receptor and adenosine 2a receptor interaction and exhibits superior properties compared to unconjugated small molecules. Covalent attachment of PEG molecules to small molecule therapeutic agents has also been described (Li, W. et al., Progress in Polymer Science, 201338:421-44).
[0306] The pharmaceutical compounds of the present disclosure may be administered to a subject in an amount that depends, for example, on the goal of administration (e.g., the desired degree of fractionation), the age, weight, sex, and health and physical condition of the subject to whom the formulation is administered, the route of administration, and the nature of the disease, disorder, condition, or symptom. The administration regimen may also take into account the existence, nature, and extent of any adverse effects associated with the administered agent. Effective dosages and administration regimens can be readily determined, for example, from safety and dose escalation studies, in vivo studies (e.g., animal models), and other methods known to those skilled in the art.
[0307] Generally, the dosage parameters are defined as the dosage that is less than the amount that may be irreversibly toxic to the subject (maximum tolerated dose (MTD)) and greater than or equal to the amount required to produce a measurable effect on the subject. Such amount is determined, for example, by the pharmacokinetic and pharmacodynamic parameters relevant to ADME, taking into account the route of administration and other factors.
[0308] The effective dose (ED) is the dose or amount of a drug that produces a therapeutic response or desired effect in some fraction of subjects who take it. The "median effective dose" or ED of a drug 50 ED is the dose or amount of a drug that produces a therapeutic response or desired effect in 50% of the population to which it is administered. 50 The ED is usually used as a measure of the reasonable expectation of a drug's effect, but not necessarily the dose that a clinician would deem appropriate taking into account all relevant factors. Therefore, in some situations, the effective dose may be calculated as the ED 50 In other situations, the effective dose is calculated as ED 50 In still other situations, the effective dose is less than the calculated ED 50 is the same as
[0309] Additionally, an effective dose of a compound of the present disclosure can be an amount that, when administered to a subject in one or more doses, produces a desired result compared to a healthy subject. For example, for a subject experiencing a particular disorder, an effective dose can be one that improves a diagnostic parameter, measure, marker, etc. of that disorder by at least about 5%, at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, or more than 90%, where 100% is defined as the diagnostic parameter, measure, marker, etc. exhibited by a normal subject.
[0310] In embodiments, the compound dosage is contained in a "unit dosage form." The term "unit dosage form" refers to a physically discrete unit, each unit containing a predetermined amount of a compound (e.g., ketamine, methoxetamine, deschloroketamine, mescaline, tryptamine, phenethylamine, lysergamide, racemorphan, levorphanol, or racemethorphan, 3-methylmethcathinone, ethylone, diphenhydramine, etc.) sufficient to produce a desired effect, or a hydrate, solvate, or pharmaceutically acceptable salt thereof. It will be understood that the parameters of the unit dosage form will depend on the particular drug and the effect to be achieved.
[0311] Oily suspension can be prepared by suspending active ingredient in vegetable oil, such as peanut oil, olive oil, sesame oil or coconut oil, or mineral oil such as liquid paraffin.Oily suspension can contain thickening agent, such as beeswax, hard paraffin or cetyl alcohol.Sweetener and flavoring agent such as those mentioned above can be added to make the oral preparations more palatable.
[0312] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, and optionally one or more suspending agents and / or preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified herein.
[0313] Depot injections, generally administered subcutaneously or intramuscularly, can also be utilized to release the compounds disclosed herein (e.g., ketamine, methoxetamine, deschloroketamine, mescaline, tryptamine, phenethylamine, lysergamide, racemorphan, levorphanol, or racemethorphan, 3-methylmethcathinone, ethylone, diphenhydramine, etc.) over a defined period of time. Depot injections are typically either solid or oily and typically contain at least one of the formulation components described herein. Those skilled in the art are familiar with the possible formulations and uses of depot injections.
[0314] Some formulations contain one or more stabilizers. Potential stabilizers include buffers such as acetate, citrate, sodium citrate, tartrate, phosphate, histidine, bicarbonate, triethanolamine (Tris), and salts thereof. In some formulations, potential stabilizers may include antioxidants and preservatives such as ascorbic acid, acetylcysteine (NAC), sulfites (bisulfite, metabisulfite), monothioglycerol (Monothioglyercol), butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tert-butylhydroquinone (TBHQ), 2',4',5'-trihydroxybutyrophenone phenylhydrazone (THBP), ethylenediaminetetraacetic acid (EDTA), sodium formaldehyde sulfoxylate (SFS), tocopherol (vitamin E), ascorbyl palmitate, gallates (e.g., propyl gallate, octyl gallate, lauryl gallate), cysteine ethyl ether, tartaric acid, phosphoric acid, thiourea, sodium thioglycolate, nitrogen, and / or argon.
[0315] In some formulations, potential stabilizers may include bulking agents, cryoprotectants, and cryoprotectants. Considered agents include mannitol, glycine, sucrose, lactose, trehalose, dextran, povidone, sorbitol, and / or polydextrose. In some formulations, potential stabilizers may include tonicity agents. Considered agents include sodium chloride, glycerin, mannitol, dextrose, and / or glycerol. In some formulations, potential stabilizers may include antimicrobial agents, including, but not limited to, phenol, meta-cresol, benzyl alcohol, parabens (methyl, propyl, or butyl), benzalkonium chloride, benzethonium chloride, chlorobutanol, myristyl gamma picolinium chloride, 2-phenoxyethanol, phenylethyl alcohol, sorbates (sorbic acid, sodium sorbate), ethanol, and / or propylene glycol.
[0316] In some formulations, the soothing agent may include a topical analgesic such as lidocaine, benzocaine, tetracaine, bupivicaine, ropivacaine, and / or levobupivacaine.
[0317] In some formulations, emulsion stabilizers include hydroxyethyl cellulose, hydroxypropyl cellulose, and / or hydroxypropyl methylcellulose (hypromellose).
[0318] The compounds contemplated by this disclosure (e.g., ketamine, methoxetamine, deschloroketamine) may be in the form of any other suitable pharmaceutical composition now known or developed in the future.
[0319] III. Methods of Treatment Using Pharmaceutical Compositions In certain aspects, provided herein are methods of treating a disease or condition in a subject, comprising administering to the subject a pharmaceutical composition provided herein. The disease or condition will depend on the particular compound selected in the pharmaceutical composition.
[0320] dissociative compound Generally, the dissociative compounds provided herein (e.g., ketamine or an analog or derivative thereof) are useful for all of the listed indications. In some embodiments, the formulations and methods disclosed herein are used to treat pain or pain disorders. In some embodiments, chronic pain refers to pain with a duration of more than three months. Examples of pain and pain disorders include acute pain, somatic pain, gluteal pain, lower back pain, chronic back pain, chronic tail pain, chronic lower back pain, chronic malignant pain, chronic neck pain, chronic non-malignant pain, chronic pain, and pain-specific pain (NOS), such as generalized pain. In some embodiments, the pain can include pain crises, buttock pain, coccyx pain (chronic or acute), or neoplasm-related pain (chronic or acute). In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain.
[0321] In some embodiments, the pain is chronic post-procedural and / or post-surgical pain. Examples of post-procedural pain include chronic pain from bilateral total hip arthroplasty, chronic pain from bilateral total knee arthroplasty, chronic pain from left total hip arthroplasty, chronic pain from left total knee replacement, chronic pain from right total hip arthroplasty, chronic pain from right total knee replacement, chronic pain after bilateral partial hip arthroplasty, chronic pain after bilateral partial knee arthroplasty, chronic pain after left partial hip arthroplasty, chronic pain after left partial knee arthroplasty, chronic pain after right partial hip arthroplasty, chronic pain after right partial knee arthroplasty, pain from bilateral total hip arthroplasty, pain from bilateral total knee arthroplasty, pain from left total hip arthroplasty, pain from left total knee replacement, pain from right total hip arthroplasty, pain after right total knee replacement, pain after bilateral partial hip arthroplasty, pain after bilateral partial knee arthroplasty, pain after left partial hip arthroplasty, pain after left partial knee arthroplasty, pain after right partial hip arthroplasty, pain after right partial knee arthroplasty, chronic post-mastectomy pain, chronic post-mastectomy pain, and chronic post-operative pain.
[0322] In some embodiments, the pain is chronic pain due to trauma or injury. In some embodiments, the pain is a chronic pain syndrome, also known as psychosocial dysfunction due to chronic pain or chronic pain associated with psychosocial dysfunction. In some embodiments, the pain is neoplasia-related pain or pain due to neoplastic disease (chronic or acute). In some embodiments, the pain is causalgia (lower and / or upper limbs).
[0323] In some embodiments, the pain is central pain syndrome, complex regional pain syndrome I, complex regional pain syndrome II (lower extremities), or complex regional pain syndrome II (upper extremities).
[0324] In some embodiments, the disease or disorder is a psychiatric disorder.In some embodiments, the psychiatric disorder is major depressive disorder, treatment-resistant major depressive disorder, suicidal tendencies, suicidal ideation, mood disorder or persistent depressive disorder, bipolar depressive disorder type I, bipolar depressive disorder type II, chronic pain, eating disorder NOS, pain disorder NOS, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, complex regional pain syndrome, reflex sympathetic dystrophy, or any combination thereof.
[0325] In some embodiments, the disease or disorder is a cognitive disorder or neurological disorder. In some embodiments, the cognitive disorder or neurological disorder is Huntington's disease, Parkinson's disease, frontotemporal dementia, dementia, Alzheimer's disease, amyotrophic lateral sclerosis, spinal cord trauma, stroke, diffuse traumatic brain injury, HIV-associated dementia, epilepsy, Rett syndrome, dyskinesia, unspecified dystonia, or pseudobulbar affect.
[0326] In some embodiments, the formulations and methods disclosed herein are used to treat one or more personality disorders.Examples of personality disorders include avoidant personality disorder, dependent personality disorder, antisocial personality disorder, histrionic personality disorder, borderline personality disorder, obsessive-compulsive personality disorder, cyclothymic personality disorder, obsessive-compulsive disorder, and impulse control disorder (NOS).
[0327] In some embodiments, the formulations and methods disclosed herein are used to treat one or more of major depressive disorder, treatment-resistant major depressive disorder, suicidal tendencies, suicidal ideation, mood disorders, bipolar disorder (type I-depressed), bipolar disorder (type II-depressed), post-traumatic stress disorder (PTSD), panic disorder, generalized anxiety disorder, and substance abuse-induced mood disorder.
[0328] In some embodiments, the formulations and methods disclosed herein are used to treat drug addiction, including opiate addiction, benzodiazepine addiction, sedative (hypnotic or anxiolytic) addiction, alcohol addiction, stimulant addiction, cocaine addiction, cannabis detoxification, opiate addiction (with withdrawal symptoms), benzodiazepine addiction (with withdrawal symptoms), sedative (with withdrawal symptoms) addiction, alcohol addiction (with withdrawal symptoms), stimulant addiction (with withdrawal symptoms), cocaine addiction (with withdrawal symptoms), and cannabis detoxification (with withdrawal symptoms).
[0329] In another aspect, there is provided a method of treating, preventing, or ameliorating at least one symptom of a disorder, disease, or condition using the pharmaceutical compositions disclosed herein, wherein the disorder, disease, or condition is a mental or psychiatric disorder, a mood disorder, a neurological condition or disorder, type 2 diabetes and / or its complications, endometriosis, glaucoma, pain, or an inflammatory disorder.
[0330] psychotic compounds Generally, the psychotic compounds provided herein (eg, mescaline, etc.) are useful for all of the listed indications.
[0331] In some embodiments, the disease or disorder is a psychiatric disorder.In some embodiments, the psychiatric disorder is major depressive disorder, treatment-resistant major depressive disorder, mood disorder, suicide, suicidal ideation, mood disorder or persistent depressive disorder, bipolar depressive disorder type I, bipolar depressive disorder type II, chronic pain, eating disorder NOS, pain disorder NOS, panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, personality disorder, complex regional pain syndrome, reflex sympathetic dystrophy, post-concussion memory impairment and cognitive impairment, traumatic brain injury, post-chemotherapy cognitive impairment and memory impairment, inflammatory disorder, cognitive impairment, memory impairment, dementia NOS, fatigue, or any combination thereof. In some embodiments, the psychiatric disorder is major depressive disorder, treatment-resistant major depressive disorder, suicidal, suicidal disorder, mood disorder, bipolar I disorder, bipolar II disorder, post-traumatic stress disorder (PTSD), multiple trauma, anorexia nervosa, bulimia nervosa, eating disorder NOS, obsessive-compulsive disorder, substance-related disorder (e.g., cannabis dependence or withdrawal, barbiturate dependence or withdrawal, benzodiazepine dependence or withdrawal, amphetamine dependence or withdrawal, opioid dependence or withdrawal, alcohol dependence or withdrawal, cocaine dependence or withdrawal).
[0332] In some embodiments, the formulations and methods disclosed herein are used to treat one or more personality disorders.Examples of personality disorders include avoidant personality disorder, dependent personality disorder, antisocial personality disorder, histrionic personality disorder, borderline personality disorder, obsessive-compulsive personality disorder, cyclothymic personality disorder, obsessive-compulsive disorder, and impulse control disorder (NOS).
[0333] In some embodiments, the formulations and methods disclosed herein are used to treat one or more of major depressive disorder, treatment-resistant major depressive disorder, suicidal tendencies, suicidal ideation, mood disorders, bipolar disorder (type I-depressed), bipolar disorder (type II-depressed), post-traumatic stress disorder (PTSD), panic disorder, generalized anxiety disorder, and substance abuse-induced mood disorder.
[0334] In some embodiments, the formulations and methods disclosed herein are used to treat drug addiction. Examples of drug addiction include opiate addiction, benzodiazepine addiction, sedative (hypnotic or anxiolytic) addiction, alcohol addiction, stimulant addiction, cocaine addiction, cannabis detoxification, opiate addiction (with withdrawal symptoms), benzodiazepine addiction (with withdrawal symptoms), sedative (with withdrawal symptoms) addiction, alcohol addiction (with withdrawal symptoms), stimulant addiction (with withdrawal symptoms), cocaine addiction (with withdrawal symptoms), and cannabis detoxification (with withdrawal symptoms).
[0335] In some embodiments, the formulations and methods disclosed herein are used to treat pain or pain disorders. In some embodiments, when the embodiments, formulations, and methods provided herein are used to treat pain, the pharmaceutical compounds provided herein are administered as microdoses (e.g., doses below the threshold for inducing psychotic effects). In some embodiments, chronic pain refers to pain with a duration of more than three months. Examples of pain and pain disorders include acute pain, somatic pain, gluteal pain, lower back pain, chronic back pain, chronic tail pain, chronic lower back pain, chronic malignant pain, chronic neck pain, chronic non-malignant pain, chronic pain, and pain not otherwise specified (NOS), such as generalized pain. In some embodiments, the pain can include pain crises, buttock pain, coccyx pain (chronic or acute), or neoplasm-related pain (chronic or acute). In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain.
[0336] In some embodiments, the pain is chronic post-procedural and / or post-surgical pain. Examples of post-procedural pain include chronic pain from bilateral total hip arthroplasty, chronic pain from bilateral total knee arthroplasty, chronic pain from left total hip arthroplasty, chronic pain from left total knee replacement, chronic pain from right total hip arthroplasty, chronic pain from right total knee replacement, chronic pain after bilateral partial hip arthroplasty, chronic pain after bilateral partial knee arthroplasty, chronic pain after left partial hip arthroplasty, chronic pain after left partial knee arthroplasty, chronic pain after right partial hip arthroplasty, chronic pain after right partial knee arthroplasty, pain from bilateral total hip arthroplasty, pain from bilateral total knee arthroplasty, pain from left total hip arthroplasty, pain from left total knee replacement, pain from right total hip arthroplasty, pain after right total knee replacement, pain after bilateral partial hip arthroplasty, pain after bilateral partial knee arthroplasty, pain after left partial hip arthroplasty, pain after left partial knee arthroplasty, pain after right partial hip arthroplasty, pain after right partial knee arthroplasty, chronic post-mastectomy pain, chronic post-mastectomy pain, and chronic post-operative pain.
[0337] In some embodiments, the pain is chronic pain due to trauma or injury. In some embodiments, the pain is a chronic pain syndrome, also known as psychosocial dysfunction due to chronic pain or chronic pain associated with psychosocial dysfunction. In some embodiments, the pain is neoplasia-related pain or pain due to neoplastic disease (chronic or acute). In some embodiments, the pain is causalgia (lower and / or upper limbs).
[0338] In some embodiments, the pain is central pain syndrome, complex regional pain syndrome I, complex regional pain syndrome II (lower extremities), or complex regional pain syndrome II (upper extremities).
[0339] In some embodiments, the disease or disorder is an inflammatory disorder or condition associated with inflammation. Non-limiting examples of inflammatory disorders and conditions associated with inflammation include asthma, atherosclerosis, autoimmune diseases, autoinflammatory diseases, celiac disease, chronic prostatitis, colitis, diverticulitis, glomerulonephritis, inflammatory bowel disease, interstitial cystitis, mastocytosis, pelvic inflammatory disease, reperfusion injury, rheumatic fever, rheumatoid arthritis, rhinitis, sarcoidosis, transplant rejection, and vasculitis.
[0340] Opioids In certain aspects, provided herein is a method of treating pain in a subject, comprising administering to the subject a pharmaceutical composition provided herein.
[0341] In some embodiments, the pain is acute or chronic pain. In some embodiments, the pain is chronic pain.
[0342] In some embodiments, the pain is complex regional pain syndrome, central pain syndrome, chronic pain, acute pain, or painful phantom limb syndrome. In some embodiments, the pain is acute pain. In some embodiments, the pain is post-operative pain. In some embodiments, the pain is due to trauma, such as a battlefield wound. In some embodiments, the pain is cancer pain.
[0343] In some embodiments, the formulations and methods disclosed herein are used to treat pain or pain disorders. In some embodiments, chronic pain refers to pain that lasts for more than three months. Examples of pain and pain disorders include acute pain, somatic pain, gluteal pain, lower back pain, chronic back pain, chronic tail pain, chronic lower back pain, chronic malignant pain, chronic neck pain, chronic non-malignant pain, chronic pain, and pain not otherwise specified (NOS), such as generalized pain. In some embodiments, the pain can include pain attacks, buttock pain, coccyx pain (chronic or acute), or neoplasm-related pain (chronic or acute). In some embodiments, the pain is chronic pain. In some embodiments, the pain is acute pain.
[0344] In some embodiments, the pain is chronic post-procedural and / or post-surgical pain. Examples of post-procedural pain include chronic pain from bilateral total hip arthroplasty, chronic pain from bilateral total knee arthroplasty, chronic pain from left total hip arthroplasty, chronic pain from left total knee replacement, chronic pain from right total hip arthroplasty, chronic pain from right total knee replacement, chronic pain after bilateral partial hip arthroplasty, chronic pain after bilateral partial knee arthroplasty, chronic pain after left partial hip arthroplasty, chronic pain after left partial knee arthroplasty, chronic pain after right partial hip arthroplasty, chronic pain after right partial knee arthroplasty, pain from bilateral total hip arthroplasty, pain from bilateral total knee arthroplasty, pain from left total hip arthroplasty, pain from left total knee replacement, pain from right total hip arthroplasty, pain after right total knee replacement, pain after bilateral partial hip arthroplasty, pain after bilateral partial knee arthroplasty, pain after left partial hip arthroplasty, pain after left partial knee arthroplasty, pain after right partial hip arthroplasty, pain after right partial knee arthroplasty, chronic post-mastectomy pain, chronic post-mastectomy pain, and chronic post-operative pain.
[0345] In some embodiments, the pain is chronic pain due to trauma or injury. In some embodiments, the pain is a chronic pain syndrome, also known as psychosocial dysfunction due to chronic pain or chronic pain associated with psychosocial dysfunction. In some embodiments, the pain is neoplasia-related pain or pain due to neoplastic disease (chronic or acute). In some embodiments, the pain is causalgia (lower and / or upper limbs).
[0346] In some embodiments, the pain is central pain syndrome, complex regional pain syndrome I, complex regional pain syndrome II (lower extremities), or complex regional pain syndrome II (upper extremities).
[0347] In certain aspects, provided herein are methods for treating a disease or condition in a subject, comprising administering to the subject a pharmaceutical composition provided herein, wherein the disease or condition is depression or opioid overdose. In some embodiments, the disease or condition is opioid overdose, and the opioid of the pharmaceutical composition is an opioid receptor antagonist, such as naloxone or naltrexone.
[0348] Profibrotic and entactin-inducing compounds In certain aspects, provided herein is a method of treating a disease or disorder in a subject, the method comprising administering to the subject a pharmaceutical composition provided herein.
[0349] In some embodiments, the disease or disorder is acute pain or chronic pain. In some embodiments, the pain is acute pain. In some embodiments, the pain is post-operative pain. In some embodiments, the pain is due to trauma, such as a battlefield wound. In some embodiments, the pain is cancer pain.
[0350] In some embodiments, the formulations and methods disclosed herein are used to treat pain or pain disorders. In some embodiments, chronic pain refers to pain that lasts for more than 3 months. Examples of pain and pain disorders include acute pain, somatic pain, gluteal pain, lower back pain, chronic back pain, chronic tail pain, chronic lower back pain, chronic malignant pain, chronic neck pain, chroni...
Claims
1. (i) a pharmaceutical compound that contains a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof; (ii) a complexing agent which is an acid substituted cyclodextrin containing a plurality of acidic functional groups, said plurality of acidic functional groups including acidic groups which act as counterions to said protonated nitrogen atoms of said pharmaceutical compound; A pharmaceutical composition, wherein the molar ratio of said pharmaceutical compound to said complexing agent is at least 1:
1.
2. The pharmaceutical composition of claim 1, wherein the cyclodextrin is substituted with three to eight acidic functional groups.
3. The pharmaceutical composition of claim 2, wherein the cyclodextrin is sulfobutyl ether-β-cyclodextrin (SBEBCD).
4. The pharmaceutical composition of claim 1, having a lower osmolality than a composition comprising a salt of the pharmaceutical compound and a salt of the complexing agent.
5. The pharmaceutical composition of claim 1, which is substantially free of excess ions.
6. The pharmaceutical composition of claim 1, formulated for subcutaneous, intramuscular, sublingual, oral, rectal, or intranasal administration.
7. The pharmaceutical composition of claim 1, wherein the ratio of said complexing agent to said pharmaceutical compound is from about 1:4 to about 1:
10.
8. The pharmaceutical composition of claim 1, having an osmolality of about 850 mOsm / kg or less.
9. The pharmaceutical composition of claim 1, having a pH of about 4 to about 7.
10. The pharmaceutical composition of claim 1, wherein the complexing agent is present in an amount of about 10 mg / mL to about 600 mg / mL.
11. The pharmaceutical composition of claim 1, further comprising about 0.1 to about 20 molar equivalents of a non-ionized pharmaceutical compound compared to the amount of said complexing agent.
12. (i) A pharmaceutical compound containing a protonated nitrogen atom, or an enantiomer, a mixture of enantiomers, or an isotopic variant thereof, or a pharma- ceutically acceptable salt, solvate, or hydrate thereof; (ii) a conjugate base of a complexing agent comprising a plurality of acidic functional groups, the conjugate base of said complexing agent acting as a counterion of said pharmaceutical compound, said complexing agent comprising a substituted cyclodextrin; having a molar ratio of said pharmaceutical compound to said complexing agent of at least 1:1; Pharmaceutically acceptable salts.
13. The pharma- ceutically acceptable salt of claim 12, which is substantially free of excess ions.
14. The pharmaceutical compound is an arylcyclohexylamine, a 1,2-diarylethylamine, a β-keto-arylcyclohexylamine, a methoxetamine, a deschloroketamine, a N-ethyldeschloroketamine (eticyclidone), a 3-methoxyphencyclidine, a methoxyethycyclidine, an ephenidine, a lanicemine, a dextromethorphan, a dextrorphan, a methoxyketamine, a N,N-dimethyltryptamine, a N,N-diethyl ... N,N-dipropyltryptamine, N-methyl-N-propyltryptamine, N-methyl-N-isopropyltryptamine, N,N-diallyltryptamine, N-methyl-N-allyltryptamine, N-methyl-N-ethyltryptamine, N,N-diisopropyltryptamine, 4-hydroxy-N-methyl-N-ethyltryptamine, 5-methoxy-N,N-diisopropyltryptamine, O-acetylpsilocin, methylisopropyltryptamine, isopropyl lysergamide, ethyl isopropyl lysergamide, 6-allyl-6-nor-LSD, 6-ethyl-6-nor-lysergic acid diethylamide, 1-acetyl-LSD, 1-propionyl-6-ethyl-6-nor-lysergic acid diethylamide, 1-propionyl-lysergic acid diethylamide, 1-cyclopropionyl-d-lysergic acid diethylamide, N1-butyryl-lysergic acid diethylamide, 6-propyl-6-nor-lysergic acid diethylamide, mescaline, 2,5-dimethoxy-4-bromophenethylamine (2C-B), 2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine (2C-I), 2-(4-chloro-2,5-dimethoxyphenyl)ethan-1-amine (2C-C), 2,5-dimethoxy-4-iodoamphetamine, 2-[2,5-dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine, 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine), racemorphan, levorphanol, racemethorphan, buprenorphine, morphine, loperamide, codeine, hydrocodone, oxymorphone, buprenorphine, fentanyl, methadone, tramadol, α-methylacetyl fentanyl, alfentanyl, butyryl fentanyl, butyl fentanyl, carfentanyl, 3-methylcarfentanyl, 4-fluorofentanyl, β-hydroxyfentanyl, α-methylfentanyl, cis-3-methylphenanthrenyl, 13. The pharma- ceutically acceptable salt of claim 12, wherein the compound is selected from the group consisting of alpha-amphetamine, beta-hydroxy-3-methylfentanyl, remifentanil, sufentanil, 3-methylthiofentanyl, naloxone, naltrexone, cathinone, 3,4-methylenedioxyamphetamine derivatives, aminoalkyl-substituted benzofurans, substituted amphetamines, aminoindan, diphenhydramine, hydroxazine, phenylephrine, dopamine, adrenaline, lidocaine, oxymetazoline, clemastine, chlorpheniramine, and 6-chloro-2-aminotetralin.
15. Formula: [A] a [B] A pharma- ceutically acceptable salt of a pharmaceutical compound having the formula: During the ceremony, A is a pharmaceutical compound containing at least one basic nitrogen atom; B is a complexing agent containing multiple acidic functional groups; a is a number from 1 to 7, said number being selected such that the total number of basic nitrogen atoms of A is equal to the number of acidic functional groups of B; The complexing agent is a cyclodextrin; A pharma- ceutically acceptable salt having a molar ratio of said pharmaceutical compound to said complexing agent of at least 1:
1.
16. The pharma- ceutically acceptable salt of claim 15, wherein the at least one basic nitrogen atom is contained in a heterocycle.
17. The pharma- ceutically acceptable salt of claim 15, wherein the at least one basic nitrogen atom has a pKa value of about 4 to about 10.
18. A pharma- ceutically acceptable salt according to any one of claims 15 to 17, wherein a is equal to the number of acidic functional groups.
19. The complexing agent has the formula (I): 【Chemistry 1】 or a stereoisomer, mixture of stereoisomers, or isotopic variant thereof, or a pharma- ceutically acceptable salt, solvate, or hydrate thereof; During the ceremony, each R 1 is independently H or an optionally substituted alkyl, wherein at least one R 1 is substituted with an acidic functional group; Each R 2 is independently H or optionally substituted alkyl; and 19. The pharma- ceutically acceptable salt of any one of claims 15 to 18, wherein n is 6, 7, or 8.
20. The pharma- ceutically acceptable salt of any one of claims 15 to 19, wherein the complexing agent is sulfobutylether-β-cyclodextrin (SBEBCD).
